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In this study, the ability of pharmaceutical cocrystals on improving solubility and 
dissolution behaviour of poorly water soluble drug has been studied by a novel 
technique SDI300 UV imaging surface dissolution system. Pharmaceutical cocrystals of 
poorly water soluble drug carbamazepine (CBZ) were synthesized, which are 1: 1 
carbamazepine - nicotinamide (CBZ-NIC) cocrystal, and 2:1 carbamazepine - succinic 
acid (CBZ-SUC) cocrystal.  
Firstly, dissolution and solution mediated phase transformation behaviour (SMPT) of 
CBZ-NIC cocrystal was studied by in situ techniques of UV imaging and Raman 
spectroscopy. This study has shown that in situ UV imaging and Raman spectroscopy 
with a complementary technique of SEM can provide an in depth understanding of 
cocrystal dissolution processes. It has been found that CBZ-NIC cocrystal including 
other polymorphs of CBZ III and I and mixture are converting to CBZ DH during 
dissolution. 
The influence of surfactants, SLS and Tween 80, on the solubility and dissolution 
behavior of the CBZ-NIC cocrystal has been studied. Results show that the SMPT of 
CBZ III and CBZ-NIC cocrystal can be altered by inclusion of a surfactant in 
dissolution medium. However, CBZ III and CBZ-NIC cocrystal have shown different 
transformation behavior with different surfactants.  
The solubility and dissolution behaviour of CBZ-NIC cocrystal, CBZ-SUC cocrystal in 
four biomedia (simulated gastric fluid, pH1.2 HCl buffer, simulated intestinal fluid, and 
pH 6.8 PBS buffer) were studied. Results have shown that equilibrium solubility of 
CBZ samples varied in different media. The two cocrystals dissolution rates show 
different trends as that of parent drug CBZ III. This can be explained by that the 
formation of cocrystal change the dissolution ability of CBZ III. 
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Chapter 1 Introduction 
1.1 Research background 
In the pharmaceutical industry, it is the poor biopharmaceutical properties rather than 
toxicity or lack of efficacy that are the main reasons why less than 1% of active 
pharmaceutical compounds eventually get into the marketplace[1-3]. Among these 
biopharmaceutical properties, solubility remains a key issue, with drugs often discarded 
during commercial production due to their low solubility. Improving the solubility of 
drugs is currently one of the main challenges for the pharmaceutical industry. Many 
approaches have been adopted for improving the aqueous solubility of drugs including 
micronization [4-6], salt formation [7], solid dispersion [8], emulsification [9, 10], 
solubilisations using co-solvents [11], and the use of polymer drug vehicles for delivery 
of poorly soluble drugs [12]. Although these techniques have been shown to be 
effective at enhancing oral bioavailability, success of these approaches is dependent on 
the specific physicochemical nature of the molecules being studied [13-16]. Over the 
last decades, there has been growing interest in the design of pharmaceutical cocrystals, 
which emerge as a potential method for enhancing the bioavailability of drugs with low 
aqueous solubility. Apart from offering potential improvements in solubility, dissolution 
rate, bioavailability and physical stability, pharmaceutical cocrystals frequently enhance 
other essential properties of the Active Pharmaceutical Ingredient (API) such as 
hygroscopicity, chemical stability, compressibility and flowability [17]. 
Researchers have done lots of work to study the solubility and dissolution behavior of 
cocrystals, which is one of the major aspects of cocrystals research areas. For poorly 
soluble neutral compounds, cocrystallisation is a very feasible method to improve 
solubility, and cocrystals can provide higher and lower dissolution rates compared to the 
APIs. However, pharmaceutical cocrystals dissolution process is still largely 
underexploited, and many problems remain unsolved, for example, high solubility of 
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pharmaceutical cocrystals result in a supersaturation of poorly soluble APIs and further 
crystallization of APIs, which is called solution mediated phase transformation (SMPT). 
The advantage of pharmaceutical cocrystals on improving APIs dissolution rate could 
be lost if SMPT happened. So, there is a clear need for better understanding about the 
dissolution process of cocrystals in the context of pharmaceutical cocrystals 
development. In this work, a new powerful dissolution test technology, ActiPix SDI 300 
UV surface imaging system (Paraytec Ltd., York, UK), has been employed to study the 
dissolution process of cocrystals. ActiPix SDI 300 UV surface imaging system has been 
designed to improve our understanding of the kinetics and mechanism of drug substance 
release into dissolution medium. It can visualise the solution concentration distribution 
during dissolution in real time. It provides a platform for generating spatial and 
temporary information of the dissolved solution phase of a solid drug during dissolution 
when it is combined with a channel flow cell method. Through applying UV surface 
imaging system into cocrystals dissolution study, several important results have been 
achieved. 
1.2 Research aim and objectives 
The aim of this study was to investigate how pharmaceutical cocrystals can improve the 
solubility and dissolution properties of poorly water soluble drugs under different 
environments. It was expected that the mechanism of pharmaceutical cocrystals 
dissolution can be better explained and understood. 
The specific objectives of this research are briefly listed as followings: 
Objective 1: Review the background, research method, and development results of 
current cocrystals research areas, and also give a critical and cohesive literature review 
about pharmaceutical cocrystals;   
Objective 2: Synthesize and characterize two pharmaceutical cocrystals of poorly water 
soluble drug of carbamazepine (CBZ), which are 1:1 carbamazepine-nicotinamide 
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cocrystal (CBZ-NIC cocrystal) and 2:1 carbamazepine-succinic acid cocrystal (CBZ-
SUC cocrystal); 
Objective 3: Establish one dissolution testing method using UV surface imaging system, 
Raman spectroscopy and SEM to in-situ monitor the dissolution process of cocrystals 
forms of sample. Apply this method to investigate the solution mediated phase 
transformation behaviour of CBZ-NIC cocrystal during its dissolution process; 
Objective 4: Study the effects of two different surfactants, sodium lauryl sulphate and 
Tween 80, on CBZ-NIC cocrystal solubility and dissolution behaviour; 
Objective 5: Investigate the solubility and dissolution behaviour of CBZ-NIC cocrystal 
and CBZ-SUC cocrystal in four biomedia, including pH1.2 HCl buffer, pH 6.8 
phosphate buffer, simulated gastric fluid, and simulated intestinal fluid. 
1.3 Thesis structure 
This thesis is organized into 8 chapters: 
Chapter 1 briefly described the background, objectives, and structure of the proposed 
PhD research. 
Chapter 2 presented a brief and systematic overview of pharmaceutical cocrystals. The 
definitions and basic theories of pharmaceutical cocrystals and recent progresses in 
pharmaceutical cocrystals were introduced in this chapter. 
Chapter 3 introduced all materials and analytical approaches used in this study. The 
principles and experimental settings of all analytical techniques were given in this 
chapter. Operations of instrument and methods development were described in details. 
Preparation of dissolution media and different test samples were also given in this 
chapter. 
  Chapter 1 
4 
 
Chapter 4 characterised all samples used in this study. The characterisation results of 
different forms of CBZ samples (CBZ I, CBZ DH) two cocrystals of CBZ, which are 
CBZ-NIC cocrystal, CBZ-SUC cocrystal were given. The molecular structures of CBZ-
NIC cocrystal and CBZ-SUC cocrystal were also presented in this chapter. 
Chapter 5 established the method to monitor the dissolution process of a cocrystal 
through in situ UV imaging and Raman spectroscopy in combination with a 
complementary technique of SEM. In this chapter, evolution of the intrinsic dissolution 
rate (IDR) of CBZ-NIC cocrystal was monitored by the UV imaging dissolution system. 
The solid state change that might occur during dissolution of the cocrystal was 
monitored by in situ Raman Spectroscopy. 
Chapter 6 investigated the role of surfactants in inhibiting the solution mediated phase 
transformation (SMPT) of a cocrystal. Two surfactants of sodium lauryl sulphate and 
Tween 80 were selected to investigate their effects on the solubility and intrinsic 
dissolution rate of CBZ-NIC cocrystal in this chapter. 
Chapter 7 studied the solubility and dissolution behaviour of CBZ, CBZ-NIC cocrystal, 
CBZ-SUC cocrystal in simulated gastric fluid, pH1.2 HCl buffer, simulated intestinal 
fluid, and pH 6.8 PBS buffer. 
Chapter 8 summarized the presented work and results obtained from this research. 
Further opportunities in the research area of pharmaceutical cocrystals were also 
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Chapter 2 Literature Review 
2.1 Chapter overview 
In this chapter, a brief and systematic review of pharmaceutical cocrystals was 
presented. To start with, cocrystal background was introduced, which will give the 
reader a general knowledge about cocrystal research area. The concept of the 
pharmaceutical cocrystals and several key issues of pharmaceutical cocrystals including 
cocrystals formation theory, design strategies, formation methods, physicochemical 
properties studies, characterisation techniques were individually described. Recent 
progress on pharmaceutical cocrystals, especially theoretical research development on 
cocrystals dissolution and solubility, were illustrated in this chapter. Finally, 
pharmaceutical cocrystals research of carbamazepine, a biopharmaceutics classification 
system (BCS) II drug, was reviewed.  
2.2 Cocrystal background review 
2.2.1 Cocrystal definition 
Cocrystals can be defined in a number of ways [18, 19]. A restrictive definition utilised 
by Aakeroy and Salmon [20] is that cocrystals are structurally homogeneous crystalline 
materials containing two or more components present in definite stoichiometric 
amounts. The cocrystal components are discrete neutral molecular reactants which are 
solids at ambient temperature. Based on this definition of cocrystals, a pharmaceutical 
cocrystal means a cocrystal with one of the cocrystal components as an API and the 
other components are called coformers.  
In Schultheiss’ review paper, the pharmaceutical cocrystals examples were enriched by 
including both neutral API and ionic form API [18]. A pictorial description of 
cocrystals and other possible multicomponent systems along with their respective 
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hydrates and solvates are displayed and compared in Fig. 2.1. Example 1 is a 
pharmaceutical cocrystal which formed by a neutral API and coformer through 
noncovalent interactions. Example 2 is a salt cocrystal formed by ionic API and neutral 
coformer. A pharmaceutical salt is also introduced in Fig. 2.1, example 3, which is 
formed by ionic API and acid. The difference between salt and cocrystal is that whether 
proton transfer has happened: if proton transfer has happened during one compound 
formation, the compound is salt; if no proton transfer happened, the compound is 
cocrystal. 
 
Fig. 2.1 Cocrystals, salt cocrystals, and salts along with their respective solvate/hydrate forms [18]  
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2.2.2 Crystal engineering 
A pharmaceutical cocrystal can be designed by crystal engineering with an intention to 
improve the solid-state properties of an API without affecting its intrinsic structure. 
Crystal engineering can be defined as an application of the concepts of supramolecular 
chemistry to the solid state with particular emphasis upon the idea that crystalline solids 
are actual manifestations of self-assembly [21-24]. Cocrystals are constructed from 
intermolecular interactions such as van der Waals contact forces, π···π stacking 
interactions, and hydrogen bonding [25-28]. The most common hydrogen bonds utilized 
in crystal engineering utilised in pharmaceutical cocrystals are shown in Fig. 2.2. 
Crystal engineering involves modification of the crystal packing of a solid material by 






Fig. 2.2 Typical hydrogen bonds utilized in crystal engineering 
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2.2.3 Pharmaceutical cocrystals design strategies 
As pharmaceutical cocrystals have rapidly emerged as a new class of API solids, much 
work has focused on exploring the crystal engineering and design strategies. 
Pharmaceutical cocrystals design is a multi-stage process, as schematically illustrated in 
Fig. 2.3 [29].  
In order to get a desirable cocrystal product of an API, the first step is to study the 
structure of the target API molecule and find out the functional groups which can form 
intermolecular interaction with suitable coformers.  
The next step is to choose a cocrystal coformer. The primary request for a coformer is to 
be pharmaceutically acceptable, for example, pharmaceutical excipients and compounds 
classified as generally recognized as safe (GRAS) for use as food additives. Coformer 
selection is the crucial step for designing a cocrystal.  
During the design process, there are lots of worthwhile empirical and theoretical 
guidance, such as Cambridge Structural Database (CSD), hydrogen bond theories, and 
many empirical conclusions  [13, 26, 30-39] . 
 
Fig. 2.3 Steps for cocrystal design and preparation 
The next step is cocrystal screening, which is an experimental process to determine if a 
particular coformer candidate is able to cocrystallise with a targeted API. After a small 
 Selection and 
research of APIs 
Selection 
cocrystal formers 
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scale screening exercise, proper coformers could be selected to do scale up experiments. 
Various screening methods have been developed for cocrystal screening, such as 
solution method [40], hot-stage thermal microscopy method [41-43], computed crystal 
energy landscape method [44]. 
The aim of cocrystal characterization is to investigate the physical, chemical, and 
crystallographic properties of cocrystals. Usually, characterization includes the chemical 
structural conformation and crystallographic analysis of the newly formed 
supramolecularsynthon, its thermal features, stability and solubility. Details of different 
cocrystal characterisation techniques will be given in section 2.2.5 Cocrystal 
characterisation techniques. 
The final step is the performance tests of newly formed cocrystal, which includes both 
in vitro and in vivo tests. In vitro tests focus on intrinsic dissolution and dissolution tests, 
while in vivo tests refer to animal bioavailability measurements, the measurement of the 
rate and extent of an API that reaches systemic circulation [45].  
2.2.4 Cocrystal formation methods 
To date, many ways of producing cocrystals have been reported. The most common 
formation methods are based on solution and grinding [27, 28]. The solution method is 
of great importance due to most of the cocrystals which qualify for single X-ray 
diffraction (SXRD) testing can only be prepared through this method. Solution methods 
include evaporation of a heterometric solution method, reaction crystallisation method, 
and cooling crystallisation. Grinding methods include neat grinding and solvent drop 
grinding. Apart from solution and grinding methods, there are also many newly 
emerging methods, such as cocrystallisation using supercritical fluid, hot-stage 
microscopy, and ultrasound assisted cocrystallisation.  
2.2.4.1 Solution methods 
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In practice, solution cocrystallisation is based on the following two strategies [46]: (1) 
use of solvents or solvent mixtures where the cocrystal congruently saturates and thus 
the components have similar solubility, or (2) use of nonequivalent reactant 
concentrations in order to reach the cocrystal stability region in noncongruently 
saturating solvents [29, 31, 47].  
Strategy one is adopted when the two cocrystal components have similar solubility in 
solvent and solution cocrystallisation with equimolar components will lead to the 
formation of the 1:1 cocrystal from solvent evaporation method. To date, many 
successful cocrystal examples were obtained by this method [26, 37, 48]. Strategy two 
is applied when cocrystal components have nonequivalent solubility, solution 
cocrystallisation through evaporation of an equimolar solution may result in the 
formation of single component crystal or a mixture of individual component and 
cocrystal. The reaction cocrystallisation (RC) approach has been adopted for this 
situation. RC experiments are performed by adding the less soluble reactant to a 
saturated or close to saturated solution of the more soluble reactant and then the solution 
becomes supersaturated with respect to cocrystal. Examples of cocrystal synthesized by 
RC method were reported [46, 49, 50].  
Another solution method called cooling crystallisation involves varying the temperature 
of the crystallisation system, which has recently attracted much more attention for 
potential of a large scale of cocrystal production. First, large amounts of reactants and 
solvent are mixed in a reactor typically a jacketed vessel, and then the system is heated 
to a higher temperature to make sure all solutes are totally dissolved in the solvent and 
is followed by a cooling down step. Cocrystals will precipitate when solution becomes 
supersaturated with respect to cocrystal as the temperature drops down [42]. Several 
examples of cocrystals prepared through cooling crystallisation method have been 
published [51-53]. 
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2.2.4.2 Grinding methods 
There are two different techniques for cocrystal formation via grinding [54-56]. The 
first method is neat grinding, which is also called dry grinding, consisting of mixing the 
stoichiometric cocrystal components together and grinding them either manually, using 
a mortar and pestle, or mechanically, using a ball mill or a vibratory mill. To date many 
pharmaceutical cocrystals have been successfully synthesised by neat grinding [17, 57, 
58]. The second technique for cocrystal synthesis via grinding is that of liquid-assisted 
grinding (also referred to as solvent-drop, wet cogrinding), in which minor amounts of 
an appropriate solvent is added in. Significant improvements in kinetics of cocrystal 
formation by grinding can be achieved by the addition of minor amounts of an 
appropriate solvent [37, 48, 59-61].  
2.2.4.3 Other formation methods 
Recently several novel methods have appeared in the area of pharmaceutical 
cocrystallisation. The application of supercritical fluid technology into cocrystal 
formation has been carried out by Padrela et al. [24, 62]. Ultrasound has been used to 
prepare cocrystals from solution or suspension/slurry [30, 38, 63]. Ultrasound assisted 
solution cocrystallisation has been studied using a noncongruently soluble pair of 
caffeine and maleic acid in methanol [64]. 
2.2.5 Cocrystal characterisation techniques 
Cocrystal characterisation is an important constituent part within cocrystal research. The 
basic physicochemical properties of cocrystals can usually be characterised by Powder 
X-ray Diffraction (PXRD), Single Crystal X-ray Diffraction (SXRD), Infrared 
spectroscopy (IR), Raman spectroscopy, Differential Scanning Calorimetry (DSC), 
Solid State Nuclear Magnetic Resonance Spectroscopy (SSNMR), Scanning Electron 
Microscopy (SEM), and Terahertz spectroscopy.  
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SXRD is a characterisation technique for the determination of solid-state structure of 
cocrystals at an atomic level. However, the problem is that a single pharmaceutical 
cocrystal which is qualified for SXRD testing cannot always be produced. Therefore, 
PXRD are utilised more frequently to verify the formation of cocrystals. While, PXRD 
cannot distinguish solvates, hydrates or polymorphs from cocrystals, to make things 
worse, pharmaceutical cocrystals are prone to forming isostructural phases [29].  
Raman spectroscopy is a spectroscopic technique used to study vibrational, rotational, 
and other low-frequency modes in a system, which has been demonstrated to be a 
powerful tool for distinguishing isostructural phase. There are many applications using 
Raman spectroscopy to identify characteristic peaks of cocrystal products [17, 42, 46, 
64, 65].  
IR is a very common spectroscopic technique in determining the chemical conformation 
of compounds. It can be a very powerful tool in distinguishing cocrystals from salts 
when a carboxylic acid is involved in hydrogen bond formation [66].  
Recently, high-resolution SSNMR has shown to be a versatile and powerful tool for 
characterisation of pharmaceutical cocrystals [27, 67]. The application of different kinds 
of NMR methods in pharmaceutical cocrystal characterisation was introduced by Khan 
et al. [23] 
DSC is the most widely used technique for the thermal property testing of cocrystals. 
DSC is the preferred technique for obtaining comprehensive melting point data and 
additional thermal data, such as the enthalpy of melting, can also be obtained 
simultaneously. In addition to being a characterisation technique, DSC has recently 
been used as a screening tool for rapid cocrystal screening [39, 68].  
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SEM is a type of electron microscope that images a sample by scanning it with a high-
energy beam of electrons in a raster scan pattern. It is applied to determine the cocrystal 
micrograph and particle size in many examples [48, 62, 69, 70].  
Terahertz time-domain-spectroscopy (THz-TDS) has emerged as a versatile 
spectroscopic technique and an alternative to PXRD in the characterisation of molecular 
crystals. It has been demonstrated that terahertz spectroscopy has the ability to 
distinguish between chiral and racemic hydrogen bonded cocrystals that are similar in 
molecular and supramolecular structure [71].  
It is important to stress that no single technique is adequate to completely characterise 
the properties of cocrystal. Integration of various characterization techniques could help 
elucidate a better understanding of samples when analyzing cocrystalline materials. 
2.2.6 Physicochemical properties of cocrystals 
Physical and chemical properties of cocrystals are of great importance to the 
development of APIs. The overall motivation for investigating pharmaceutical 
cocrystals as an alternative approach during drug development is the adjustment of the 
physiochemical properties to improve the overall stability and efficacy of a dosage form 
[31]. Physicochemical properties, such as crystallinity, melting point, solubility, 
dissolution, and stability, have been studied extensively by researchers. A systematical 
review of these properties was given by Schultheiss and Newman [18]. Some key 
physicochemical properties of pharmaceutical cocrystals are summarised as following. 
2.2.6.1 Melting point  
Melting point is the temperature at which the solid phase is at equilibrium with the 
liquid phase. It is a fundamental physical property and an important consideration 
during solid drug development. There are complex correlations between the melting 
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point of pharmaceutical product and its processability, solubility and stability. Large 
amount of research work has been carried out to investigate if the melting point of a 
cocrystal changes with respect to the individual components and if the melting points 
can be estimated and modulated within a series of cocrystals [1, 72, 73]. 
2.2.6.2 Stability  
Stability is a very important parameter when evaluating the properties of a 
pharmaceutical cocrystal. Usually, the stability testing of a newly developed cocrystal 
includes four aspects: relative humidity stress, thermal stress, chemical stability, and 
solution stability.  
The relative humidity stress test is used to identify the best storage conditions for the 
product because the amount of water present in the cocrystal can lead to quality 
deterioration [24, 42, 48, 74, 75]. Thermal stress and chemical stability are relatively 
less studied areas about cocrystal properties. Very few reports were found [76, 77] and 
these limited studies showed that thermal stress studies can provide valuable 
information about physicochemical stability. Solubility stability is defined by 
Schultheiss and Newman [18] as the ability of the cocrystal components to stay in 
solution and not readily crystallise. Solution stability is an important parameter during 
drug development. Stability experiments accompany solubility or dissolution 
experiments to provide a more complete understanding of the behaviour of cocrystals in 
release media. 
2.2.6.3 Solubility  
Solubility is another important parameter for evaluating the properties of a 
pharmaceutical cocrystal. Traditional methods for improving solubility of poorly water 
soluble drugs include salt formation [78], solid dispersion (emulsification) [8], and 
particle size reduction (micronisation) [79], solubilisation of drugs in co-solvents [11] 
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and micellar solutions [9]. However, there are practical limitations with these 
techniques [13, 62], the success of these approaches is dependent on the specific 
physicochemical nature of the molecules being studied. Pharmaceutical cocrystallisation 
as a novel way to improve the physicochemical properties of a drug such as solubility, 
which can potentially be applied to a wide range of molecules and has attracted great 
interest from researchers [1, 5, 13, 29, 42, 80-86]. Many valuable research results have 
been obtained and these are selectively described as following. 
Shiraki et al. [82] tried to improve the solubility of two APIs, exemestane (EX) and 
megestrol acetate (MA), through preparing two novel cocrystals, exemestane-maleic 
acid (EX-MAL) and megestrol acetate-saccharin (MA-SA) from organic solutions with 
different particle sizes. Aakeroy’s study showed that cocrystals can not only increase 
but also decrease the solubility of active ingredient [1]. Researchers hypothesized that if 
they can incorporate an API with a series of crystalline solids characterized by 
considerable structural consistency, then may be able to fine-tune aqueous solubility. 
This hypothesis was demonstrated by systematically modulated aqueous solubility of an 
anticancer drug (hexamethylenebisacetamide) through cocrystallisation method. In 
addition to experimental studies, some theoretical research on cocrystal solubility has 
been carried out. More details on theoretical research about pharmaceutical cocrystals’ 
solubility will be given in section 2.3. 
2.2.6.4 Intrinsic Dissolution Rate (IDR)  
Intrinsic dissolution measures the rate of dissolution of a pure drug substance from a 
constant surface area, which is independent of formulation effects and measures the 
intrinsic properties of the drug as a function of dissolution media, e.g. pH, ionic strength 
and counter-ions.  The sample used in the intrinsic dissolution test is pressed into a disk 
or pellet, which should be no form change upon pressing and the disk needs to remain 
intact during the experiment. Most of the APIs studied for cocrystallisation are 
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classified as BCS II drugs, which have high permeability and low solubility. Thus, IDR 
is a good indicator for the in vivo absorption efficiency of APIs.  Although the IDR is an 
important parameter to be investigated, it may become more complicated with 
cocrystals. Various factors need to be considered and extra experiments may be needed 
to obtain and interpret intrinsic dissolution data on cocrystals correctly [18]. Large 
amount of research has been carried out on cocrystal solubility and intrinsic dissolution 
behaviour, many instructive results have been obtained and these are selectively 
described as followings. 
In Shiraki et al.’s stduy [82], the IDRs of two newly formed cocrystal EX-MAL and 
MA-SA have been improved compared to the respective original crystals. LEE studied 
the dissolution characteristics of an acetaminophen-theophylline (AT) cocrystal 
compared with its pure components and physical mixtures [87]. In Lee’s research, 
intrinsic dissolution behaviour was conducted using a rotating disk. Results show that 
the AT cocrystal had a faster dissolution rate than AT physical mixtures, and the 
dissolution profiles were congruent (1:1 mole ratio) under different pH conditions. 
Although cocrystallisation method was developed to be an approach to improve the 
solubility and dissolution behaviour of API, not all the cocrystals exhibit better 
dissolution behaviour. Christine Grossjohann and coworkers examined the 1:1 cocrystal 
benzamide-dibenzyl sulfoxide, comprising the poorly water soluble dibenzyl sulfoxide 
(DBSO) and the more soluble benzamide (BA) [88]. Dissolution was examined through 
intrinsic dissolution studies. Dissolution studies revealed that dissolution of DBSO from 
the cocrystal was not enhanced in comparison to the pure compound or a physical mix. 
In some cases, the higher dissolution rate cannot obtain or maintain for longer time, this 
is due to a phenomenon ‘solution mediated phase transformation’ which will be 
discussed later in section 2.3.3. 
2.2.6.5 Bioavailability  
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Bioavailability expresses the rate and extent of a drug which reaches into the systemic 
circulation, one of the principal pharmacokinetic properties of drugs. The ultimate goal 
for cocrystal investigation is to improve the bioavailability of an API. Animal 
bioavailability is an important parameter to consider when preparing new forms of a 
compound. There are limited numbers of animal bioavailability studies on cocrystals. 
The cocrystal of glutaric acid and 2-[4-(4-chloro-2-fluorphenoxy) phenyl] pyrimidine-4-
carboxamide was used to demonstrate an improvement in the oral bioavailability of the 
API in dogs [42]. Single dose dog exposure studies confirmed that the cocrystal 
increased plasma AUC (area under the plasma concentration time curve) values by three 
times at two different dose levels. Another pharmacokinetic study on indomethacin-
saccharin cocrystal also showed an improved bioavailability of cocrystal over pure API, 
indomethacin [70]. 
2.3 Theoretical development on solubility prediction of pharmaceutical 
cocrystals 
2.3.1 Prediction of cocrystal solubility  
Pharmaceutical cocrystals, which emerge as a potential approach to improve the 
solubility and dissolution of poorly water soluble drug, have attracted extensive 
research. However, true cocrystal solubility is not readily measured for highly soluble 
cocrystals because they can transform to the most stable drug form in solutions. Large 
amount of theoretical research on cocrystal solubility has been carried out with the 
purpose to provide a more appropriate method for cocrystal solubility measurement and 
explain the mechanism of solubility improvement by cocrystal. Rodríguez-Hornedo’s 
research group has done lots contribution on cocrystal solubitliy study. In one of 
Rodriguez-Hornedo’s study, the solubility and thermodynamic stability of 
pharmaceutical cocrystals has been predicted based on eutectic point  information [84, 
86]. 
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Definition of cocrystal eutectic point 
The cocrystal eutectic point or transition concentration, invariant point, is a key 
parameter that establishes the regions of thermodynamic stability of cocrystal relative to 
its components [84-86]. This is an isothermal invariant point where two solid phases 
coexist in equilibrium with solution. For poorly water soluble drugs and more soluble 
coformers, we consider the eutectic point for solid drug and cocrystal in equilibrium 
with solution. 
Cocrystal eutectic constants and prediction of solubility behavior 
In Rodriguez-Hornedo’s publication [86], the cocrystal to drug solubility ratio (α) is 
shown to determine the excess eutectic coformer concentration and the eutectic constant 
(Keu), which is the ratio of solution concentrations of cocrystal components at the 
eutectic point. The solution eutectic composition and cocrystal solubility ratio are a 
function of component ionization, complexation, solvent, and stoichiometry. These 
fundamental relationships can be applied to predict the solubility and thermodynamic 
stability of new cocrystals. 
Three equations and equilibrium constants are considered to predict the cocrystal 
solubility, eutectic composition, and solution complexation from the eutectic of solid 
drug A and cocrystal AyBz where B is coformer 
                                                                                          (Equ.2-1) 
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where      ,    , and     are the intrinsic drug soubility in pure solvent, cocrystal 
solubility product, and complexation constant, respectively.  Combining      ,    , and 
    gives the concenteration of complex at the eutectic as  
                                       [  ]        (        




                      (Equ.2-4) 
As described in definition of cocrystal eutectic point section, for poorly water soluble 
drugs and more soluble coformers, we consider the eutectic for solid drug and cocrystal 
in equilibrium with solution. This eutectic is most relevant for describing cocrystal 
solubility, stability, and equilibrium behavior relative to the drug. The eutectic constant 
(   ) is the concentration ratio of total coformer to total drug that satisfies the 
equilibrium Equ.2-1 to 3. 
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Considerations of ionization for either component can be added to this equation. For the 
case of a monoprotic acidic coformer and basic drug Equ.2-5 is rewritten as 
                          
[ ]  
[ ]  
 
[ ]          [ ]        [  ]
[ ]          [ ]        [  ]
 






   
 
    
 )
   
(  
          
[  ]
)    (        
(   )
)
   
     (  
[  ]
      
)    (        
(   )
)






             (Equ.2-6) 
where [  ] is the hydrogen ion concentration and    is the dissociation constant for the 
acidic conformer or the conjugate acid of the basic drug. Considering the case of 
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components with multiple    values and negligible solution complexation the     as a 
function of pH is 
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where g and m are the total number of acidic groups for each component and j and q are 
the total number of basic groups. In this case, the eutectic constant is a function of the 
cocrystal solubility product, drug solubility, and ionization. Letting the ionization terms 
for drug and coformer equal       and            Equ.2-7 simplifies to 
                                          (
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    can also be expressed as a function of the cocrystal to drug solubility ratio (α) in 
pure solvent using the previously described equation for cocrystal solubility [84] 
                                          
    (   )                                           (Equ.2-9) 
                            where               (          )                         (Equ.2-10) 
                   and             √            
      
 
 (    )
   
             (Equ.2-11) 
For a drug with known solubility, Equ.2-9 allows prediction of cocrystal solubility from 
the eutectic constant or vice versa. For a 1:1 cocrystal (i.e., y=z=1) Equ.2-9 becomes 
     
  indicating that     is the square of the solubility ratio of cocrystal to drug in 
pure solvent. Thus, a cocrystal with two times higher solubility has a four times greater 
   . Furthermore, a     greater than 1 indicates the 1:1 cocrystal is more soluble than 
the drug, whereas cocrystals less soluble than the drug have     values below 1. The 
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derived equations apply to any ionization or temperature condition as long as the 
appropriate equilibrium constants and solubilities are taken into consideration.  
Cocrystal transition concentration determination 
 
Fig. 2.4 Flowchart of method used to establish the invariant point and determine equilibrium solution 
transition concentrations of cocrystal components[84] 
Methods used for the determination of transition concentrations     hve been presented 
in David J. Good’s publication [84]. A flowchart of two methods used to determine 
cocrystal transition concentrations is given in Fig. 2.4. Method 1: The measurements of 
cocrystal     values were performed by precipitating cocrystal as a result of stirring 
excess solid drug in a coformer solution wherein cocrystal synthesis occurs through 
reaction crystallization method. Method 2:     values were also obtained by dissolution 
of cocrystal in saturated drug solutions containing excess solid drug. Each cocrystal 
   was determined from both supersaturated cocrystal conditions by reaction 
Method 1 Method 2 
Add drug to a near 
saturated coformer 
solution 
Add cocrystal and 
drug to saturated 
drug solution 
slurry for 24 hrs 
Does XRPD indicate 
mixed solid phase? 
Sample liquid for 
HPLC analysis 








   
Add coformer (method1) 
or cocrystal (method2) & 
slurry 24hrs 
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crystallization method and from undersaturation by cocrystal dissolution. Samples were 
confirmed to have two solid phases (drug and cocrystal) at equilibrium for at least 24 
hours before the solution was isolated from the solids and analysed by HPLC. An 
aliquot of the solid phase was isolated from solution for X-ray analysis then solid 
reactant(s) were added as required to reach mixed solid phase equilibrium. This process 
was repeated in 24 hours iterations until a stable mixed solid phase was achieved. 
Samples were held at constant temperature for all transition concentration 
measurements. 
2.3.2 Cocrystal dissolution in surfactant solutions 
Pharmaceutical cocrystals, as a promising way to improve the bioavailability of poorly 
soluble drug with higher aqueous solubility, its solubility and dissolution behaviour has 
been widely studied. The dissolution of cocrystals in surfactant solutions will be 
discussed in this section. 
Cocrystal forms with higher solubility are however characterized by conversion to a less 
soluble form of the parent drug when exposed to solvent or solution. This phenomenon 
is called solution mediated phase transformation, which will be discussed in next 
section. Current approaches aim at delaying the conversion to drug but may require high 
additive levels to achieve transient stability. Neal Huang and Naír Rodríguez-Hornedo 
have discovered that micellar additives with different solubilisation capacity for 
cocrystal components, such as surfactants, impart thermodynamic stability to otherwise 
unstable cocrystal phases [89-91]. The theoretical foundation for controlling cocrystal 
solubility and stability is presented by considering the contributions of micellar 
solubilisation and ionization of cocrystal components [90]. For a 1:1 cocrystal RHA, 
where R represents a nonionizable drug, HA represents a weakly acidic coformer, and 
M represents micellar surfactant, the relevant equilibria are listed below, 
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The subscript aq denotes species in the aqueous phase. The subscript m refers to species 
in the micellar phase. Ksp is the cocrystal solubility product. Ka is the ionization constant 
for the coformer HA.   
 ,   
   and  
   are the micellar solubilisation constants for 
cocrystal components and their ionized forms. Activities are replaced by concentrations 
as a first approximation applicable to dilute solutions. All the equilibrium constants 
used in above equations are given below, where the terms in brackets refer to 
concentrations. 
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Through derivation, the total solubility of cocrystal RHA, SRHA,T, is expressed in terms 
of experimentally accessible solution properties as, 
                   √   (     [ ]) (  
  
[  ]
     [ ])              (Equ.2-22) 
where the micellar surfactant concentration [M] is the total surfactant concentration 
minus the critical micellar concentration (CMC).  
It is evident from Equ.2-22 that cocrystal solubility is not linearly dependent on micellar 
concentration. This is in contrast to the linear dependence of the micellar solubilization 
of a single component solid phase of a nonionizable drug R: 
                                     (    
 [ ])                                      (Equ.2-23) 
where       is the solubility of crystal R in the aqueous pseudo phase. 
Eq. 2-22 and 2-23 are shown graphically in Fig. 2.5 for the case of a nonionizable, 
hydrophobic drug and its cocrystal with an ionizable, hydrophilic coformer, 
where  
    , and Equ.2-22 can be further simplified as 
                                    √     [ ]                                  (Equ.2-24) 
Fig. 2.5 (a) reveals that cocrystal and drug solubility surfaces intersect along a curve of 
given surfactant concentration and pH values and identifies stability region for cocrystal 
or drug by two critical parameters. The first parameter is the surfactant critical 
stabilization concentration (CSC) or the surfactant concentration where cocrystal and 
drug solid phases are in equilibrium with the solution. The second parameter is the 
pHmax or the pH value at the CSC. Fig. 2.5 (b) shows the distribution of the drug in 
micellar and aqueous environments. The cocrystal thermodynamic stability relative to 
the drug decreases with surfactant concentration. A thermodynamically unstable 
cocrystal in pure solvent becomes stable at the CSC where all curves intersect. 
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Cocrystal is more soluble than the drug below CSC, equally soluble to drug at CSC, and 
less soluble than the drug above CSC. 
 
 
(a)                                 (b) 
Fig. 2.5 (a) cocrystal RHA(blue/green) and drug R (yellow) solubility dependence on surfactant 
concentration and pH (b) distribution of drug  between the aqueous and micellar environments in 
surfactant solutions at equilibrium with cocrystal RHA and crystal R [90]. 
The existence of CSC and pHmax (in the case of ionisable cocrystal component) is a 
consequence of the lower rate of increase of cocrystal solubility with surfactant 
concentration as compared with that of drug solubility. It is evident from Equ. 2-24 and 
Equ. 2-23 that cocrystal solubility depends on √[ ] (when   
    ), whereas the drug 
solubility depends on [M]. 
The theoretical analysis in this study demonstrates how surfactant additives with 
different solubilisation capacity for cocrystal components can impart thermodynamic 
stability to otherwise unstable cocrystal phases. 
2.3.3 Solution mediated phase transformation 
Solubility improvement of poorly soluble drug compounds is a key aspect to ensuring 
the successful development of many new drugs. Methods used to improve the solubility 
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of drug compounds include salt formation, forming an amorphous solid or dispersion 
and using a metastable polymorph, as well as cocrystal formation [48, 82, 87, 92]. All 
these solubility enhancement approaches can improve the drug dissolution rate which is 
one of the key factors affecting the drug absorption. However, these approaches can 
also result in a phenomenon called ‘solution mediated phase transformation’ (SMPT) 
which is crystallization of a stable solid phase during dissolution of a metastable phase 
caused by supersaturated conditions in solution or at the surface of the dissolving solid. 
A main concern of the SMPT is that the advantage of the improved drug dissolution rate 
could be lost if crystallization of a stable phase occurs during dissolution, as the 
dissolution rate will gradually change to that of the stable crystalline form [93].  
SMPT is facilitated through exposure to a liquid. The SMPT can be described as three 
key stages: (1) dissolution of a metastable phase to create a local supersaturation, (2) 
nucleation of a stable phase, and (3) growth of the stable phase. Nucleation and growth 
of the more stable phase often occurs on the surface of the metastable phase, reducing 
the advantage of the formation of the drug metastable forms. Therefore, transformation 
to a less soluble solid during dissolution is an important aspect to consider when 
evaluating approaches to increase the solubility of a poorly soluble drug [93, 94]. 
 
Fig. 2.6 Phase diagram for a monontropic system [94] 
  Chapter 2 
27 
 
A detailed kinetic analysis is available for processes involving SMPT in Davey and 
Cardew’s publication [94, 95]. SMPT can proceed by a mechanism in which crystals of 
the stable phase grow and those of the metastable phase dissolve. Davey and Cardew 
discussed the kinetic with a generalised phase diagram for a monotropic system, shown 
in Fig. 2.6. It is clear that for a solution having composition x and temperature Tx 
precipitation can yield both the metastable phase 1 and the stable phase 2. The 
composition x is supsaturated with metastable phase 1, thus metastable phase 1 first 
precipitation. The starting point for the transformation is slurry of monosized crystals of 
phase 1 in contact with a saturated solution containing nuclei of phase 2. As these nuclei 
grow so the solution composition falls below the solubility of phase 1 and the solution 
becomes undersaturated with respect to this phase. The crystals of phase 1 thus dissolve 
producing supersaturation for the continued growth of phase 2.  This dissolution-growth 
process continues until all phase 1 has disappeared and the solution composition has 
fallen to the solubility of phase 2.  
SMPT has been extensively studied for the formations of salts, polymorphs and 
amorphous solids over many years [96-107]. Recently, much work has been carried out 
to grow hollow needle crystals through the solvent mediated phase transitions [108-110]. 
However, there are very few reports on studies of the solution mediated phase 
transformation of cocrystals, among which different dissolution behaviours of 
cocrystals have been found [48, 80, 90, 92, 111, 112]. Some case studies about this 
aspect are selectively indicated as followings. 
Lee studied the dissolution characteristics of an acetaminophen-theophylline (AT) 
cocrystal compared with its pure components and physical mixtures [87]. Results show 
that the AT cocrystal had a faster dissolution rate than AT physical mixtures. Thus, the 
AT cocrystal exhibited higher transient solubility compared with its two pure 
components. Equilibrium solubilities of theophylline from the cocrystal were lower than 
transient values due to SMPT of cocrystal to theophylline hydrate but no precipitation 
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of free acetaminophen occurred. Childs prepared three cocrystals of fluoxetine 
hydrochloride (FH) [80], which are 1:1 cocrystal of fluoxetine hydrochloride - benzoic 
acid (FH-BZ), 2:1 cocrystal of fluoxetine hydrochloride-succinic acid (FH-SC), and 
fluoxetine hydrochloride - fumaric acid (FH-FM). The results of IDR experiments show 
that cocrystals FH-BZ and FH-FM dissolve more slowly than FH, and cocrystal FH-SC 
dissolves more quickly than FH. Powder dissolution experiments demonstrated that the 
solid present at equilibrium corresponds to the cocrystal for FH-BZ and FH-FM, while 
FH-SC completely transformed to FH upon prolonged slurry in water. Researchers have 
found that a compound, AMG 517 formed a 1:1 co crystal with sorbic acid. During 
powder dissolution test, the concentration of drug dissolving from the cocrystal 
decrease from 10 times that of the parent drug at 1 hour to the same level of free drug at 
2.5 hours due to the SMPT [72]. Another example, the powder dissolution rate of the 
fluoxetine HCl-succinic acid cocrystal exhibited 1.7 times that of fluoxetine HCl alone, 
but it decreased to the level of the pure drug in 20 minutes [80]. SMPT of both the 
indomethacin-saccharin and acetaminophen-theophylline cocrystals was affected by 
solution pH [48, 111]. The cocrystal of a low solubility compound with glutaric acid 
was found to have an IDR of the compound alone in water at 37C and a SMPT started 
at 90 minutes [92]. It has been found that the mechanisms of dissolution enhancement 
of two cocrystals of Exemestane-maleic acid (EX-MAL) and Megestrol acetate-
saccharin (MA-SA) were different, in which with the cocrystal EX-MAL, fine particle 
formation resulted in dissolution rate enhancement, whereas with the cocrystal MA-SA, 
enhancement was due to the maintenance of the cocrystal form and rapid dissolution 
before transformation to the original crystal [112].  
Recently, the theoretical study of effects of surfactant additives on cocrystals 
dissolution, which described in former section, has shown that surfactants can impart 
thermodynamic stability to cocrystals that otherwise convert to parent drug solids in an 
aqueous solution [90]. SMPT also be applied to interpret the solvent-drop grinding 
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method of preparing cocrystals [37, 59, 61, 113]. In this manner, the solution mediated 
conversion is advantageous for controlling cocrystallization kinetics and polymorph 
selection. Although these transformations do not occur during a dissolution process, it is 
interesting to note this application of  SMPT [93]. 
Characterisation of the solid state transition is important for SMPT phenomenon 
research. Much work has been done to monitor the solid phase transition during 
intrinsic dissolution in a channel flow-through dissolution apparatus using in situ 
Raman spectroscopic measurements. Combined with multivariate analysis techniques 
such as principal component analysis and partial least squares, Raman spectroscopy has 
demonstrated that it cannot only detect different crystallised solid forms but also 
quantitatively assess each of solid compositions, offering a deeper understanding of the 
SMPT phenomena during dissolution [106, 114-118].  
2.4 Carbamazepine (CBZ) cocrystals studies 
2.4.1 CBZ introduction 
CBZ (5H-dibenz (b, f) azepine-5-carboxamide) (other brand name: Tegretol, Equetro, 
Epitol, et al.) was discovered by chemist Walter Schindler in 1953 [119], and now it is a 
widely prescribed anticonvulsant and mood-stabilizing drug used primarily in the 
treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. CBZ with the 
chemical name of 5H-dibenz (b, f) azepine-5-carboxamide is a white or off-white 
powdered crystal. It has at least four anhydrous polymorphs, a dihydrate as well as other 
solvates [97, 120-123]. The molecule structure of CBZ is shown in Fig. 2.7. CBZ is 
classified as a class II drug, with the properties of low water solubility and high 
permeability, in the BCS. Solubility of CBZ has been studied by many researchers [99, 
124-127]. Improving its solubility or dissolution rate can enhance the bioavailability of 
CBZ. Since CBZ has been discovered, large amount of research has been done on the 
formation, morphology, transformation, solubility and dissolution behavior of CBZ 
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aimed to improve the bioavailability of it.  
NH2
 
Fig. 2.7 Molecular structure of CBZ   
At the beginning of this study, three candidate model drugs were valuated, which are 
indomethacin, ibuprofen, and CBZ. Indomethacin [1- (4-chlorobenzoyl) -5-methoxy-2-
methyl-1H-indole-3-acetic  acid] is  a  BCS  class  II  drug  with anti-inflammatory,  
antipyretic  and  analgesic  properties. Indomethacin exists in polymorphic forms   and 
 , and the latter of which is thermodynamically stable at room temperature and is 
practically insoluble in water. The  poor  solubility  of  indomethacin  is  claimed  to  be  
responsible  for  its  low  and  erratic  oral  bioavailability.  Ibuprofen, (RS) -2- (4-(2-
methylpropyl) phenyl) propanoic acid, is a non-steroidal anti-inflammatory drug. It is 
used for the relief of arthritis, fever, as an analgesic, and additionally it possesses an 
antiplatelet effect. Ibuprofen  is  only  very  slightly  soluble  in  water,  less  than  1  mg 
of ibuprofen dissolves in 1 mL water. In  fact,  indomethacin and ibuprofen  has  been  
classic model  compounds  for  demonstrating  the  ability  of  cocrystallisation method 
to improve solubility and dissolution rate. Some research about cocrystallisation of 
indomethacin and ibuprofen has been reported [7, 22, 41, 48, 70]. So, at the beginning 
of this study, indomethacin and ibuprofen were also selected as candidate model drugs. 
But the preliminary UV imaging dissolution test of indomethacin and ibuprofen 
demonstrate that these two drugs are not suitable for UV imaging dissolution method. 
Indomethacin has an extraordinary slow dissolution rate which cannot be detected by 
UV imaging system after hours of dissolution. For ibuprofen, its compressibility is not 
suitable for UV imaging dissolution system. A firm ibuprofen sample compacts cannot 
be prepared. Ibuprofen solid sample will flow away under the dissolution flow medium 
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in few minutes after a sample compacts loading into the dissolution cell. Only CBZ 
exhibit a proper dissolution rate under the UV imaging dissolution test system. Finally, 
CBZ was selected as the only model drug for cocrystal preparation and dissolution 
study. 
2.4.2 CBZ cocrystal studies 
Recent years, pharmaceutical cocrystal emerges as a potential approach to enhance the 
solubility of poorly soluble drug, which has been applied to improve the CBZ solubility. 
About forty coformers have been reported in the literature can form cocrystals with 
CBZ, which have been summarized in Table 2.1. Quantitative research has been carried 
out on the formation, properties and bioavailability of CBZ cocrystals. As the result, 
many useful results have been obtained and these are selectively indicated as followings. 
Table 2. 1 Examples of CBZ cocrystals reported in the literature 
CBZ cocrystals referrences 
1:1 CBZ-acetone, 1:1 CBZ-DMSO,  2:1CBZ-
terephthalaldehyde, 1:1 CBZ-acetic acid , 1:1  CBZ-butyric 
acid , 2:1CBZ- adamantane-1,3,5,7-tetracarboxylic acid, 
1:1 CBZ-formamide  
Fleischman[73] 
1:1 CBZ-nicotinamide (NIC) Weyna, Chieng et al. [37, 49, 73, 128-130] 
2:1CBZ-benzoquinone Weyna, Fleischman[37, 73] McMahon[131] 
1:1 CBZ-saccharin, Weyna, Fleischman et al. [37, 73, 132]   
1:1 CBZ-trimesic acid, 1:1 CBZ-5-nitroisophthalic acid Fleischman, McMahon [73, 131]  
2:1 CBZ-4,4’-bipyridine, 1:1 CBZ-cinnamic acid, 2:1 CBZ-
4-aminobenzoic acid,1:1CBZ-2,6-pyridinedicarboxylic acid 
Weyna, McMahon [37, 131] 
2:1 CBZ-succinic, 1:1 CBZ-benzoic, 1:1CBZ-ketoglutaric 
acid, 2:1 CBZ-maleic acid, 2:1 CBZ-glutaric acid, 2:1 
CBZ-malonic acid, 2:1 CBZ-oxalic, 2:1 CBZ-adipic acid, 
1:1 CBZ-camphoric acid, 1:1 CBZ-4-hydroxybenzoic acid, 
1:1 CBZ-salicylic acid, 1:1 CBZ-1-Hydroxy-2-naphthoic, 
1:1CBZ-DL-Tartaric, 1:1CBZ-L-Tartaric, CBZ-glycolic, 
CBZ-fumaric acid, CBZ-DL-malic acid, CBZ-L-malic acid 
Childs[46] 
1:1 CBZ-2,2,2-Trifluoroethanol Lohani[133] 
2:1 CBZ-furfural Johnston[134] 
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1:1 CBZ-aspirin (acetylsalicylic acid) Vishweshwar, McMahon et al.  [37, 131, 135]  
2:1 CBZ-terephthalaldehyde,  Weyna[37] 
1:1 CBZ-isonicotinamide Habgood[44] 
2.4.2.1 CBZ cocrystals preparation strategies  
Researchers have summarized that, generally, there are two strategies have been 
adopted for CBZ cocrystallisation: one strategy is to employ the peripheral hydrogen 
bonding capabilities that are not engaged in the pure form of CBZ; the second strategy 
involves breakage of the CBZ amide-amide dimer and formation of a supramolecular 
heterosynthon between CBZ and coformer [73]. The two strategies explain the 
formation of CBZ cocrystals on the molecular level. Both the two CBZ cocrystallisation 
strategies were employed by McMahon to prepare CBZ cocrystal with properly selected 
coformers [131], to exploit the hydrogen bonding capabilities of the primary amide 
moiety found in CBZ.  
2.4.2.2 CBZ cocrystals preparation methods and kinetics 
So far, lots CBZ cocrystals have been obtained by different preparation methods. In 
Childs’ study [46], four different screening techniques were used to form CBZ 
cocrystals containing pharmaceutically acceptable carboxylic acids. Tween-seven 
unique solid phases utilizing eighteen carboxylic acid coformers were generated. This 
study demonstrated that CBZ cocrystals can be formed in aqueous media and the 
coformer solution concentration and solubility are important factors for the formation 
and stability of CBZ cocrystals. The CBZ-NIC cocrystal was chosen as a model system 
to study the reaction cocrystallization pathways and kinetics in aqueous and organic 
solvents by Rodríguez-Hornedo[49]. Another example focused on solvent drop grinding 
as a method for CBZ cocrystallisation [37], and results revealed that eight CBZ  
cocrystals that were grown from solution can also be prepared by solvent drop grinding 
method. Recently, Di Profio’s research group has prepared CBZ-saccharin cocrystals by 
using a new membrane-based technology [136]. Some research work has been carried 
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out to study on the CBZ cocrystal formation kinetics. Seefeldt investigated the 
cocrystallization pathways and kinetics of carbamazepine and NIC from amorphous 
equimolar phases [128]. The formation kinetics of CBZ-NIC cocrystal prepared by neat 
grinding with different initial polymorphic forms of CBZ (form I, III and dihydrate) 
were studied by Chieng et al.[129].  
2.4.2.3 CBZ cocrystals properties studies 
The stability of CBZ-NIC cocrystal prepared by neat grinding with different initial 
polymorphic forms of CBZ (form I, III and dihydrate) were studied by Chieng et 
al.[129]. CBZ-NIC cocrystals were stored under certain conditions with different 
temperatures and relative humidity for up to 28 days. Results showed that the CBZ-NIC 
cocrystal is stable when stored under elevated temperature and humidity conditions. 
Water molecules appear to have a significant effect on the stability of CBZ-NIC 
cocrystals: high humidity promotes cocrystal formation and stability during storage. 
CBZ cocrystal has been compared with marketed products in Hickey’s study [132]. The 
preparation of 1:1 cocrystal of CBZ-saccharin was achieved on a 30 g scale with a 
conventional cooling crystallisation process from alcohol solution without seeding. The 
study illustrates the utility of a cocrystal as a type of material that is suitable for drug 
development. The benefits of using the CBZ-saccharin cocrystal include (1) relative 
lack of polymorphism and equivalent chemical stability to the anhydrous polymorph, (2) 
favourable dissolution properties and suspension stability, and (3) comparable oral 
absorption profile in dogs compared with the commercial immediate release product. 
Efforts have been made by Rodríguez-Hornedo’s research group on studying the 
solubility and dissolution of CBZ cocrystals [84-86, 89-91, 137]. One of Rodríguez-
Hornedo’s research estimated the aqueous solubility for seven CBZ cocrystals [84], 
which was estimated to be 2-152 times greater than the solubility of the stable 
carbamazepine dihydrate form. Cocrystal solubility is shown to be directly proportional 
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to the solubility of constituent reactants for CBZ cocrystals. Another work by 
Rodríguez-Hornedo developed a mathematical model that can be applied to describe the 
solubility of CBZ-NIC cocrystal in organic solvents [137]. Two CBZ cocrystals, 1:1 
CBZ-salicylic acid (CBZ-SLC) cocrystal and 2:1 CBZ-4-aminobenzoic acid 
monohydrate (CBZ-4ABA-HYD) cocrystal, were prepared and used as model to study 
how ionization properties of cocrystal components modify the solubility-pH dependence 
of cocrystals [85]. Rodríguez-Hornedo’s research group has also studied how to 
engineer cocrystal solubility, thermodynamic stability, pHmax, and eutectic points by 
micellar solubilization using CBZ cocrystal sampels [89-91]. 
Limwikrant et al. characterized the CBZ-malonic acid (MA) cocrystal phases yielded 
via two different cogrinding methods and investigated the formation mechanism of any 
new polymorphs identified [138]. Two polymorphs of CBZ-NIC cocrystals and two 
polymorphs of   CBZ-saccharin cocrystals were prepared and characterized by Adam J. 
Matzger [65]. These results are notable because CBZ-NIC and CBZ-saccharin are 
among the most widely studied pharmaceutical cocrystals. 
2.4.2.4 CBZ cocrystals future research 
As a typical BCS II drug, CBZ has been widely studied on cocrystallisation with the 
purpose to improving CBZ solubility. However, most of these research focused on new 
cocrystal screening and formation. Not so much research has been done on its 
dissolution and solubility studies.The final target of phamarceutical cocrystallization is 
to improve the bioavailbility, which need a throughly and better understanging of the 
dissolution and solutility properties of formed cocrystals. In this study, a new 
dissolution testing technique of UV imaging surface dissolution system was adopted to 
study CBZ cocrystals dissotluion and solubiltiy behaviour. Solution mediated phase 
transformation on CBZ cocrystals in solvent was studied. Investigation of the effects of 
surfactants on stablizing CBZ cocrystals has been done. CBZ cocrystals dissoltuion in 
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biomedia was carried out to study the relation of cocrystla dissoltuion in vitro and in 
vivo. All these reserarch has been performed around one purpose: to give a better 
understanding of pharmaceutical cocrystals dissoltuion and solubiltiy behaviour. 
2.5 Introduction of pharmaceutical cocrystal coformers: nicotinamide and 
succinic acid  
At the begging of this study, several coformers were screened to make cocrystal with 
the model drug of CBZ. Among these coformers, NIC is the most widely study 
coformer to cocrystallize with CBZ. Large amounts of research has been reported about 
CBZ-NIC cocrystal. For  cocrystal dissoluiton testing by the UV imaging dissolution 
system method, it has one requirement that the API should have special UV absorbption 
wavelength, at which the coformer does not have aborption. As CBZ cocrystal coformer, 
NIC can meet this requirement for UV imaging method. We choose NIC as our first 
coformer. The second coformer, SUC acid, it represents a group of coformers: 
dicarboxylic acid coformer group. Dicarboxylic acid has make up the majority of CBZ 
cocrystal coformers. SUC is one of the dicarboxylic acid coformer which can meet the 
UV absorption requirement for UV imaging dissolution system method.  
NIC (pyridine-3-carboxamide) is the amide of nicotinic acid (vitamin B3). NIC is a 
water soluble vitamin and is part of the vitamin B group. It has four known polymorphs, 
I-IV, with the room temperature stable phase I melting at 129.5 °C. The molecular 
stucture for NIC is shown in Fig. 2.8.  The amide group in NIC is the most useful 
function group to form cocrystal through hydrogen bond [29]. NIC has been widely 
used  in cocrystal formation,  many NIC cocrystals have been reported, such as 1:1 
trans-cinnamic acid-NIC cocrystal [139], 1:1 celecoxib-NIC cocrystal [140], ibuprofen-
NIC cocrsytal [141],  1:1 theophylline-NIC cocrystal [17], 1:1 acetazolamide-NIC 
cocrystal [113]. And NIC has also been used as coformer to cocrystallize with CBZ, the 
most commonly reported drug  to form cocrystal [37, 49, 73, 128-130]. 






Fig. 2.8 Molecular structures of NIC and SUC 
SUC (butanedioic acid) is a diprotic, dicarboxylic acid with structural formula HOOC-
(CH2)2-COOH, shown in Fig.2.8. It is a white, odorless solid, melting at 184°C. 
Carboxylic acids have been investigated as cocrystal formers most extensively [29], 
which is attributable to that the carboxylic functional groups can serve as both hydrogen 
bond donor and acceptor to facilitate cocrystal formation. SUC as a dicarboxylic acid is 
one of the most common pharmaceutically acceptable cocrystal formers used in 
pharmaceutical cocrystals. Many SUC cocrystals have been sucessfully prepared, such 
as  2:1 piroxicam-SUC cocrystal [142], 2:1 meloxicam-SUC cocrystal [57], 2;1 CBZ-
SUC cocrystal [46]. 
2.6 Definitions of basics of pharmaceutical physical chemistry [143] 
Solution 
A solution can be defined as a mixture of two or more components that form a single 
phase, which is homogeneous down to the molecular level. The two components are 
solvent and solute. Solvent determines the phase of the solution and usually constitutes 
the largest proportion of the system.  Solutes are the components dispersed as molecules 
or ions throughout the solvent. Usually, the solutes are said to be dissolved in the 
solvent. 
Solubility 
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The extent to which the dissolution proceeds under a given set of experimental 
conditions is referred to as the solubility of the solute in the solvent. Thus, the solubility 
of a substance is the amount of solute that passes into solution when equilibrium is 
established between the solution and excess substance (undissolved solute solid). 
Type of solution 
Solutions may be classified based on the physical phase of the solutes and solvent. 
Solutions studied in pharmaceutical research area all have liquid solvents. And, the 
solutes are predominantly in solid phase. Solutions talked about in this study are made 
with solid solutes in liquid solvents. 
Ideal solutions and real solutions 
Ideal solution is a solution with thermodynamic properties analogous to those of a 
mixture of ideal gases. The vapour pressure of the solution obeys Raoult’s law, and the 
activity coefficient (which measures deviation from ideality) of each component is 
equal to one. Vapour pressure is referred to the pressure exerted by the vapour at 
equilibrium between the vaporous and liquid phases. Raoult’s law states that the partial 
vapour pressure exerted by a volatile component in a solution at a given temperature is 
equal to the vapour pressure of the pure component at the same temperature. The 
majority of real solutions do not exhibit ideal behaviour, because the forces of 
interactions between the solute -solute, solute-solvent, and solute-solvent are unequal. 
These inequalities change the effective concentration of solute and solvent, and 
consequently, deviations from Raoult’s law are exhibited by real solutions. 
Ionization of solutes 
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Solutes have the ability to dissociate into ions when the dielectric constant of solvent is 
high enough to cause sufficient separation of the attractive force between the oppositely 
charged ions. The dissociation of water can be represented as, 
                                                   
                                                (Equ. 2-25) 
In order to measure the concentration of    in solutions, the concept of pH was 
introduced. pH is defined as, 
                                                         [ 
 ]                                         (Equ. 2-26) 
pH has important implications in pharmaceutical science. 
Many drugs are weak acids or weak bases. For these drugs, equilibria exist between 
undissociated drug molecules and their ions in solutions. For a weak acid drug HA the 
equilibrium may be represented as, 
                                                                                                     (Equ. 2-27) 
For a weak basic drug B, the equilibrium may be represented as, 
                                                                                                     (Equ. 2-28) 
The ionization constant    for weak acid is defined as following equation, 
                                                   
[  ][  ]
[  ]
                                                 (Equ. 2-29) 
The symbol pKa is introduced to represent the negative logarithm of the acid 
dissociation constant Ka and equation 2-29 is rewritten as  
                   
[  ][  ]
[  ]
         
[  ]
[  ]
         
  
  
  (Equ. 2-30) 
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   and    represent the concentrations of the unionized and ionized species respectively. 
This equation is named as the Henderson-Hasselbalch equation. 
For weak base with one ionisable group, the Henderson-Hasselbalch equation can be 
obtained through the same derivation process, shown below 
                                                            
  
  
                                (Equ. 2-31) 
where    and    represent the concentrations of the protonated and unionized species in 
the solution. pKa values of drugs are very useful data to reflect the ionization behaviour 
of drugs, a series of important drugs’ pKa values can be found in pharmaceutical 
handbook. 
Kinetics of drug release 
The kinetics of drug release have been widely studied. Many mathematical models and 
theories have been established aimed to give better understanding about the drug release 
process. Among these theories, diffusion is the principal release mechanism, which has 
been thoroughly studied. The diffusion controlled mathematical model of drug release is 
based on Higuchi model. Higuchi published a mathematical model on 1961 which can 
be used to illustrate drug release from diffusion-controlled systems[144]. He analysed 
the kinetics of release from an ointment assuming that the drug is homogeneously 
dispersed in the planar matrix and the medium into which it is released acts as a perfect 
sink under pseudo steady-state conditions. Higuchi derived following equation for the 
cumulative amount q(t) of drug released at time t: 
                                                   
 ( )
  
  √                                              (Equ. 2-32) 
where    is the cumulative amount of drug released at infinite time and K is a 
composite constant.  
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Noyes-Whitney equation describing the dissolution process 
In 1897, Noyes and Whitney published mathematical model which provide a better way 
to understand the drug dissolution process [145]. The classic Noyes-Whitney equation 
described that the solid substance dissolution rate would be affected by its solution 
concentration, the equation is shown below: 
                                                     
  
  
  (     )                             (Equ. 2-33) 
where dM/dt is the dissolution rate; dM is the amount of drug dissolved in unit time t; 
k is dissolution rate constant;  Cs is the solubility of the drug; Ci is the concentration of 
the dissolved drug. 
Basics of drug molecule design[146] 
Drug design, or rational drug design, is the inventive process of finding new 
medications based on the knowledge of biological target. The drug is usually an organic 
small molecule which activates or inhibits the function of a biomolecule such as a 
protein, which in turn results in therapeutic benefit to patients. The aims of drug design 
are to improve drug pharmacokinetic properties, to optimise chemical and metabolic 
stability, to optimise hydrophilic-hydrophobic balance. Drugs must have both 
hydrophilic and hydrophobic (lipophilic) characteristics. The hydrophilic characteristic 
of drug make it soluble in aqueous conditions, the hydrophobic characteristic facilitate 
the drug to permeate cross cell membranes. Usually, the larger alkyl group in drugs 
increase its hydrophobicity; the polar group increase its hydrophilic property. The 
hydrophilic and hydrophobic properties of drugs can be adjusted by removing or 
involving target function groups. A proper hydrophilic-hydrophobic balance help drug 
reach the desired therapeutic efficacy. 
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Biopharmaceutics classification system  
The biopharmaceutics classification system (BCS) is a system to differentiate drugs on 
the basis of their solubility and permeability. According to the BCS, drug substances are 
classified into four classes based on their aqueous solubility and permeability membrane 
properties, shown in Fig. 2.9. 
 
Fig. 2. 9 Biopharmaceutics classification system (BCS) 
For BCS II and BCS IV drugs, the solubility enhancement can improve its oral 
bioavailability. Especially for BCS II drugs, which have low solubility and high 
permeability, solubility enhancement is an important strategy to improve the oral 
bioavailability. The model drug studied in this work, carbamazepine (CBZ), is a BCS II 
drug. 
Therapeutic range profile 
Therapeutic range refers to either the dosage range or blood plasma or serum 
concentration which can treat disease effectively while staying within the safety range. 
Fig. 2.10 shows a normal therapeutic range profile. From the figure, it can be seen 
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higher efficacy and very lower toxicity or adverse effects. Therapeutic range is an 
important parameter for medicine dosage development. 
 
Fig.2. 10 Therapeutic range profile [147] 
Polymorphism and transformation 
In material sciences, polymorphism is a solid crystalline phenomenon of a given 
compound resulting from the ability of at least two different crystal structures of the 
molecules of that compound in the solid state. There are two types of polymorphism, 
monotropic and enantiotropic system. For a monotropic system, any transition between 
different polymorph is irreversible. For an enantiotropic system, it may be possible to 
convert reversibly between the two polymorphs on heating and cooling or through 
physical contact with a lower energy polymorph. For the model drug in this study CBZ, 
four polymorphs have been reported, CBZ form I to IV [148]. Among these polymorphs, 
CBZ form III is most stable form at room temperature and used in the marketed tablets 
products. CBZ III can transform to CBZ I through heating. 
Polymorphism is very important in drug and commercial product development in the 
pharmaceutical industry due to the properties of formulated pharmaceutical products 
such as bioavailability and stability are often directly related with the physicochemical 
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and mechanical properties of the existing polymorphs in the formulation. In 
pharmaceutical industry, many drugs are under the regulatory approval for only a single 
crystal form or polymorph.  
Phase diagram 
Phase diagram is a chart used to show conditions at which thermodynamically distinct 
phases can occur at equilibrium. Lines in a phase diagram represents equilibrium or 
phase boundaries, which refer to lines that mark conditions under which multiple phases 
can coexist at equilibrium. Phase transition occurs along line of equilibrium. 
Cocrystal system can be described by an isothermal ternary phase diagram. Typical 
phase diagrams for a 1:1 cocrystal are shown in Fig. 2.11. These phase diagrams contain 
the following information: three chemical constituents, which are two cocrystal 
components A and B, and the solvent; four phases, which are liquid, crystalline drug, 
coformer and cocrystal. The phases exsit in each region are: 1: solution; 2: A and 
solvent; 3: A and cocrystal; 4: B and solvent; 5: B and cocrystal; 6: cocrystal. The 
intersection points M and N are so called “invariants’’ or “eutectic”. This is an 
isothermal invariant point where two solid phases (component A/B and cocrystal) 
coexist in equilibrium with solution. 
In Fig. 2.11(1), A and B have similar solubilities in solvent and solution 
cocrystallisation with equimolar components will lead to the formation of the 1:1 
cocrystal from solvent evaporation. Cocrystal components A and B have non-equivalent 
solubilities shown in Fig. 2.11(2) and solution cocrystallisation through evaporation of 
an equimolar solution may result in the formation of single component crystal. The 
reaction cocrystallisation  approach has been adopted for this situation, which are 
performed by adding reactant B to a saturated or close to saturated solution of reactant 
A and then the solution becomes supersaturated with respect to cocrystal AB, where 
cocrystallisation proceeds along the route R as shown in Fig. 2.11(2). From descriptions 
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above, cocrystal ternary phase diagram can give instructions on cocrystallisation 
method selection. 
 
Fig.2. 11 Typical cocrystal isothermal ternary phase diagram 
In vitro vs in vivo  
In vitro dissolution studies of drugs means test the dissolution behaviour of drugs in 
test-tubes, flasks, or petri dishes etc. rather than in human or animal bodies. In vivo 
dissolution studies are testing drug dissolution behavior using a living organism. In vivo 
testing is often performed over in vitro because it is better suited for observing the 
overall effects of an experiment on a living subject. But in vitro dissolution studies are 
more widely employed at the beginning of drug development. The in vitro studies 
results can give some instruction for in vivo dissolution studies. The relationships 
between in vitro dissolution and in vivo input rate have been categorized into different 
levels. For novel drug delivery systems and modified release products, the 
establishment of in vitro dissolution and in vivo correlations helps in establishing 
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2.7 Chapter conclusions 
Pharmaceutical cocrystals, which emerge as a potential method for enhancing the 
bioavailability of drugs with low aqueous solubility, have attracted lots researchers’ 
interest. In this chapter, a brief and systematic overview of pharmaceutical cocrystals 
was presented.  
Firstly, concept and several key issues of pharmaceutical cocrystals including cocrystals 
formation theory, design strategies, formation methods, physicochemical properties 
studies, characterisation techniques were individually described. The fundament theory 
about cocrystal design was explained by crystal engineering. The pharmaceutical design 
strategy was illustrated by six steps in the design flowchart. Two main methods were 
introduced for pharmaceutical cocrystals formation, solution method and grinding 
method. Some analytical techniques, IR, Raman spectroscopy, and DSC et al. were 
introduced for physicochemical properties characterisation of cocrystals. 
After the background review about pharmaceutical cocrystals, theoretical development 
on cocrystal solubility study was illustrated in this chapter. Cocrystal solubility and 
thermodynamic stability behaviour can be predicted by eutectic constant. The effects of 
surfactant on stabilizing cocrystal were studied to maintain the solubility advantage of 
pharmaceutical cocrystals. The phenomenon of SMPT happened during cocrystal 
dissolution process was introduced in this part. 
Finally, pharmaceutical cocrystals research on CBZ, a BCS II drug, was reviewed. Two 
strategies for CBZ cocrystal preparation were given. Many reported CBZ cocrystals 
examples were introduced, including its formation strategies, preparation methods and 
kinetics, polymorph studies, properties compared with marketed products, et al. 
Opportunities for further development of CBZ pharmaceutical cocrystals were 
discussed at last.   
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Chapter 3 Materials and Methods 
3.1 Chapter overview 
In this chapter, materials and analytical methods used in this study were introduced. 
Firstly, all materials were given in details, including the name, formula, purity, and 
manufacturer.  
Then, several analytical methods were introduced including IR, DSC, TGA, HPLC, 
light microscopy, UV-Vis spectroscopy, surface tension meter, SEM, UV imaging 
dissolution system, and Raman spectroscopy. These analytical approaches have been 
applied in order to identify the formation of cocrystal and characterise its 
physicochemical properties. FTIR and ATR-FTIR were used to perform qualitative 
analysis of cocrystal structure by providing IR spectrum. Raman spectrometer was 
employed to qualitative characterise cocrystal and quantitative analysis of phase 
transition of samples during dissolution process. DSC and TGA were utilised to do 
thermal analysis of tested samples. Leica microscope and SEM were used to do 
morphology characterisation of solid compacts in dissolution test. HPLC was used to 
measure the solubility. UV-Vis spectrometry was utilised to get the UV absorbance 
spectra of drugs and based on this information to select proper research samples for 
dissolution tests. CAM 200 surface tension meter was used to identify the critical 
micelle concentration of surfactant solutions through measure its surface tension. 
Specially, ActiPix D100 UV imaging dissolution system was utilised in this research to 
study dissolution behaviour. In this chapter, the analytical methods were introduced 
from the aspects of principle of these methods, instrumental models, experimental 
settings and operational procedures. Methods for measurement of cocrystal eutectic 
points and solubilities were also described in this chapter.  
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Finally, all sample preparation works in this thesis were presented. The preparations of 
five dissolution media (pH4.5 acetate buffer (0.06M), pH 1.2 HCl buffer, simulated 
gastric fluid (SGF), pH 6.8 phosphate buffer solution (PBS) and simulated intestinal 
fluid pH 6.8 (SIF)) were given. Different forms of CBZ, CBZ dihydrate (CBZ DH), and 
CBZ form I (CBZ I), were prepared. Two CBZ cocrystals were prepared, which are 1: 1 
carbamazepine - nicotinamide (CBZ-NIC) cocrystal, and 2:1 carbamazepine - succinic 
acid (CBZ-SUC) cocrystal.  
3.2 Materials 
All materials were used as received, no further process on it. 
Table 3.1 Raw materials for experiment 
Materials Formula Purity/grade Manufacturer 
carbamazepine 
form III 
C15H12N2O ≥99.0% Sigma-Aldrich Company Ltd., Dorset, UK 
nicotinamide  C6H6N2O ≥99.5% Sigma-Aldrich Company Ltd., Dorset, UK 
succinic acid C4H6O4 ≥99.0% Sigma-Aldrich Company Ltd., Dorset, UK 
ethyl acetate  C4H8O2 >99% Fisher Scientific, Loughborough, UK 
ethanol  CH3CH2OH >99% Fisher Scientific, Loughborough, UK 
sodium acetate  C2H3NaO2 99% Sigma-Aldrich Company Ltd., Dorset, UK 
acetic acid  C2H4O2 ≥99.7% Sigma-Aldrich Company Ltd., Dorset, UK 
potassium bromide  KBr 
≥99% purity, for 
spectroscopy IR 
grade 
Fisher Scientific, Loughborough, UK 
double distilled 
water 
H2O double distilled 
Lab made by Bi-Distiller (WSC044.MH3.7, 
Fistreem International Limited, 
Loughborough, UK) 
Tween 80 C64H124O26 ≥99.0% Fisher Scientific, Loughborough, UK 
sodium lauryl 
sulfate  
NaC12H25SO4 >99% Fisher Scientific, Loughborough, UK 
methanol  CH3OH HPLC grade Fisher Scientific, Loughborough, UK 
sodium chloride NaCl ≥99.5% Sigma-Aldrich Company Ltd., Dorset, UK 






KH2PO4 ≥99.0%  Sigma-Aldrich Company Ltd., Dorset, UK 
sodium hydroxide  NaOH 0.2M Fisher Scientific, Loughborough, UK 
hydrochloric acid  HCl 0.2M Fisher Scientific, Loughborough, UK 
hydrochloric acid   HCl 1M Fisher Scientific, Loughborough, UK 
pepsin powder - 
general purpose 
grade 
Fisher Scientific, Loughborough, UK 
pancreatin powder - for biochemistry Fisher Scientific, Loughborough, UK 
0.45 μm nylon 
syringe filter 
- - 
Thermo Scientific Nalgene, Rochester, NY, 
USA 
3.3 Methods 
3.3.1 ActiPix SDI 300 UV imaging dissolution system 
3.3.1.1 Introduction to UV imaging dissolution system 
Traditional dissolution testing determines drug release to the bulk, but does not enable 
an understanding of the events happening close to the surface of a solid or a tablet. UV 
imaging is a new imaging approach that can be used to study the dissolution behavior of 
chemical compounds. UV imaging instrumentation offers recording of absorbance maps 
with a high spatial and temporal resolution which facilitates the abundant collection of 
information regarding the evolving solution concentrations [150]. A lot of researches 
have been carried out to develop the utility of SDI 300UV imaging dissolutions system, 
many accomplishments have been obtained [151-153].  
An ActiPix SDI 300 UV surface imaging system (Paraytec Ltd., York, UK) was used to 
study the dissolution behaviour in this work. The system is shown in the photograph in 
Fig. 3.1. ActiPix SDI 300 UV surface imaging system is a new technology that has been 
designed to improve our understanding of the kinetics and mechanism of drug substance 
release into dissolution medium. It has the ability to offer a better handle on oral dosage 
drug product development by looking directly at the solid-liquid interface during the 
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dissolution process. The fundamental theory for the design and development of UV 
imaging dissolution system relies on the fact that most pharmaceutical drug substances 
contain a UV chromophore, and that UV absorbance is a sensitive and robust 
measurement approach. The use of an imaging detector of UV surface imaging system 
can record a 2D UV movie of the dissolution process at the surface of a drug. With 
spatially resolved absorbance and thus concentration data, UV imaging system can give 
information on the concentration gradient and how it changes with experimental 
conditions. 
 
Fig. 3.1 Photo of ActiPix SDI 300 UV surface imaging dissolution system 
The ActiPix SDI 300 UV surface imaging system comprises a sample flow cell, syringe 
pump, temperature control unit, UV lamp and detector, and control and data analysis 
system [150, 152-155]. The schematic of ActiPix SDI 300 UV imaging system is shown 
in Fig. 3.2. The syringe pump is used for infusion of the dissolution medium which 
passes through the temperature control unit to the channel flow cell in which the 
dissolution process occurs. The main parts of flow cell cartridge are a Quartz cell 
(63mm4mm7mm (LWH)) and a plastic sample holder. Before a dissolution test 
starts, the sample compact is loaded on the sample holder and then inserted into the 
Quartz cell. The UV light source of SDI 300 UV imager is a pulsed Xenon lamp with a 
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replaceable wavelength filter. The detection area is a 9 mm7 mm (12801024 pixels) 
complementary metal oxide semiconductor (CMOS) image sensor for recording light 
transmission through the flow cell.  
 
Fig. 3.2 Schematic of ActiPix SDI 300 dissolution system showing temperature controller, sample holder, 
dissolution flow cell, and UV imaging detector array 
Real time UV image of absorbance map of tested sample during dissolution in flow cell 
can provided by UV imaging dissolution system, one UV image sample is shown in Fig.  
3.3. In this image, the area in blue colour shows the background (pure buffer) 
absorbance and tense light colour indicates high absorbance at the lower right corner. 
The test sample was located at the bottom centre of image and the contours depict lines 
with the same absorbance. The absorbance map indicates the spatial concentration 
distribution of the dissolved sample in the flow cell at the recording time, which was 
affected by the flow rate and diffusion coefficient of target compound. In order to 
determine the rate of dissolution from the UV dissolution images recorded, an IDR of 
each image is calculated from the flow rate, absorbance intensities in the measurement 
zone, surface area of the compact and molecular weight and extinction coefficient of the 
drug. 
Digital temperature controller Syringe pump 
Focusinglens 
Single wavelength filter  
Sample surfaces 
Waste outlet 










Fig. 3.3  UV image by SDI 300 UV imaging dissolution system 
The build in software of UV imaging dissolution system can calculate and provide 
results of intrinsic dissolution rate (IDR) of tested samples based on following equations 
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where    = velocity at z; M = molecular weight;    = concentration at z; W = width of 
flow cell, see Fig. 3.4;    = effective pixel height; S = surface area of sample; H = 
height of low cell in observation region; Q = volume flow rate. Equ.3-1 and 3-2 are the 
equations used to combine molecular absorbance with the profile of fluid velocity. In 
summary, taken what is known about the molecule (molecular weight, extinction 
coefficient) and applied to absorbance data to arrive at a mass. This is the mass that 
passes through a measurement slit (  ) at a given velocity (  ), which is orthogonal to 
the solid surface. An integration of all the measurement slits divided by the exposed 








Medium flow direction  




Fig. 3.4 Flow cell used in UV imaging system 
3.3.1.2 Operation of UV imaging dissolution system 
Filter selection for UV imaging system 
Before dissolution testing, one proper UV filter should be selected for UV imaging 
dissolution system. The requirement for filter is that our target compound (CBZ) has 
obviously absorbance under the wavenumber of selected UV filter, while other 
components are not sensitive to this wavenumber. UV absorbance spectra of CBZ, NIC, 
and SUC were obtained and used for selection of an appropriate filter for UV imaging 
dissolution tests. 
The UV spectra of CBZ, NIC, and SUC are shown in Fig. 3.5. CBZ has significant 
absorbance at 300 nm, while the SUC and NIC have no absorbance at this wavelength. 
This means the amount of CBZ in the mixture of CBZ and NIC or SUC can be 
quantitative analyzed by UV imaging dissolution system equipped with a 300 nm UV 
filter without disturbance of NIC or SUC. So, a UV filter with wavelength of 300 nm 











Fig. 3.5 UV spectra of CBZ, NIC, and SUC 
UV imaging calibration 
UV imaging calibration was performed by imaging a series of CBZ standard solutions 
in the test buffers with a series of different concentrations. The standard solutions were 
infused one by one from lower to higher concentrations, each of which was infused for 
several minutes at a flow rate of 1 mL/min. Buffer was infused before and after the 
series of standard solutions for several minutes in order to detect a baseline drift. The 
absorbance for each standard solution in each image was calculated by the average of a 
fixed absorbance area (width: from 2.1-7.0 mm; height: 1.0-2.5 mm) located in the 
centre of the viewing area. Experiments were repeated three times for construction of a 
UV calibration curve.  Six calibrations were carried out in this study for CBZ tested by 
UV imaging in different buffers. 
(1) Calibration in acetate buffer 
UV imaging calibration was performed by imaging a series of CBZ standard solutions 
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by averaging time dependent absorbance profiles over the three calibration experiments. 
Because the absorption for 3.17×10
-1
 mM and 4.23×10
-1
 mM solutions have deviation 
from linearity, the five lowest concentrations were used to construct a CBZ calibration 
curve shown in Fig. 3.6. Calibration equation and molecular absorbance coefficient 
were shown in Table 3.2. The calibration curve was validated with a series of standard 
solutions with known concentrations, validation result was also shown in Table 3.2. 
 
Fig. 3.6 UV imaging calibration curve: CBZ in pH 4.5 acetate buffer at 37 C 
(2) Calibration in water 
UV imaging calibration was performed at 25 C by imaging a series of CBZ standard 











 mM, and 2.54×10
-1
 mM. Calibration curve is shown in 
Fig. 3.7.  
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Calibration equation and molecular absorbance coefficient were shown in Table 3.2. 
The calibration curve was validated by a series of CBZ standard solutions in different 
surfactant concentration solutions, validation results shown in Table 3.2. The results 
show that SLS and Tween 80 did not affect the accuracy of the model and the 
calibration curve was applicable for the dissolution test with surfactant solutions.  
(3) Calibration in four biomedia 
UV imaging calibration was performed by imaging a series of CBZ standard solutions 
in four biomedia, including SGF, pH 1.2 buffer, pH 6.8 buffer and simulated intestinal 











 mM, and 
3.39×10
-1
 mM. Calibration curves were constructed by plotting absorbance of each 
solution against its concentration, which were shown in Fig. 3.8.  
 
Fig. 3.8 UV imaging calibration curve: CBZ in SGF, pH 1.2 HCL buffer, pH6.8 PBS, and SIF (37C) 
Calibration equations and molecular absorbance coefficients of CBZ in different 
medium were listed in Table 3.2. The calibration curves were validated with standard 
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by UV imaging and the concentrations were calculated based on corresponding 
calibration curve, results shown in Table 3.2. 
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a: CBZ concentration 
b: molecular absorbance coefficient 
c: real concentration of validation standard solutions 
d: measured concentration of validation standard solutions  
e: add10.403 mM SLS in H2O 
f: add 7.634 mM Tween80 in H2O 
Sample compacts preparation 
Before the UV imaging dissolution testing, test sample compacts need to be prepared, 
which was made by filling sample into sample cup (stainless steel cylinder, inner 
diameter: 2mm) and compressed with a set of press tools (shown in Fig. 3.9) which 
including: Quickset MINOR torque screw driver (Torqueleader, M.H.H. engineering Co. 
Ltd., England), pozi screw driver and three press plates. The details for sample compact 
preparation are: Tighten the middle plate to the base plate using pozi screw driver; insert 
one sample cup into the middle plate; insert the sample powder (around 5mg); insert the 
compression rod into the top plate; load the top plate into the middle plate through the 
location holes (the sample will stick to the compression rod); lightly tighten the top 
plate screws; set the scale on the torque wrench (40cNm used in this study); compress 
the sample with setted torque wrench, turn the wrench handle until it ‘click’, leave at 
compressed for 1 min then release the handle; take the sample cup out with pliers.   




Fig. 3.9 UV imaging sample press tools 
Dissolution testing procedures 
When sample compact is ready, dissolution test can start. A dissolution test was 
performed as following:  set up the equipment and fill the system with buffer; program 
the UV imaging test method; drive bubbles out of the cartridge to get a clear imaging 
area; start the test program; after recording a dark image and reference image, pause 
recording and insert a sample compact; fill the Quartz dissolution cell with buffer (1 
mL/min) and make sure no bubbles in the cell or pipe, then start the pump programme 
and resume the UV image recording. Each sample has been tested in triplicate. When 
finish experiment, IDR can be calculated by the build in software through input some 
basic information about the testing, such as the molecular weight of sample, flow rate, 
and the molecular absorbance coefficient obtained through calibration. 
Sample cups 
Torgue wrench 
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3.3.2 Enspectr R532 Raman spectrometry 
3.3.2.1 Introduction to Enspectr R532 Raman spectrometry 
Raman spectroscopy is a spectroscopic technique used to observe vibrational, rotational, 
and other low-frequency modes in a system [156, 157]. It relies on Raman scattering, of 
monochromatic light, usually from a laser in the visible, near infrared, or near 
ultraviolet range. The Raman effect occurs when light impinges upon a molecule and 
interacts with the electron cloud and the bonds of that molecule. For the spontaneous 
Raman effect, which is a form of light scattering, a photon excites the molecule from 
the ground state to a virtual energy state, shown in Fig. 3.10 When the molecule relaxes 
it emits a photon and it returns to a different rotational or vibrational state. The 
difference in energy between the original state and this new state leads to a shift in the 
emitted photon's frequency away from the excitation wavelength. If the final vibrational 
state of the molecule is more energetic than the initial state, the emitted photon will be 
shifted to a lower frequency for the total energy of the system to remain balanced. This 
shift in frequency is designated as a Stokes shift. If the final vibrational state is less 
energetic than the initial state, then the emitted photon will be shifted to a higher 
frequency, and this is designated as an anti-Stokes shift. Raman scattering is an example 
of inelastic scattering because of the energy transfer between the photons and the 
molecules during their interaction. The shift in energy gives information about the 
vibrational modes in the system. Raman spectroscopy is commonly used in chemistry, 
since vibrational information is specific to the chemical bonds and symmetry of 
molecules. Therefore, it provides a fingerprint by which the molecule can be identified. 
A common laboratory instrument that uses this technique is a Raman spectrometer, 
which is used to get the Raman spectrum of test samples. Sample is illuminated with a 
laser beam. Light from the illuminated spot is collected with a lens and sent through a 
monochromator. Wavelengths close to the laser line due to elastic Rayleigh scattering 
are filtered out while the rest of the collected light is dispersed onto a detector. 




Fig. 3. 10 Energy-level diagram showing the states involved in Raman [157] 
EnSpectr R532
®
 Raman spectrometer (Enhanced Spectrometry, Inc., Torrance, USA), 
shown in Fig. 3.11, is used for measuring Raman spectra of liquids, solids, powders, 
and gels. The equipment set consists of a 20-30 mW output power laser source with a 
wavelength of 532 nm, Czerny-Turner spectrometer, scattered light collection and 
analysis system. The instrument is equipped with a low-noise multichannel detector for 
measurement of intensity and spectral parameters of scattered light. A built-in USB 
controller provides the PC connection. The equipment set consists of a single grating 
spectrometer without moving parts connected to a firmly fixed laser assembly. The 
spectral range of the equipment (140-6000 cm
-1
) covers the vibration regions of organic 
and inorganic molecules as well as photoluminescence visible range. It takes one second 
to measure a spectrum of an unknown substance, determine positions and relative 
intensities of Raman and luminescence lines-the fingerprints of a substance under study, 
search and find the matching spectra in the reference database. In this study, EnSpectr 
R532
®
 Raman spectrometer was used to measure Raman spectra and characterize 
samples. 




Fig. 3.11 EnSpectr R532® Raman spectrometer 
3.3.2.2 Operation of Enspectr R532 Raman spectrometry 
Raman spectroscopy qualitative characterisation 
Raman spectra were obtained using an EnSpectr R532
®
 Raman spectrometer. The 
measurements were carried out at room temperature. The integration time was 200 
milliseconds and each spectrum was obtained based on an average of 50 or 100 scans. 
In situ Raman spectroscopy method 
In situ monitoring of solution mediated phase transformations was carried out by the 
same Raman spectrometer as used in Raman spectra characterization, with a special 
sample stage connect to the spectrometer. The experiment set up is shown in Fig. 3.12. 
A test compact was immersed in a small cup with 5mL dissolution medium on an 
adjustable stage at room temperature. The spectrometer was fixed on the top of the stage 
vertically. The cup position can be controlled accurately at both vertical and horizontal 
directions to achieve a higher quality spectrum. The Raman spectra during in situ 
monitoring were automatically collected every 5 minutes for 3 hours controlled by a 
LabVIEW programme. The same integration time and scans were set for each spectrum 
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as those of the off-line measurements. Experiments of in situ Raman monitoring for 
each test sample were performed in triplicate. 
 
Fig. 3.12 Schematic diagram of in situ monitoring of dissolution by EnSpectr R532
@
 Raman spectrometer 
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Fig. 3.13 Raman calibration curve for (a) mixture of CBZ III and CBZ DH; (b) mixture of CBZ-NIC 
cocrystal and CBZ DH 
In order to quantify the percentage of CBZ DH crystallised during the dissolution of 
CBZ III and CBZ-NIC cocrystal, Raman calibration work has been done in the 
following steps. CBZ III and CBZ-NIC cocrystal were blended separately with CBZ 
DH to form binary physical mixtures at 20% (w/w) intervals from 0 to 100% of CBZ 
DH in the test samples. Each sample was prepared in triplicate and measured by Raman 
spectroscopy. Ratios of the characteristic peak intensities were used to construct the 
calibration models (details about characteristic peak were described in Chapter 4). For 
CBZ III and CBZ DH mixture, the ratio of peak intensity at 1040 to 1025 cm
-1
 were 
used to make calibration curve; for CBZ-NIC cocrystal and CBZ DH mixture, the ratio 
of peak intensity at 1035 to 1025 cm
-1
 were used to make calibration curve. Calibration 
curves for CBZ III and CBZ DH mixture, CBZ-NIC cocrystal and CBZ DH mixture 
were obtained and shown in Fig. 3.13. Equations fitted for the calibration cuves were 
shown in Table 3.3. The calibration equations were validated by mixtures with known 
proportions, and the results for validation were shown in Table 3.3. 
Table 3.3 Raman calibration equations and validations 
mixture calib equations 
validation  
   
     
  |   
     
















CBZ DH % 
Raman spectra peak ratio of 1035/1025 for   
CBZ-NIC cocrystal and CBZ DH mixture 
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CBZ III and CBZ DH 
y = -0.0053x + 0.9057 
R² = 0.9894 
70 73 4 
CBZ-NIC cocrystal and CBZ DH 
y = -6E-05x
2
 + 0.0004x + 0.8171 
R² = 0.896 
70 82 17 
y: characteristic peak ratio of 1040/1025 for CBZ III and CBZ DH mixture, and 1035/1025 for  CBZ-NIC 
cocrystal and CBZ DH mixture 
x: percentage of CBZ DH in the mixture  
PDH
r
: real DH percentage 
PDH
m
: measured DH percentage 
3.3.3 Infrared (IR) Spectroscopy  
3.3.3.1 Introduction to IR Spectroscopy[158] 
IR spectroscopy is the spectroscopy of the infrared region of the electromagnetic 
spectrum. Infrared light has a longer wavelength and lower frequency than the visible 
light. The IR spectroscopy technique can be used to identify and qualitative study 
chemical molecules.  
The fundamental theory underpinning IR spectroscopy is that molecules absorb specific 
frequencies which are characteristic of their structures. The frequencies of the absorbed 
radiations match the transition energy of the bonds or groups that vibrates. The energies 
are determined by the structure of the molecular potential energy surfaces, the 
associated vibronic coupling, and the masses of the atoms. The infrared spectra of 
samples can be recorded through passing a beam of infrared light through the samples. 
When the frequency of the IR is the same as the vibrational frequency of a bond, the 
absorption occurs. Determination of the transmitted light gives the quantitative 
information about absorbed energy for each frequency. Alternatively, the whole 
wavelength range is scanned at once using a Fourier transform instrument. Fourier 
transform infrared (FTIR) spectroscopy is a characterisation technique that capable to 
record infrared spectra. Infrared light is passing through an interferometer and then 
through the sample (or the sample first then interferometer). The distribution of infrared 
light that passes through the interferometer is changed by a moving mirror inside the 
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FTIR equipment. The signal directly recorded, named "interferogram", represents light 
output as a function of mirror position. Fourier transform data-processing technique 
transforms the raw data into the desired result (the sample's spectrum): Light output as a 
function of infrared wavelength (or wavenumber).  
3.3.3.2 Operation of IR Spectroscopy 
Two FTIR spectrometer techniques were used in this study, which are Shimadzu FTIR-
8300 (Shimadzu Europa, Milton Keynes, UK) and ALPHA A4 sized Benchtop 
Attenuated total reflectance-fourier transform infrared spectroscopy (ATR-FTIR) 
(Bruker UK Limited).  
Measurement settings for Shimadzu FTIR-8300are: resolution 4 cm
-1
, data range 4000-
400 cm
-1
, and number of runs per spectrum 5, sample was prepared using the KBr pellet 
technique. Sample was prepared according to next procedures: 1) small amount of test 
sample was mixed thoroughly with relative more KBr (three spatulas of sample mixed 
with seven spatulas of KBr) in a mortar while grinding with the pestle; 2) appropriate 
amount of mixed sample and KBr powder was added to cover bottom in IR sample 
pellet die; 3) Place the die in press and press at 5000-10000 psi; 4) carefully remove the 
pressed sample from die and place in the FTIR sample holder and the sample was ready 
for testing. Before testing sample, a reference sample was tested by the FTIR as 
background. 
ALPHA A4 sized Benchtop ATR-FTIR spectrometer was used in later part of this study 
for IR spectra measurement. ATR is the abbreviation of Attenuated total reflectance. It 
is a sampling technique used in conjunction with infrared spectroscopy which enables 
samples to be examined directly in the solid or liquid state without further preparation. 
Measurement settings for ALPHA ATR-FTIR are: resolution 2cm
-1
, data range 4000-
400 cm
-1
. The ALPHA ATR-FTIR spectrometer has a smaller size which occupies the 
footprint of an A4 sheet of paper. ALPHA ATR-FTIR spectrometer equipped with a 
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single-reflection diamond ATR sampling module, which make the sample handling 
greatly simplified. Sample can be tested directly without pre-processing.  
3.3.4 Ultraviolet–visible spectrometry (UV-Vis) 
UV-Vis is the absorption spectroscopy in the ultraviolet-visible electromagnetic spectral 
region. In the UV-Vis electromagnetic spectrum region, chemical molecules undergo 
electronic transitions. Molecules which contain π-electrons or non-bonding electrons 
can absorb the energy in the form of ultraviolet or visible light to excite these electrons 
from the ground state to higher anti-bonding molecular orbitals.  
The apparatus used in ultraviolet-visible spectroscopy technique is called UV-Vis 
spectrophotometer. A UV-Vis spectrophotometer is composed with the following basic 
parts: a light source, a sample holder, a diffraction grating in a monochromator or a 
prism used for separating the different wavelengths of light, and a detector. UV 
spectrophotometer can be employed to measure UV absorbance map of samples through 
scan the sample solutions in a UV wavelength range. And UV-Vis spectrophotometer 
can also be used to do quantitative analysis based on Beer-Lambert Law. The Beer-
Lambert law states that the UV absorbance of a sample solution is directly proportional 
to the concentration of the absorbing species and the path length. Thus, for a fixed path 
length, UV-Vis spectroscopy can be used to measure the concentration of the absorbing 
species in a solution. 
UV-Vis spectrophotometer measures the intensity of light passing through a sample 
solution, and compares it to the intensity of light before it passes through the sample. 
The Beer-Lambert law, shown as following Equ.3-1, 
       (
  
 
)                                  (Equ. 3-1) 
  Chapter 3 
66 
 
where A is the measured absorbance,    is the transmitted intensity at a given 
wavelength,     is the intensity of the incident light, L is the path length through the 
sample solution, and C is the concentration of the absorber. For each species and 
wavelength,   is a constant named as the molar absorptivity or molecular extinction 
coefficient. The value for   can be obtained through calibration curve. For calibration, a 
series of test sample solutions with known concentration are tested by UV-Vis 
spectrophotometer from lower concentration to higher concentration. Calibration curve 
is obtained by plotting the absorbance of each solution versus its concentration. The 
molecular extinction coefficient   can be calculated from the gradient of the linear 
calibration curve. 
In this study, UV spectra of CBZ, NIC and SUC were obtained using a Heλios γ UV–
Vis spectrophotometer (Thermo Electron Corporation, Cambridge, UK). Measurement 
settings for UV–Vis spectrophotometer are: resolution 2 cm
-1
, data range 200 - 400 nm. 
The results were used for filter selection in UV imaging dissolution experiments. 
3.3.5 Differential scanner calorimetry (DSC) 
3.3.5.1 Introduction to DSC[159] 
DSC is a thermoanalytical technique in which the thermal effects of tested samples, 
such as the melting point and enthalpies of phase transitions, can be measured. The 
fundamental theory for the DSC technique is that when the sample undergoes a physical 
transformation such as phase transitions, the amount of heat flow to the sample will 
change compared with the reference which tries to maintain both at the same 
temperature. Whether less or more heat the sample needed depends on whether the 
physical transformation process is exothermic or endothermic. When a sample 
undergoes the endothermic phase transition, like a solid sample melts to a liquid, it will 
require more heat flowing to the sample to increase its temperature at the same rate as 
the reference. On the other hand, when sample undergoes exothermic processes (such as 
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crystallization) less heat is needed to increase its temperature. Through observing the 
difference in heat flow between the sample and reference, DSC equipment is capable to 
measure the amount of heat absorbed or released during such physical phase transitions.  
3.3.5.2 Operation of DSC 
In this study, DSC measurements were conducted for all test samples using a Perkin 
Elmer Jade DSC (PerkinElmer Ltd, Beaconsfield, UK). The Jade DSC was controlled 
by Pyris Software. The temperature and heat flow of the instrument were calibrated 
using an indium and zinc standards. Test samples (8-10 mg) were analysed in crimped 
aluminium pans with pin-hole pierced lids. Measurements were carried out at a heating 
rate of 20C/min under a nitrogen flow rate of 20 mL/min.  
3.3.6 Thermal gravimetric analysis (TGA) 
3.3.6.1 Introduction to TGA[160] 
TGA is a method of thermal analysis in which changes in physical and chemical 
properties of materials are measured as a function of increasing temperature, or as a 
function of time. TGA is commonly used to determine selected characteristics of 
materials that exhibit either mass loss or gain due to decomposition, oxidation, or loss 
of volatiles (such as moisture).  
The basic principle underlying TGA technique is a high degree of precision in three 
measurements: mass change, temperature, and temperature change. Thus, the basic parts 
of TGA apparatus are a precision balance with a pan loaded with the sample, and a 
programmable furnace. The furnace can be programmed in two ways: heating at a 
constant heating rate, or heating to acquire a constant mass loss with time. For a thermal 
gravimetric analysis by TGA apparatus, sample is continuously weighs as it is heated. 
As the temperature increasing, components of the sample are decomposed resulting in 
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the weight percentage of each mass change can be measured and recorded. TGA testing 
results are plotted with mass loss on the Y-axis versus temperature on the X-axis.  
3.3.6.2 Operation of TGA 
In this study, TGA for CBZ DH was run in a Perkin Elmer Pyris 1 TGA (PerkinElmer 
Ltd, Beaconsfield, UK). Weight calibration was performed using standard references of 
alumel and nickel. Samples (8-10 mg) in crucible baskets were used for TGA runs from 
25-190C with a constant heating rate of 20C /min under a nitrogen purge flow rate of 
20 mL/min. The water content of CBZ DH was obtained through TGA testing. 
3.3.7 High performance liquid chromatography (HPLC) 
3.3.7.1 Introduction to HPLC 
HPLC is a chromatographic technique used to separate a mixture of compounds in 
analytical chemistry and biochemistry with the purpose of identifying, quantifying or 
purifying the individual components of the mixture. In HPLC, small volume of analyte 
is injected through a loop in a continuously flowing solution (mobile phase) that passes 
through a column packed with porous stationary phase (usually various surface-
modified versions of silica). While passing through the column these analytes in 
solution are capable of interacting with end groups on the surface of the column. Given 
that different compounds have different affinity to the column content results in 
separation of compounds in the course of chromatography. The separated analytes then 
flow through a detector (usually UV-Vis) and the detector’s readings are treated by 
instruments software and presented as a chromatogram showing the peaks which 
correspond to individual compounds eluted from the column.  The time point that 
corresponds to the peak maximum is referred to the retention time, the area under the 
peak, width, and height of the peak of individual compound in the analyte are used for 
the quantitative analysis. In this study, HPLC technique is one of most important 
  Chapter 3 
69 
 
techniques which has been used in lots quantitative analysis work for cocrystal 
solubility measurement. 
3.3.7.2 Operation of HPLC 
In this study, sample concentrations were analysed by Perkin Elmer series 200 HPLC 
system. A HAISLL 100 C18 column (5µm, 250×4.6mm) (Higgins Analytical, Inc. 
Mountain View, USA) at ambient temperature was used. The mobile phase composed 
of 70% methanol and 30% water, and the flow rate was 1mL/min using an isocratic 
method. Concentration of CBZ, NIC, and SUC has been measured under the 
wavelength of 285, 250, and 210 nm respectively. HPLC calibration has been done for 
the three chemicals; the standard curves were shown in Fig. 3.14. Calibration equations 
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Fig. 3.14 HPLC calibration curve for measurement of (a) CBZ (b) NIC (c) SUC 
HPLC calibration curves were validated by standard solutions of CBZ, NIC and SUC 
with known concentration, run the standard solutions and calculate its concentration 
using calibration curves respectively. The calculated concentrations were compared 
with real concentration, results shown in Table 3.4. 
Table 3.4 HPLC calibration and validation 
test sample calib equations 
validation  
      |      |   % 
CBZ y = 52569x+40920, R² = 0.9996 50 51 2 
NIC y = 24761x-53758, R² = 0.9997 100 97 3 
SUC y= 630.2x-105798, R² = 0.9993 5000 5310 6 
x: in unit of  μg/mL 
  : validation solution real concentration, μg/mL 
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3.3.8 Leica microscope 
Microscope is an apparatus which can be used to observe samples that are too small for 
the naked eye. There are many types of microscopes. The most common type of 
microscope is the optical microscope which uses light to photo the sample. An optical 
microscope equipped with one or more lenses producing an enlarged image of sample. 
Optical microscopes contains refractive glass and occasionally of plastic or quartz, to 
focus light into the eyes or another light detector. The microscope used in this study is 
an optical microscope, LEICA DM 750 microscope. 
LEICA DM 750 microscope equipped a lens of ten-time magnification, infinity 2-1C 
camera and Studio Capture Video microscopy software (version 4; Studio86 Designs, 
Lutterworth, UK) was used in this work to study the morphology of solid samples. All 
sample compacts were analysed prior to and after a UV imaging dissolution test using a 
LEICA DM 750 microscope. 
3.3.9 Scanning electron microscope (SEM)[161] 
SEM is an electron microscope that provides images of a sample through scanning the 
sample with a focused beam of electrons.  Various signals produce as the resulting of 
interaction between electrons emitted by SEM and with atoms at or near the surface of 
the sample. These signals can be detected and provide information about the sample's 
surface topography and composition. The resolution of SEM can be better than one 
nanometer. Sample can be observed under different conditions:  in high vacuum, low 
vacuum and in wet conditions.  
The types of signals by a SEM mentioned in above paragraph include secondary 
electrons, characteristic X-rays, back-scattered electrons, light (cathodoluminescence), 
specimen current and transmitted electrons. In secondary electron imaging, the SEM 
can provide very high-resolution images of a sample surface, resolution less than 1 
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nanometer in size. Back-scattered electrons are beam electrons which are reflected from 
the sample by elastic scattering. Images produced by back-scattered electrons can 
provide information about the distribution of different elements in the sample.    
Characteristic X-rays are occurred as the result of the electron beam removes an inner 
shell electron from the sample, causing a higher-energy electron to fill the shell and 
release energy. The composition and the abundance of elements in samples can be 
determined by characteristic X-rays. 
In this study, SEM micrographs were photographed by a ZEISS EVO HD 15 scanning 
electron microscope (Carl Zeiss NTS Ltd, Cambridge, UK). The test sample was 
mounted with Agar Scientific G3347N carbon adhesive tab on Agar Scientific G301 
5.0"  aluminium specimen stub (Agar Scientific Ltd, Stansted, UK) and photographed at 
a voltage of 10.00KV.  
3.3.10 CAM 200 surface tension meter 
Surface tension is a contractive tendency of the surface of a liquid that allows it to resist 
an external force. Surface tension has the dimension of force per unit length or of 
energy per unit area. In this study, a KSV CAM 200 surface tension meter is used to 
measure the surface tension of surfactant solutions. KSV CAM 200 is a computer 
controlled and user programmable video based instrument designed for the 
measurement of: Surface and Interfacial tension, Static Contact Angles, Dynamic 
Contact Angles, and Surface Free Energy of Solids. The light source of CAM 200 is 
LED based. The LEDs are housed in a reflective sphere which integrates their light and 
directs it towards the sample. The light is strobed and monochromatic. These features 
help to assure a sharp image. CAM 200 uses a Jai CV-M50 monochrome video camera 
module using a CCD solid stage image sensor. The objective lens provided with the 
camera is telecentric with a 55 mm focus length. The result was analyzed by CAM200 
software. 
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The critical micelle concentration (CMC) is defined as the concentration of surfactants 
above which micelles form and all additional surfactants added to the system go to 
micelles. CMC is an important characteristic of a surfactant, which can be determined 
from the break in the curve of surface tension versus log of surfactant concentration. In 
this study, the CMCs of two surfactants, SLS and Tween 80, were determined in 
aqueous solutions in the presence of saturated CBZ as following. A series of above 
surfactant solutions were prepared and the surface tensions of these solutions were 
tested by KSV CAM200 surface tension meter at room temperature. Figure has been 
drawn by plotting surface tensions vs. concentrations. As the concentration of surfactant 
increases, surface tension decreases and finally levels at the minimum value. The point 
where surface tension curve reach its minimum value is described as CMC, shown in 
Fig. 3.15. 
 
Fig. 3.15 Surface tension of a surfactant solution with increasing concentration, formation of micelles[162] 
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3.3.11 Solubility test methods 
3.3.11.1 Equilibrium solubility test 
In this study, all solubility tests were determined using an air-shaking bath method. 
Excess amount of samples were added into a small vial containing certain volume of 
media and vortexes for 20 seconds. The vials were placed in a horizontal air-shaking 
bath at certain temperature at 100 rpm for certain hours. Aliquots were filtered through 
0.45µm filters (Thermo Scientific Nalgene, Rochester, NY, USA) and diluted properly 
for determination of the concentrations of targeted components by HPLC. Solid 
residues were retrieved from the solubility tests and air dried for 30 minutes. All of 
dried solids were characterized by FTIR, Raman and DSC. All solubility tests were 
carried out in triplicate. 
3.3.11.2 Cocrystal eutectic points measurement test 
The solubility of CBZ was measured as a function of the coformers’ concentration in 
order to determine the eutectic point of cocrystal. To measure solubility of CBZ as 
function of coformers’ concentration, known amounts of coformer of increasing 
concentration (initial coformer concentration) were dissolved in 5mL of buffer in screw 
capped vials. Then excess amount of solid CBZ DH was added to each vial. Air-shaking 
bath method was used to measure the solubilities of two components after certain time 
of equilibrium. Solid phases at equilibrium were confirmed by IR, Raman and DSC. All 
tests were carried out in triplicate. 
Through the measurement of CBZ solubility as function of NIC in water at 25°C [84, 86] 
using above method, eutectic point of CBZ-NIC cocrystal in water was determined. 
Then, CBZ-NIC cocrystal eutectic points were measured as a function of SLS or Tween 
80 concentration in water at 25°C, by adding excess CBZ DH in a solution of mixture of 
surfactant and near saturated NIC for 72 hours equilibrium. 
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The solubility of CBZ as function of two coformers (NIC and SUC) in four media (pH 
1.2 HCl buffer, pH 6.8 PBS, SGF, and SIF) was determined respectively using the same 
method above mentioned. The experiments were performed at 37C for 24hours 
equilibrium. 
3.4 Preparations 
3.4.1 Dissolution media preparation 
Five dissolution media were prepared in this work, which are pH4.5 acetate buffer 
(0.06M), pH 1.2 hydrochloric acid buffer (pH 1.2 HCl buffer), simulated gastric fluid 
(SGF), pH 6.8 phosphate buffer solution (PBS) and simulated intestinal fluid pH 6.8 
(SIF). The preparation details for each medium are listed as following 
pH4.5 acetate buffer (0.06M): Dissolve 2.99 g sodium acetate in water, add 14 mL of 2 
M acetic acid ( make up 60.05 g  glacial acetic acid up to 500 mL with water), and 
dilute to 1000 mL with water [163]. 
pH 1.2 HCl buffer: Mix 250.0 mL of 0.2 M sodium chloride (Dissolve 11.69 g of 
sodium chloride in water  and dilute to 1000.0 mL)  and 425 mL of 0.2 M hydrochloric 
acid, and dilute to 1000.0 mL with water [164]. 
SGF: Dissolve 2.0 g of sodium chloride and 3.2 g of pepsin powder in water, add 80 mL 
of 1 M hydrochloric acid and dilute to 1000.0 mL with water [164]. 
pH 6.8 PBS: Mix 250.0 mL of 0.2 M potassium dihydrogen phosphate (KH2PO4) and 
112 mL of 0.2 M sodium hydroxide, and dilute to 1000.0 mL with water [164]. 
SIF: Mix 77.0 mL of 0.2 M sodium hydroxide (NaOH), 250.0 mL of a solution 
containing 6.8 g of potassium dihydrogen phosphate (KH2PO4), and 500 mL of water. 
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Add 10.0 g of pancreas powder, mix and adjust the pH if necessary. Dilute to 1000.0 
mL with water [164]. 
3.4.2 Test samples preparation 
Preparation of Carbamazepine dihydrate (CBZ DH)  
Excess amount of anhydrous CBZ III was added into double distilled water and stirred 
for 48 hours at constant temperature 37C. The suspension was filtered and dried for 30 
minutes on the filter. TGA was used to determine the water content in the isolated solid 
and confirm complete conversion to the hydrate. 
Preparation of Carbamazepine form I (CBZ I) 
CBZ I was prepared by heating CBZ III at 170C in an oven for 2 hours [165]. Raman 
spectroscopy and DSC were used to confirm conversion of CBZ III to CBZ I.  
Preparation of physical mixture of CBZ III and NIC (CBZ-NIC mixture) 
1:1 molar ratio mixture of CBZ III and NIC was prepared by mixing 0.4 mmol CBZ III 
(94.5 mg) and 0.4 mmol NIC (48.8 mg) thoroughly. 
Preparation of CBZ-NIC cocrystal 
CBZ-NIC cocrystal was prepared through an evaporation method. A 1:1 molar ratio 
mixture of CBZ III (94.5 mg, 0.4 mmol) and NIC (48.8 mg, 0.4 mmol) was completely 
dissolved in 20 mL of ethyl acetate in a 50 mL conical flask with aid of stirring and 
slightly heating. The solution was allowed to evaporate in a controlled fume hood (room 
temperature, air flow 0.50-1.0 m/s). When all the solvent evaporated, solid product was 
obtained on the bottom of the flask. The approximate yield was 127.9 mg (89.3%).  
Preparation of physical mixture of CBZ III and SUC (CBZ-SUC mixture) 
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2:1 molar ratio mixture of CBZ III and SUC was prepared by mixing 8 mmol CBZ III 
(1.8962 g) and 4 mmol SUC (0.4722 g) thoroughly. 
Preparation of CBZ-SUC cocrystal 
CBZ-SUC cocrystal was prepared according to the method described in Child’s 
publication [46]. CBZ (8 mmol, 1.8962 g) and SUC (4 mmol, 0.4722 g) were dissolved 
in a mixture of 60 mL ethanol and 30 mL ethyl acetate with 30 minutes of sonication, 
followed by heating to 54 °C for approximately 45 minutes. The resulting clear solution 
was filtered through a 0.2 μm nylon filter into a clean glass jar and the jar was capped. 
White precipitate was observed after several minutes. The solution was allowed to 
evaporate slowly overnight (in fume hood without air flow), followed by fast 
evaporation for 2 days (in fume hood at air flow 0.50-1.0 m/s). The resulting dried 
solids were composed of blades and plates. The approximate yield was 2.2 g (93%). 
3.5 Chapter conclusions 
This chapter introduced all materials, methods, and sample preparation in this study. 
Firstly, all materials used in this study were presented in details，which including the 
name, formula, purity, and producer. Then, research methods including analytical 
techniques and experiments were introduced. A number of different analytical 
approaches have been applied to identify the formation of test samples and characterise 
its physicochemical properties, such as FTIR, ART-FTIR, Raman spectrometry, DSC, 
TGA, SEM et al. ActiPix SDI 300 UV imaging dissolution system, which used in the 
solubility and dissolution behaviour study of cocrystal, have been fully introduced in 
this chapter. Solubility test methods: air-shaking bath method for equilibrium solubility 
test; method for measurement of cocrystal eutectic points and critical micelle 
concentration were given in this chapter. Finally, test samples and dissolution media 
preparation were presented. Five dissolution media were used in this study, which are 
pH4.5 acetate buffer (0.06M), pH 1.2 HCl buffer, SGF, pH 6.8 PBS and SIF. The 
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preparation methods for different CBZ samples (CBZ I, CBZ DH, CBZ-NIC, CBZ-
SUC cocrystals and mixtures) were introduced.   
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Chapter 4 Sample Characterisations 
4.1 Chapter overview 
In this chapter, test samples prepared in this study were characterized, and the 
characterisation results were discussed. Different forms of CBZ samples, CBZ DH, and 
CBZ I, and two CBZ cocrystals, CBZ-NIC cocrystal, and CBZ-SUC cocrystal, were 
characterised. Different characterisation techniques, such as TGA, Raman spectroscopy, 
IR spectroscopy, and DSC were used to characterise these newly formed products. 
Characterisation results were given and discussed. All characterisation results have 
demonstrated the successfully formation of CBZ I, CBZ DH and the two CBZ 
cocrystals. The molecule structures of CBZ-NIC cocrystal, and CBZ-SUC cocrystal 
were also presented in this chapter. 
4.2 Materials and methods 
4.2.1 Materials 
Anhydrous CBZ III, NIC, and SUC, ethyl acetate, ethanol and potassium bromide were 
used in this chapter; details of this material can be found in chapter 3 materials and 
methods.  
4.2.2 Methods 
FTIR, ATR, Raman spectroscopy, DSC, TGA have been applied to do the 
characterisation. FTIR spectra of CBZ III, NIC, CBZ-NIC cocrystal and mixture were 
obtained by a Shimadzu FTIR-8300 spectrometer. IR spectrum of CBZ-SUC cocrystal 
was obtained by an ALPHA A4 sized Benchtop ATR-FTIR spectrometer. Details about 
these techniques can be found in chapter 3 materials and methods.  




4.3.1 TGA analysis of CBZ DH 
 
Fig. 4.1 TGA thermograph of CBZ DH 
TGA thermograph of CBZ DH is shown in Fig. 4.1. According to the three TGA results, 
the average of the water content of CBZ DH is 12.759±0.007% (means, n=3). This 
value is slightly lower than the theoretical stoichiometric water content of 13.2% w/w, 
which may be due to a small portion of water loss inside the TGA equipment at the 
initial temperature under the nitrogen flow. The TGA result demonstrates the formation 
of CBZ DH. 
4.3.2 DSC analysis of test samples 
DSC results of different CBZ forms 
The DSC traces and thermal data for CBZ DH, CBZ I, and CBZ III are presented in Fig.  
4.2, (DSC data shown in Table 4.1). CBZ I had a single melting transition with a peak 
around 195C and CBZ III first melt around 175C, then recrystallized and formed a 
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more stable form, CBZ I, in agreement with reported thermal behaviour [98]. The 
dehydration process of CBZ DH happened during 80-120C. After dehydration process 
under DSC heating conditions, CBZ DH converted back to CBZ III which melted 
around 175C and then recrystallized and formed a more stable form CBZ I, which 
melted around 195C [166].  
 
Fig. 4.2 DSC thermograph of: CBZ DH, CBZ I and CBZ III 
Table 4.1 DSC thermal data for test samples 
Sample Onset (C) Peak(C)   (   ) 
CBZ III 169.45 174.81 10.8492 
190.09 195.12 115.7066 
CBZ I 188.36 194.19 111.127 
CBZ DH 174.11 177.36 10.9556 
190.81 194.96 78.1268 
NIC 120.34 133.07 171.5889 
CBZ-NIC mixture 121.64 127.97 49.4972 
158.08 162.29 97.6472 
CBZ-NIC cocrystal 158.80 163.84 115.6588 
SUC 188.84 196.03 195.0547 
CBZ- SUC mixture 177.46 182.00 16.0541 
184.02 188.66 107.7684 
CBZ- SUC cocrystal 190.54 195.38 134.0538 
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DSC results of CBZ-NIC Cocrystal 
DSC curve patterns of CBZ III, NIC, CBZ-NIC mixture, and CBZ-NIC cocrystal are 
shown in Fig. 4.3, (DSC data shown in Table 4.1). A DSC curve of pure NIC has shown 
an endothermic peak attributed to melting around 129-133C. CBZ-NIC physical 
mixture shows a complex thermal behaviour. An endothermic event around 130C was 
due to melting of NIC, and a major endothermic peak was around 162C resulting from 
the melting of newly formed CBZ-NIC cocrystal under DSC heating. The DSC thermal 
graph for CBZ-NIC cocrystal has shown a single endothermic transition attributed to 
the melting transition with a peak round 163C, which is in the range of between the 
melting points of two individual pure compounds. The thermal behaviour of the CBZ-
NIC cocrystal is distinct with a different melting transition from that of either of the 
individual compounds, suggesting the formation of a new compound, in agreement with 
the reported thermal behaviour of CBZ-NIC cocrystal [73].  
 
Fig. 4.3 DSC thermograph of CBZ-NIC cocrystal 
DSC results of CBZ-SUC cocrystal 
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The DSC thermal graphs of CBZ III, SUC, CBZ-SUC mixture, and CBZ-SUC cocrystal 
are shown in Fig. 4.4 (DSC data shown in Table 4.1). DSC curve of pure SUC has 
shown an endothermic peak attributed to melting around 196 C. CBZ-SUC physical 
mixture has more than one melting peak around 182-188 C due to the coexistence of 
two components. CBZ-SUC cocrystal has a single endothermic peak around 195 C 
attributed to the melting of cocrystal shown in DSC figure. The single melting point 
demonstrates that CBZ-SUC cocrystal is a new prepared pure compound rather than a 
physical mixture of CBZ and SUC.  
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80 100 120 140 160 180 200 220
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Fig. 4.4 DSC thermograph of CBZ-SUC cocrystal 
4.3.3 IR spectroscopy analysis of CBZ-NIC cocrystal and CBZ-SUC cocrystal 
The IR spectra for CBZ III, NIC and CBZ-NIC cocrystal are presented in Fig. 4.5. 
Characteristic peaks are in agreement with spectra reported in the literatures [167, 168]. 
The IR spectrum for CBZ III has peaks at 3465 and 1677 cm-1, corresponding to 
carboxamide N-H and C=O stretch, respectively. The spectrum of NIC has a peak 
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corresponding to  carboxamide N-H stretch at 3364 cm
-1
, double peaks at 1695 and 
1680 cm
-1
 for C=O stretch. The IR spectrum of CBZ-NIC mixture shows both CBZ and  
























Fig. 4.5 IR spectrum of CBZ III, NIC, CBZ-NIC mixture and cocrystal 
NIC, and mixture, which suggesting that both molecules are present in a new phase. The 
carboxamide N-H and C=O stretching frequencies of CBZ were shifted to 3449 and 
1658 cm
-1
 respectively. This suggests that the carboxamide group of CBZ has formed a 
strong hydrogen bond. While, the N-H stretching frequency of NIC shifted to higher 
position at 3390 cm
-1
, C=O stretching peak frequency moved to 1683 cm
-1
. Summary of 
IR peak identities of CBZ, NIC and CBZ-NIC cocrystal is shown in Table 4.2. 
Table 4.2 IR peaks summary of CBZ, NIC and CBZ-NIC cocrystal 
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Compound Peak position (cm
-1
) Assignment 
CBZ III 3465,3338, 3278, 3152 -NH2 
1677 -(C=O)- 
NIC 3364 -NH2 
1695, 1680 -(C=O)- 
CBZ-NIC Cocrystal 3449 -NH2 of CBZ 
3390 -NH2 of NIC 
1683 -(C=O)- of NIC 
1658 -(C=O)- of CBZ 
The ATR-FTIR spectra for CBZ III, SUC, CBZ-SUC mixture and CBZ-SUC cocrystal 
are presented in Fig. 4.6. SUC has following characteristic peaks: two peaks at around 
1651 and 1198 cm
-1
 corresponding to the stretching vibration of carbonyl group; a 
characteristic peak at 1406 cm
-1
 for the hydroxyl bending, and some weak peak around 




































Fig. 4.6 IR spectrum of CBZ, SUC, CBZ-SUC mixture and CBZ-SUC cocrystal 
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2500 to 3000 cm
-1 
for hydroxyl stretching; a characteristic peak at 1309 cm
-1
 for the 
symmetric stretching vibration of carboxylic group. The IR spectrum of CBZ-SUC 
mixture shows both CBZ and SUC characteristic peaks. Spectrum of CBZ-SUC 
cocrystal has different pattern from mixture which demonstrates the formation of 
cocrystal. The carboxamide N-H and carbonyl stretching frequencies of CBZ were 
shifted to 3469 and 1697 cm
-1
 respectively. The hydroxyl and carbonyl stretching of 
SUC shifted to higher position at 3022 and 1679 cm
-1 
respectively. IR peaks are 
summarized in Table 4.3. 
Table 4.3 IR peaks summary of CBZ, SUC and CBZ-SUC cocrystal 
Compound Peak position (cm
-1
) Assignment 







CBZ- SUC cocrystal 3469 -NH2 of CBZ 
1697 -(C=O)- of CBZ 
3022 -OH of SUC 
1679 -COOH of SUC 
4.3.4 Raman spectroscopy analysis of CBZ-NIC cocrystal and CBZ-SUC cocrystal 
Raman analysis for CBZ-NIC system 
Raman spectra of CBZ DH, CBZ I, CBZ III, NIC, CBZ-NIC mixture and CBZ-NIC 
cocrystal are shown in Fig. 4.7 (spectra data shown in Table 4.4), in agreement with 
existing data reported in the literatures [116, 167, 169, 170].  




(a)Raman spectrum for the range of 0-3600cm-1 
 
(b) Enlarged Raman spectrum for the range of 0-1800 cm-1 
Fig. 4.7 Raman spectrum of CBZ DH, CBZ I, CBZ III, CBZ-NIC mixture and CBZ-NIC cocrystal 
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There are several characteristic peaks available to compare and identify different CBZ 
samples. CBZ III has a double peak at 272 cm
-1
 and 253 cm
-1 
due to lattice vibration, 
while CBZ I and CBZ DH only have a single peak at 253 cm
-1
 and the peak at 272 cm
-1 
disappear. There are two C-H bending peaks at 1040 cm
-1
 and 1025 cm
-1
 from the 
ortho-substitued benzene ring of CBZ molecule and the relative intensities of these two 
peaks decreases from 0.97 of CBZ III to 0.38 of CBZ DH [167]. Therefore the change 
in the relative intensities of these two C-H bending modes can also be used to indicate 
the solid transition from CBZ III to CBZ DH during dissolution.  
CBZ III and CBZ DH show triple peaks in the rage of wavenumbers 3070-3020 cm
-1
, 
including one non-aromatic C-H stretch peak at 3020 cm
-1
, one aromatic C-H stretch 
peak at 3043 cm
-1
  and one aromatic asymmetric stretch peak around 3071 cm
-1
. CBZ I 
has double peaks at this area, a sharp peak at 3025 cm
-1
 due to  non-aromatic C-H 
stretch and a broad peak at 3060 cm
-1
 due to aromatic C-H stretch. The relative 
intensities of Raman spectra at 3060 and 3025 cm
-1
 positions for CBZ I and CBZ DH 
are 1.29 and 0.66 respectively. The change of this ratio was used to indicate the 
transition of CBZ I to CBZ DH during in situ Raman experiments.  
Two most significant peaks for NIC are pyridine ring stretching peak at 1042cm
-1
 and 
C-H stretching peak at 3060 cm
-1
. Raman spectrum for CBZ-NIC mixture shows both 
characteristic peaks from CBZ III and NIC. It has double peaks at 272 and 253 cm
-1
 
resulting from CBZ III.  The peak intensity at 1040 cm
-1 
becomes higher than peak 
intensity at 1025 cm
-1
 due to the strong ring stretch peak at 1042 cm
-1
 from NIC and the 
same phenomenon can be observed that the peak intensity increases at 3060 cm
-1
. The 
ratio of the spectral intensities at 1040 to 1025 cm
-1
 was monitored during in situ Raman 
experiments for CBZ-NIC mixture to indicate the solid transition from mixture to CBZ 
DH.  
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For CBZ-NIC cocrystal, its Raman spectrum shows a single peak at 264 cm
-1
 and the 
pattern of spectrum in the ranges of 1020-1040 cm
-1
 and 2950- 3500 cm
-1
 are different 
from those of the physical mixture. Differences among the Raman spectra of CBZ-NIC 
cocrystal, CBZ III, NIC and CBZ-NIC mixture have demonstrated that CBZ-NIC 
cocrystal is not just a physical mixture of the two components and that a new structure 
has been generated. A ratio of the spectral intensities at 1035 to 1025 cm
-1
 was 
monitored during in situ Raman experiments for CBZ-NIC cocrystal to indicate the 
solid transition from cocrystal to CBZ DH 
Raman analysis for CBZ-SUC system 
Raman spectra of CBZ III, SUC, CBZ-SUC cocrystal and CBZ-SUC mixture are shown 
in Fig. 4.8, which is in agreement with data reported in the literatures [46]. 
 
(a)Raman spectrum for the range of 0-4000cm-1 
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(b) Enlarged Raman spectrum for the range of 0-1800 cm-1 
Fig. 4.8 Raman spectrum of CBZ, SUC, CBZ-SUC mixture and CBZ-SUC cocrystal 
CBZ III has exhibited all the characteristic peaks as described in the former part of 
‘Raman analysis of CBZ-NIC system’. SUC shows two characteristic peak around 2930 
and 2970 cm
-1 
corresponding to the O-H stretching of carboxylic group. Raman 
spectrum of CBZ-SUC mixture shows both CBZ and SUC characteristic peaks. The 
Raman spectrum of CBZ-SUC cocrystal shows a distinctive pattern compared with 
CBZ-SUC mixture. Single peak has been found around 170 and 260 cm
-1
 for cocrystal. 
The intensity of peak at 1040 cm
-1
 in mixture spectrum is comparable to that of peak at 
1020 cm
-1
, while in cocrystal’s spectrum the peak at 1040 cm
-1
 almost disappear. The 
triple peaks in the range of 3020 to 3070 cm
-1
 in spectra of CBZ and mixture became 
double peaks in cocrystal spectrum. 
Table 4.4 Raman peaks for CBZ III, CBZ I, CBZ DH, NIC, SUC, CBZ-NIC cocrystal, and CBZ-SUC 
cocrystal 
Compound Peak position (cm
-1
) Assignment 
CBZ III double peak at 272, 253 lattice vibration 
0 200 400 600 800 1000 1200 1400 1600 1800
0 200 400 600 800 1000 1200 1400 1600 1800
0 200 400 600 800 1000 1200 1400 1600 1800
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 1040, 1025, peak intensity ratio 0.97 C-H bending 
 triple peaks at 3020, 3043, and3071 
non-aromatic C-H stretch 
aromatic C-H stretch 
aromatic asymmetric stretch 
CBZ I single peak at 253 lattice vibration 
 double peaks at 3025, 3060 
non-aromatic C-H stretch 
aromatic C-H stretch 
CBZ DH single peak at 253 lattice vibration 
 1040, 1025, peak intensity ratio 0.38 C-H bending 
 triple peaks at3020, 3043, and3071 
non-aromatic C-H stretch 
aromatic C-H stretch 
aromatic asymmetric stretch 
NIC 1042 pyridine ring stretch 
 3060 C-H stretch 
SUC 2930 OH stretch 
 2970 OH stretch 
CBZ-NIC cocrystal single peak at 264 lattice vibration 
 distinctive peaks at 1020-1040 C-H bending 
 distinctive peaks at 2950-3500 C-H stretch 
CBZ-SUC cocrystal single peak at 260 lattice vibration 
 single peak at 1040 C-H bending 
 double peak at 3020, 3060 O-H stretch-H stretch 
4.3.5 Molecular structures of CBZ-NIC cocrystal and CBZ-SUC cocrystal 
IR, Raman, and DSC characterization results have demonstrated the formation of the 
cocrystals: CBZ-NIC cocrystal, and CBZ-SUC cocrystal. The molecular structures of 
CBZ-NIC cocrystal and CBZ-SUC cocrystal were presented in this section [41, 84]. 
The molecular structure of CBZ-NIC cocrystal and CBZ-SUC cocrystal are shown in 
Fig. 4.9. 1:1 CBZ-NIC cocrystal has an amide-to-amide structure. CBZ-NIC cocrystal is 
formed through hydrogen bonds in which the carboxamide groups from both CBZ and 
NIC provide hydrogen bonding donors and acceptors. For 2:1 CBZ-SUC cocrystal, the 
two carboxylic groups of SUC form hydrogen bonds with the carboxamide groups from  








Fig. 4.9 Molecular structures of CBZ, NIC, SUC, CBZ-NIC cocrystal, and CBZ-SUC cocrystal 
CBZ result in a cocrystal with 2:1 component molecular ratio. The hydroxyl from 
carboxylic group of SUC serve as hydrogen bonding donor which form hydrogen bond 
with the carbonyl of CBZ carboxamide. The carbonyl of carboxylic group from SUC 
serve as hydrogen bonding acceptor which form hydrogen bonding with amino of CBZ.  
4.4 Chapter conclusions 
In this chapter, different CBZ samples were characterised, which are CBZ DH, CBZ I, 1: 
1 CBZ-NIC cocrystal, and 2:1 CBZ-SUC cocrystal. All characterisation results have 
demonstrated the successfully formation of CBZ I, CBZ DH and the two CBZ 
cocrystals. Raman spectroscopy analysis provide characteristic peak intensities ratio 
which can be used in monitoring the solid transition between different CBZ forms 
during dissolution. The molecule structures of CBZ-NIC cocrystal, and CBZ-SUC 
cocrystal were also presented in this chapter, which give readers a better understanding 
of the cocrystal structure formation.  
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Chapter 5 In Situ Monitoring of Carbamazepine-Nicotinamide 
Cocrystal Intrinsic Dissolution Behaviour 
5.1 Chapter overview 
In this chapter the phase transition behaviour of cocrystals was studied by in situ 
monitoring of dissolution processes using state of arts techniques of a UV imaging 
dissolution system and Raman spectroscopy. Evolution of the intrinsic dissolution rate 
(IDR) of CBZ-NIC cocrystal was monitored by ActiPix SDI 300 UV imaging 
dissolution system during dissolution. The solid state change that might occur during 
dissolution of the cocrystal was monitored by in situ Raman Spectroscopy. Intrinsic 
dissolution behaviour of CBZ polymorphs (CBZ form III, CBZ DH, CBZ form I) and 
physical mixture of CBZ form III and NIC were studied and compared. 
5.2 Materials and methods 
5.2.1 Materials 
Anhydrous CBZ III, sodium acetate, acetic acid, and NIC, ethyl acetate, potassium 
bromide and double distilled water were used in this chapter. The dissolution medium 
used in this study was pH4.5 acetate buffer (0.06M). Details about the materials and 
dissolution medium preparation can be found in chapter 3 materials and methods, 
section 3.1 materials.  
CBZ DH, CBZ I, CBZ-NIC cocrystal, and physical mixture of CBZ III and NIC were 
prepared and used in this chapter. Preparation and characterisation of these samples can 
be found in chapter 3, section 3.4 preparations and chapter 4 sample characterisations. 




UV imaging dissolution experiment 
An ActiPix SDI 300 UV surface imaging system (Paraytec Ltd., York, UK) was used to 
study the dissolution behaviour of CBZ-NIC cocrystal, CBZ III, CBZ I, CBZ DH and 
CBZ-NIC mixture. Details of a description of this dissolution testing system can be 
found in section 3.3.1.1 Introduction to UV imaging dissolution system. 
UV imaging dissolution experiments were carried out at 37C at a single wavelength 
filter of 300 nm. Dissolution experiments were performed with a standard acetate buffer 
(pH4.5), flow rate at 0.2 mL/min. Each sample has been tested for 3 hours in triplicate. 
The sample compacts used for UV imaging dissolution tests were analysed prior to and 
after a UV imaging dissolution test using a LEICA DM 750 microscope and an 
EnSpectr R532
®
 Raman spectrometer. Details about the UV imaging test and 
calibration procedures can be found in section 3.3.1.2 Operation of UV imaging 
dissolution system.  
In situ monitoring of solution mediated phase transformations 
In situ monitoring of solution mediated phase transformations of CBZ-NIC cocrystal, 
CBZ III, CBZ I, and CBZ-NIC mixture to CBZ DH was carried out using EnSpectr 
R532
®
 Raman spectrometer. The experiment set up and operation procedures can be 
found in section 3.3.2 Enspectr R532 Raman spectrometry.  Experiments of in situ 
Raman monitoring for each test sample were performed in triplicate. 
In addition to Raman spectroscopy, the solid state transformations on the surfaces of the 
drug compacts were investigated by SEM. The compacts were withdrawn from the cups 
at various time points (5, 30, 90 and 180 minutes) and SEM micrographs of the 
compacts were photographed by a ZEISS EVO HD 15 scanning electron microscope 
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(Carl Zeiss NTS Ltd, Cambridge, UK). Details about SEM technique can be found in 
section 3.3.9 Scanning electron microscope. 
5.3 Results 
5.3.1 UV imaging dissolution tests 
In situ UV imaging dissolution tests  
Dissolution behaviours of five samples CBZ DH, CBZ I, CBZ III, CBZ-NIC cocrystal 
and mixture were monitored by the ActiPix SDI 300 UV imaging dissolution system at 
a constant flow rate of 0.2 mL/min for 3 hours. The UV images of absorbance maps of a 
released sample at different selected time points were shown in Fig. 5.1. The absorbance 
map in each image indicates the spatial concentration distribution of the dissolved CBZ 
in the flow cell at the recording time, which was affected by the flow rate and diffusion 
coefficient of CBZ. The effect of the density gradients of the solution on the local 
solution concentration distribution was not significant because there is a clear upward 
diffusion of the dissolved CBZ into the bulk buffer solution as the downstream distance 
increases to form a stable plume. The pattern of the dissolved CBZ is in agreement with 
expectations from the convective-diffusion theory, which describes transport-controlled 
dissolution involving two fundamental processes of molecular diffusion and forced 
convection as a result of fluid flow [171].     
From these recorded images, it is clearly shown that different samples have different 
absorbance profiles which are changing as a function of the dissolution time. Generally 
the highest absorbance profile for each sample was obtained around 5 minutes after a 
dissolution test started and then it gradually declined to a steady state around 30 minutes. 
CBZ DH generated the thinnest plume of the dissolution layer which became stable 
around 5 minutes after the dissolution test started, indicating that CBZ DH has the 
smallest and most stable dissolution rate among the five samples. Compared with CBZ  
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DH, the other four samples show relative thicker plumes of the absorbance area of CBZ 
when the samples were loaded in the flow cell, in particular for CBZ-NIC cocrystal and 
mixture. It is revealed that both of CBZ-NIC cocrystal and mixture have higher 
dissolution rates. Similar to those of CBZ DH, the absorbance pattern of dissolution 
images of CBZ-NIC cocrystal was stable, indicating a constant dissolution rate and 
stable form of the cocrystals. However, for CBZ-NIC mixture, although a thicker plume 
of dissolution layer was obtained at the beginning of the test, the size of dissolution 
layer quickly decreased to the level of CBZ DH due to quickly dissolved NIC. For CBZ 
III and CBZ I, there was a significant decrease in the size of absorbance area for the first 
20 minutes of the dissolution tests and became stable after that. This can be explained 
by the precipitation of a more stable form CBZ DH on the surfaces of the compacts to 
reduce the dissolution rate of the test samples in the buffer.  
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Change in the dissolution rate and crystallization of a stable form of CBZ DH were 
confirmed with images of sample compacts by light microscopy in Fig. 5.2. Prior to the 
dissolution tests, all of the compact surfaces were very smooth. After dissolution tests, 
the microscope images show that small needle shaped crystals have appeared on the 
compact surfaces for CBZ DH, CBZ I, CBZ III and CBZ-NIC cocrystal, indicating that 
the solid state changes due to crystallization of CBZ DH from the supersaturated 
solutions on the compact surfaces. However, it is shown that there is a significantly 
different surface morphology of the CBZ-NIC mixture compact after a dissolution test. 
There were a lot of holes that appeared on the surface due to dissolved NIC, which can 
explain the reasons of the significant changes of dissolution images recorded.   
Comparison of the Raman spectra of test samples prior to and immediately after a UV 
imaging dissolution test are shown in Fig. 5.3.  
 
(a1) CBZ DH Raman spectrum from 0-3600cm
-1




(b1) CBZ I Raman spectrum from 0-3600cm
-1
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(c1) CBZ III Raman spectrum from 0-3600cm
-1




 (d1) CBZ-NIC cocrystal Raman from 0-3600cm
-1




 (e1) CBZ-NIC mixture Raman from 0-3600cm
-1
      (e2) CBZ-NIC mixture Raman from 0-1800cm
-1
 
Fig. 5.3 Raman spectra of the compacts before and after 3-hours UV imaging dissolution tests 
There is no change of CBZ DH Raman spectra during a 3 hours test. All Raman spectra 
of the other samples show some differences between before and after the dissolution 
tests in Fig. 5.3 (b)-(e). For CBZ I, the most obviously change happened around 3060 
cm
-1
 area: double peaks become triple peaks, shown in Fig. 5.3(b). The main changes of 
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Raman spectrum for CBZ III have been pointed out by arrows in Fig. 5.3(c), including 
two characteristic changes: the ratio of relative intensities of peak at 1040 cm
-1
 to peak 
at 1025 cm
-1
 decreases, and double peaks disappear around 250 cm
-1
. For CBZ-NIC 





 and 1035 cm
-1
 to 1025 cm
-1
  decrease shown in Fig. 5.3(d). The main changes 
of Raman spectrum of CBZ-NIC mixture are the same as those of CBZ III in Fig. 5.3(e). 
All these changes show the tendency of solid state conversion to CBZ DH, indicating 
precipitation of CBZ DH on the compact surfaces. 
Evolution of the IDRs of CBZ DH, CBZ I, CBZ III, CBZ-NIC cocrystal and mixture 
during dissolution is shown in Fig. 5.4. Within the first 3 minutes, all IDRs of the test 
samples reached its maximum values, summarised in Table 5.1. During the course of 3 
hours dissolution test, the IDR of CBZ DH is almost constant at 0.0065 mg/min/cm
2
, 
indicating amount of CBZ DH precipitated from solution is not significant. The IDR 
profiles of CBZ I and CBZ III are similar, in which the maximum IDRs were obtained
 
Fig. 5.4 Intrinsic dissolution rates as a function of dissolution time obtained by UV imaging at a flow rate 
of 0.2 mL/min (n=3) 
in 2 minutes and then decreased quickly to relative stable values. However, the 
transition times are different for two samples. CBZ I has the IDRmax of 0.0134 
mg/min/cm
2
 which declined to 0.080 mg/min/cm
2


























  Chapter 5 
101 
 
decreased gradually to the CBZ DH level within 2 hours. Transition time of CBZ III is 
much faster than that of CBZ I, which took about 30 minutes to decline the IDRmax of 
0.0103 mg/min/cm
2 
 to that of CBZ DH. The biggest variability of the IDR of CBZ-NIC 
mixture has been displayed in Fig. 5.4 and its IDRmax is the biggest among the five test 
samples due to effect of a very high concentration of NIC in the solution. Evolution of 
the IDR profile of CBZ-NIC mixture is similar to that of CBZ III within 35 minutes but 
with a higher value of 0.0080 mg/min/cm
2
, which was affected by continuously 
dissolved NIC from the compact. When most of NIC in the mixture had dissolved, the 
IDR declined to a lower value of 0.0063 than that of CBZ DH due to reduction of the 
compact surface area for dissolution. Compared with CBZ I, CBZ III and CBZ-NIC 
mixture, the IDR of CBZ-NIC cocrystal is constant over time. It reached the maximum 
value of 0.0123 mg/min/cm
2
 and declined slowly during dissolution and it became the 
highest IDR since the 8
th
 minute among all the five samples.  


















CBZ DH 0.0069±0.0011 4 0.0065±0.0005 5 0.2100±0.0050* 0.1978±0.0161** 
CBZ III 0.0103±0.0031 2 0.0070±0.0004 30 0.3135±0.0949** 0.2141±0.0123** 
CBZ I 0.0134±0.0023 2 0.0080±0.0002 15 0.4078±0.0688** 0.2425±0.0063** 
CBZ-NIC cocrystal 0.0123±0.0004 3 decreasing ----- 0.3746±0.0111** ----- 
CBZ-NIC mixture 0.0248±0.0055 2 0.0080±0.0003 35 ----- ----- 
*: measured solubility; **: calculated solubility  
5.3.2 In situ monitoring of solid state transformation during dissolution using 
Raman spectroscopy 
In situ monitoring of the solution mediated phase transformations of CBZ III, CBZ I, 
CBZ-NIC cocrystal, and CBZ-NIC mixture to CBZ DH was carried out using the 
Enspectr R532 Raman spectroscopy, described in the previous section 3.3.2. In total, 36 
spectra were recorded for each sample during 3 hours dissolution. The Raman spectra at 
different selected time points were shown in Fig. 5.5. Similar to the previous result, 
there was no change of CBZ DH Raman spectra during the 3 hours dissolution test in 
Fig. 5.5 (a). The dynamic evolutions of Raman spectra of the other four samples are 
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clearly shown in Fig. 5.5 (b)-(e) and details of progression to CBZ DH have been 
revealed.  
  
(a1) CBZ DH Raman 0-3600 cm
-1




(b1) CBZ I Raman 0-3600 cm
-1




(c1) CBZ III Raman 0-3600 cm
-1
                (c2) CBZ III Raman 0-1800 cm
-1
 


























































(d1) CBZ-NIC cocrystal Raman 0-3600 cm
-1




(e1) CBZ-NIC mixture Raman 0-3600 cm
-1




Fig. 5.5 Raman spectra of compact surfaces at different selected times (at 0, 2, 15, 30, 60, 180 min): (a) 
CBZ DH; (b) CBZ I; (c) CBZ III; (d) CBZ-NIC cocrystal; (e) CBZ-NIC mixture 
In order to quantify the solid state change during dissolution, ratios of characteristic 
spectral intensities for each sample are used as indicators for a phase change during 
dissolution are summarized in Table 5.2, in which the ratios of start and end of the 
experiments are presented. Details about the selection of characteristic peak for each of 
samples have been described in section 4.3.4. 
Table 5.2 Indicators used in situ Raman spectrometer monitoring (n=3) 
Ratio of intensities 1035/1025 1040/1025 3060/3025 
begin finish begin finish begin finish 
CBZ DH 0.24±0.04 0.38±0.01 0.66±0.02 
CBZ III   0.97±0.10 0.73±0.02   
CBZ I     1.29±0.06 0.76±0.02 
CBZ-NIC cocrystal 0.65±0.08 0.25±0.04     
CBZ-NIC mixture   1.2±0.18 0.49±0.04   
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Evolution of the selected peak ratios during dissolution are shown in Fig. 5.6. For CBZ 
DH, all of three ratios selected were constant during dissolution as the same of those 
before a test, indicating they are the characteristic peaks which keep constant during 
dissolution. For CBZ III, the peak intensity ratio of 1040 to 1025 cm
-1
 decreased from 
0.97 to 0.73 while CBZ DH value is 0.38, indicating a fraction of CBZ DH formed on 
the surface of the compact. For CBZ I, the ratio of 3060 to 3025 cm
-1
 dropped from 1.29 
to 0.76, while CBZ DH has a ratio of 0.66. Obviously, neither CBZ III nor CBZ I has 
completed the hydrate conversion. For CBZ-NIC cocrystal, the peak ratio of 1035 to 
1025 cm
-1
 decreased from 0.65 to 0.25, very close to DH of 0.24. For CBZ-NIC mixture, 
the peak ratio of 1040 to 1025 cm
-1
 decreased from 1.2 to 0.49, indicating more CBZ III 
in the mixture was converted into CBZ DH. This may be due to removal of NIC, 
leading more dissolution medium to get into the compact to facilitate the hydrate 
transition of CBZ III. 
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(c) 
Fig. 5.6 Evolution of ratios of characteristic peaks: (a) 1035/1025 for CBZ DH and CBZ-NIC cocrystal; 
(b) 1040/1025 for CBZ DH, CBZ III and CBZ-NIC mixture; (c) 3060/3025 for CBZ DH and CBZ I 
5.3.3 SEM 
SEM characterisation of the surfaces of sample compacts has been carried out. Five 
sample compacts were placed into the medium buffer for 3 hours separately. During the 
3 hours dissolution, SEM micrographs of each sample compact were taken at five time 
points: 0, 5, 30, 90, and 180 minutes, shown in Fig. 5.7.  
SEM photos in the first column were taken before dissolution testing, all sample 
compacts have smooth surfaces and no particular shaped crystal was observed for each 
of samples. Significant change happened to all samples only after 5 minutes when 
contacting with the medium buffer solution.  
SEM photos in the second column were taken after 5 minutes dissolution in medium, it 
can be seen that the smooth surfaces have disappeared and some needle-shaped CBZ 
DH crystals were observed on the surfaces of all sample compacts. And these newly 
formed CBZ DH crystals have the similar shape as those of CBZ DH uncompressed 
sample, shown in Fig. 5.8. Among five samples, the smallest amount of needle-shaped 
crystals was observed on the surface of CBZ DH compact. There are several crystal 
clusters scattered on CBZ DH compact surface while the other four sample compact 
surfaces are covered with needled crystals completely. Long needle-shaped crystals 
were formed on the surfaces of both CBZ III and CBZ I compacts due to 
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Fig. 5.7 SEM photos taken off-line of the compact surfaces during dissolution at different time points (0, 
5, 30, 90, and 180min)  




Fig. 5.8 SEM photo for CBZ DH uncompressed sample 
evenly formed on the surface of CBZ III compact compared with those of CBZ I, which 
may be due to a lower supersaturated solution of CBZ generated. It was not a surprise 
that similar CBZ DH crystals were found on the surface of CBZ-NIC mixture as those 
of CBZ III, but there were many holes appeared on the compact surface due to the quick 
dissolve of NIC, which can be seen clearly by visual inspection. On the surface of CBZ-
NIC cocrystal compact, smaller sizes of CBZ DH were found compared with CBZ III, I 
and mixture. It could explain the reason that CBZ-NIC cocrystal has the highest IDR 
due to slower growth of CBZ DH crystals from the solution. 
SEM photos in the last three columns were taken after 30 minutes, 90 minutes and 180 
minutes dissolution respectively. As dissolution time longer, surface of sample 
compacts exhibited some changes. SEM photos for CBZ DH show that the crystal size 
increases slightly, but the amount of crystals is constant. After 30 minutes, there were 
no significant change of CBZ DH crystals on the surfaces of CBZ III and CBZ I 
compacts, indicating the equilibrium state could have established with the solution. For 
CBZ-NIC mixture, the compact surface appears many caves due to dissolved NIC after 
30 minutes. For CBZ-NIC cocrystal, it appears that more CBZ DH crystals are 
precipitated but there was no evidence of growth of crystals. 
5.4 Discussion 
From the UV imaging dissolution tests, it is clearly shown that all of test samples of 
CBZ III, CBZ I and CBZ-NIC cocrystal and mixture have undergone solution mediated 
phase transformations by precipitating a lower free energy state of CBZ DH. However, 
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the kinetics of these phase transformations is different. Based on the IDR profiles 
obtained from UV images recorded for CBZ III and CBZ I, it was suggested that the 
transformation process happened rapidly once a supersaturated free CBZ concentration 
was generated during dissolution, which cannot be maintained in solution. It followed 
the three stages of the transformation: creating a local supersaturation; nucleation of a 
stable phase; growth of the stable phase, which was confirmed by the UV images in Fig. 
5.1 and SEM micrographs in Fig. 5.7. However, for CBZ-NIC cocrystal, the growth of 
crystallised CBZ DH was very slow. The transformation mechanism of CBZ-NIC 
cocrystal can be considered as the following two main stages:  
First, CBZ-NIC cocrystal dissolved congruently and exhibited higher transient 
solubility compared with its pure component CBZ III. The maximum transient 
solubility can be considered as the apparent solubility. From the IDR curves in Fig. 5.4, 
apparent solubility of CBZ III, CBZ I and CBZ-NIC cocrystal can be predicted based on 
the measured solubility of CBZ DH because an IDR is directly proportional to its 
solubility, summarised in Table 5.1. The apparent solubility of CBZ-NIC cocrystal is 
0.3746 mg/mL compared with its pure component CBZ III of 0.3135 mg/mL and is less 
than that of CBZ I apparent solubility of 0.4078 mg/mL. Apparent solubility of CBZ III 
and I is in good agreement with the reported data [99]. The apparent solubility is in 
order of CBZ I > CBZ-NIC cocrystal > CBZ III > CBZ DH.  
Second, during CBZ-NIC cocrystal dissolution, a supersaturated free CBZ 
concentration was generated and can be maintained due to the complexity. When the 
cocrystal dissolved into the dissolution medium as the CBZ-NIC 1:1 complex, 
dissociation rate from CBZ-NIC complex to individual compounds decides the rate of 
solution medicated phase transformation. If the dissociation rate from CBZ-NIC 
complex in solution to individuals is slow, the crystallization of CBZ DH can be 
delayed, which can be indicated from the IDR-time profiles generated from the 
dissolution tests. CBZ-NIC mixture shows a significantly larger IDR at the beginning 
and this was caused by the effect of dissolved NIC on the UV absorbance.  From the 
10
th
 minute, the IDR of the mixture became smaller than that of the cocrystals and this 
may be due to the reduced NIC effect. Loss of NIC during dissolution can generate 
several holes on the compact surface, leading to a lower IDR, shown in Fig. 5.2. 
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Eventually the IDR of the CBZ-NIC mixture is smaller than that of CBZ DH due to the 
reduced surface area for dissolution. Although free CBZ and NIC coexisted in the 
solution for a while, there was no evidence of formation of a complex. CBZ-NIC 
cocrystal has revealed significant advantages than the two anhydrous samples CBZ III 
and CBZ I with the highest IDR and slowest phase conversion rate. The change rate of 
IDR of CBZ-NIC cocrystal is the slowest among the test samples. IDR of CBZ-NIC 
cocrystal has been declined by 81% over 3 hours, compared with 74% decrease for CBZ 
I in 15 minutes and 87% for CBZ III in 30 minutes. The enhancement of solubility and 
dissolution rate is significant about 1.8 times of that CBZ DH at the beginning and 
declined to 1.2 times after a 3-hour dissolution test. The stable IDRs in Table 5.1 is in 
order of CBZ-NIC cocrystal > CBZ I  CBZ III  CBZ DH>CBZ-NIC mixture. 
In situ Raman monitoring results with SEM measurements for CBZ-NIC cocrystal, 
physical mixture, CBZ III and CBZ I have shown that CBZ DH crystals have 
crystallised on the surface of the compacts. Evolution of a ratio of characteristic peaks 
in Fig. 5.6 can be used to study the conversion kinetics of the samples. There is no 
conversion for CBZ DH so that the ratios of characteristic peaks should keep constant 
as the same as those before a test, which have been confirmed by the results in Fig. 5.6. 
A first-order kinetics model [116] was used to study the rate of conversation and the 
unconverted portion in a compact during dissolution as  
                                                          Y=B+Ae
-kt
                                  (Equ.5-1) 
where k represents the rate of conversion, B and A are constants. The unconverted 
portion on a compact surface can be calculated as 
Percentage of unconverted portion = (B-BDH)/ (B0- BDH)      (Equ.5-2) 
where B0 is the ratio of characteristic peaks for the pure form of a sample and BDH is the 
ratio of characteristic peaks for the pure CBZ DH shown in Table 5.2. 
The fitted curves for each of the samples are shown in Fig. 5.6 and the calculated 
conversion rate constants and unconverted portions after 3-hour dissolution are in Table 
5.3. The results of CBZ III and CBZ I are very close to the published data [116].  
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The rate of conversion represents the speed of phase conversion. CBZ III has a faster 
conversion rate from the starting material (CBZ III) to CBZ DH compared with that of 
CBZ I, which is consist with the UV imaging results. The UV imaging results show that 
the IDR value transition time of CBZ III is much faster than that of CBZ I. After the 
IDR data decreasing in the first 15 minutes of dissolution for both CBZ III and CBZ I, 
CBZ III kept decreasing to a much lower IDR level than CBZ I in the followed 30 
minutes. While CBZ I took about 2 hours to decrease to the similar level as CBZ III, 
and kept it for the last hour. At the end of 3-hours dissolution, CBZ III has a slightly 
lower IDR than that of CBZ I, however the Raman analysis has shown that CBZ III has 
a higher unconverted portion than that of CBZ I.  A higher unconverted portion of CBZ 
III means that a smaller percent of CBZ DH was found on the surface of CBZ III 
sample compact. Although less CBZ DH on CBZ III sample compact, it has a lower 
dissolution rate due to the lower apparent solubility of CBZ III (0.3135mg/mL) 
compared with that of CBZ I (0.4078mg/mL). Although a higher unconverted portion 
was found on the compact surface of CBZ III, the overall dissolution rate is lower than 
that of CBZ I. For CBZ-NIC mixture, it is not surprised that that it has a faster 
conversion rate and lower portion of unconverted CBZ III compared with those of CBZ 
III alone, which are consistent with those of UV imaging results. For CBZ-NIC 
cocrystal, it has a lower unconverted portion than those of CBZ form III and form I. The 
finding can be confirmed from the SEM micrographs in Fig. 5.7, in which more CBZ 
DH crystals are precipitated on the surface of CBZ-NIC cocrystal compact. However, 
the CBZ-NIC has a higher conversion rate than those of CBZ III and I, which is 
contradictory to that of the UV imaging results, in which the equilibrium solubility and 
dissolution rate of CBZ-NIC cocrystal are much higher than those of CBZ III and I. 
Therefore study of solid stage conversion alone during dissolution will not be enough to 
understand the dissolved drug in the solution.  


















Unconverted portion (%) 7.83±1.19 13.72±6.05 62.32±8.29 15.92±2.33 




5.5 Chapter conclusions 
In this chapter, phase transition behaviour of CBZ-NIC cocrystal during dissolution and 
improvement of dissolution rate have been studied.  
Cocrystals have shown huge potential to improve the dissolution rate and absorption of 
a poorly water soluble drug. However, solution mediated phase transformation of 
cocrystals could greatly reduce the enhancement of its apparent solubility and 
dissolution rate. On the other hand, the time scale of solution mediated phase 
transformation of cocrystals is an important consideration for potentially improved 
bioavailability. Therefore evolution of the drug concentration in the solution during 
dissolution of cocrystal needs to be understood and evaluated. Relationship between 
dissociation rate of the cocrystal complex in the solution and dissolution rate of 
cocrystal solid is important, which will influence the crystallization of the component 
with low solubility of drug compound and the dissolution profile of the cocrystal.  
Dissolution and transformation behaviour of CBZ-NIC cocrystal was studied by 
different in situ techniques of UV imaging and Raman spectroscopy. It has been found 
that CBZ-NIC cocrystal including other polymorphs of CBZ III and I and mixture are 
converting to CBZ DH during dissolution. Compared with CBZ III and I, the rate of 
IDR of CBZ-NIC cocrystal decreases slowly, indicating the rate of crystallization of 
CBZ DH from the solution is slow. In situ solid-state characterisation during dissolution 
has shown the evolution of conversion of CBZ-NIC cocrystal and polymorphs to its 
dihydrate form, which cannot completely be understood by merely measuring the 
dissolved drug concentration. This study has shown that in situ UV imaging and Raman 
spectroscopy with a complementary technique of SEM can provide an in depth 
understanding during dissolution. The information from the experiments on 
transformation behaviour of CBZ-NIC cocrystal is valuable for understanding the 
mechanisms of cocrystal dissolution. 
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Chapter 6 Investigation of the Effects of Surfactants on 
Carbamazepine-Nicotinamide Cocrystal Solubility and Dissolution 
Behaviour 
6.1 Chapter overview 
In order to critically evaluate and understand the role of surfactants in inhibiting the 
solution mediated phase transformation (SMPT) of a cocrystal, two surfactants of 
sodium lauryl sulphate (SLS, or Sodium dodecyl sulfate SDS) and Tween 80 
(Polysorbate 80) were selected to investigate their effects on the solubility and intrinsic 
dissolution rate (IDR) of CBZ-NIC cocrystal in this chapter. SLS is an anionic 
surfactant and Tween 80 is a nonionic surfactant, both of which have been widely used 
in various drug dosage forms to control wetting, stability, and solubilisation of 






















Fig. 6.1 Molecular structure of SLS and Tween80 
The solubility of CBZ-NIC cocrystal at different concentrations of surfactant solutions 
was predicted from measurement of eutectic points or transition concentrations where 
solid cocrystal and drug are in equilibrium with solution [84-86]. Evolution of the IDR 
of CBZ-NIC cocrystal at different concentrations of surfactant solutions was monitored 
by the UV imaging dissolution system during dissolution. The solid-state changes of 
CBZ-NIC cocrystal after dissolution were quantified by Raman spectroscopy. 
Comparison of solubility and intrinsic dissolution behaviour of CBZ polymorphs (form 
III and DH) and physical mixture of CBZ form III and NIC were also given in this 
chapter.  
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6.2 Materials and methods 
6.2.1 Materials 
Anhydrous CBZ III, NIC, ethyl acetate, Tween 80, SLS, methanol (HPLC grade), and 
double distilled water were used in this chapter, details about this material are listed in 
chapter 3 Materials and methods. CBZ DH, 1:1 CBZ-NIC cocrystal and equimolar 
physical mixture of CBZ III and NIC were prepared as described in section 3.4.2 Test 
samples preparation. 
6.2.2 Methods 
6.2.2.1 Equilibrium solubility 
The solubility of CBZ DH, CBZ-NIC cocrystal, and physical mixture in both water and 
surfactant solutions were determined using an air-shaking bath method. Details about 
this method were described in section 3.3.11.1 Equilibrium solubility test.  The tests 
have been done at 25C for 72 hours. CBZ and NIC concentrations were determined by 
Perkin Elmer series 200 HPLC. Surfactant solutions used in this study are at the 
following concentrations: 0.35, 1.7, 3.5, 6.9, 10.4, 17.3, 34.7 mM SLS; and 0.076, 0.76, 
1.5, 2.3, 3.8, 7.6, 17.3, 34.7 mM Tween80. All solubility tests were carried out in 
triplicate. 
6.2.2.2 Cocrystal eutectic points 
Cocrystal eutectic points or transition concentrations were measured as a function of 
SLS or Tween 80 concentration in water at 25°C [151, 172]. Details of the measurement 
can be found in section 3.3.11.2. Cocrystal eutectic points measurement test. 
For 1:1 AB cocrystal without consideration of ionization for either component, its 
aqueous solubility was determined from eutectic concentration measurements by 
following equation [84], 
                                        √    √[ ]  [ ]                                  (Equ.6-1) 
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where     is the cocrystal solubility product and [ ]   and [ ]   are the eutectic 
concentrations of drug and coformer at equilibrium. 
6.2.2.3 Critical micelle concentration and solubilisation capacity 
The critical micellar concentrations (CMCs) of SLS and Tween 80 were determined in 
aqueous solutions in the presence of saturated CBZ from the surface tension dependence 
on surfactant concentration by a KSV CAM200 surface tension meter at room 
temperature.  
The molar solubilisation capacities of SLS and Tween 80 for CBZ can be obtained 
according to the following equation: 
                                                 (    
   [ ])                           (Equ.6-2) 
where         is the solubility of CBZ in micellar solution;         is the solubility of 
CBZ in water; [ ]        is the surfactant micellar concentration; and C is the 
surfactant concentration. 
6.2.2.4 Intrinsic dissolution study by UV imaging system 
The dissolution behaviour of CBZ III, the CBZ-NIC cocrystal, and the physical mixture 
of CBZ III and NIC in both pure water and at different concentrations of surfactant 
solutions was studied by an ActiPix SDI 300 UV surface imaging system (Paraytec Ltd., 
York, UK). Details of description of the system can be found in section 3.3.1 ActiPix 
SDI 300 UV imaging dissolution system. All dissolution tests were performed at 25C 
in triplicate. The concentrations of each surfactant used in the study were: 0.35 and 10.4 
mM of SLS solutions, 0.076 and 7.6 mM of Tween 80 solutions.  
The sample compacts used in UV imaging dissolution tests were analysed prior to and 
immediately after dissolution tests using a LEICA DM 750 microscope and EnSpectr 
R532
®
 Raman spectrometer. The percentage of CBZ DH crystallised during dissolution 
were quantitative analysed by Raman spectroscopy. 




6.3.1 Results of solubilisation by surfactants 
The equilibrium solubility of CBZ DH (CBZ III), CBZ-NIC cocrystal and physical 
mixture of CBZ III and NIC in water, and at different concentrations of SLS and Tween 
80 after 72 hours are shown in Fig. 6.2 and details of data are in Table 6.1. Generally, 
there was no significant difference in the solubility between the parent drug (CBZ), 
cocrystal and the physical mixture. FTIR, and Raman spectra (shown in Appendix, 
A1.1.1-2) of solid residue indicated that CBZ-NIC cocrystal had totally converted to 
CBZ DH, therefore the same solubility of cocrystal and CBZ DH was found. 
 
Fig. 6.2 Solubility of CBZ as function of surfactant concentration 
 
Table 6.1 Equilibrium solubility of CBZ DH, CBZ-NIC cocrystal and physical mixture at 25C as 




(CBZIII) (mM) cocrystal physical mixture 
 
mM CBZ CBZ (mM) NIC (mM) CBZ (mM) NIC (mM) 
 
0.000 (water) 0.5380.038 0.5020.028 2.6130.140 0.5750.036 2.5690.164 
 
0.347 0.4760.020 0.4730.030 2.4820.162 0.5500.024 2.7760.042 
 
1.734 0.4570.015 0.4500.041 2.3820.230 0.5250.020 2.6720.103 
SLS 3.468 0.4610.011 0.4870.019 2.4490.109 0.5160.021 2.5650.104 
 


















Surfactant concentration (mM) 
CBZ DH in SLS CBZ-NIC cocrystal in SLS
Physical mixture in SLS CBZ DH in Tween 80
CBZ-NIC cocrystal in Tween 80 Physical mixture in Tween 80
SCBZ,T=SCBZ, aq[1+0.176* (C-0.651)]
SCBZ,T=SCBZ, aq[1+0.581* (C-6.169)]




10.403 1.7620.202 1.7040.088 2.4750.140 1.6840.062 2.5460.081 
 
17.339 4.5570.859 4.1390.173 16.0664.084 4.4120.234 15.3371.066 
 
34.677 9.3850.191 9.3240.212 14.1480.607 9.7320.481 17.0101.081 
 
0.000 (water) 0.5380.038 0.5020.028 2.6130.140 0.5750.036 2.5690.164 
 
0.076 0.6230.034 0.5200.023 2.5810.077 0.6460.033 2.5740.102 
 
0.763 0.5740.039 0.5310.026 2.4420.055 0.5730.041 2.5340.148 
 
1.527 0.6430.054 0.5880.032 2.4530.062 0.6360.005 2.6360.009 
Tween 80 2.290 0.6830.052 0.6830.025 2.5760.073 0.7140.024 2.6250.060 
 
3.817 0.8280.021 0.7830.048 2.5780.045 0.9020.114 2.7850.279 
 
7.634 1.0920.083 1.0350.048 2.4400.023 1.1540.120 2.6470.124 
 
17.328 1.8410.149 2.0970.225 15.7550.253 2.1770.206 17.5354.597 
 
34.733 3.8300.095 3.8710.407 15.1820.410 3.7890.126 16.4181.112 
 
Based on the measured solubility data of CBZ, the molar solubilisation capacities and 
CMCs of SLS and Tween 80 can be estimated, as summarized in Table 6.2. It is shown 
that the estimated CMCs of SLS and Tween 80 are in good agreement with those 
measured by the surface tension technique. The change of surface tension at different 
surfactant concentrations of aqueous solutions in the presence of saturated CBZ is 
shown in Fig. 6.3. Tween 80 has a higher solubilisation capacity at a low concentration 
due to its lower CMC. However, the anionic surfactant SLS showed a dramatic 
solubilizing ability with CBZ when its concentration was higher than its CMC. When 
the concentration of SLS is higher than a critical value of 8.567 mM, SLS has a higher 
solubilisation capacity for CBZ than Tween 80, which can be seen from the solubility 
data of CBZ in Fig.6.2. 
Table 6.2 Estimated molar solubilisation capacity and CMC 




CMC estimated (mM) CMC measured (mM) 
SLS 0.581 6.196 5.5 
Tween 80 0.176 0.651 0.012 – 1.05 
 
 





               
(b) Tween 80 
Fig. 6.3 Surface tension versus surfactant concentration: (a) SLS; (b) Tween80 
The apparent solubility of CBZ was measured as a function of the coformer NIC 
concentration in order to determine CBZ-NIC cocrystal eutectic point (shown in 
Fig.6.4), in which four regions can be identified:  
Region I: from 0 to 1000 mM initial NIC concentrations, the solubility of CBZ increases 
rapidly with increasing concentration of NIC, indicating the 1:1 complex formation of 
CBZ and NIC. The solubility of CBZ can increase up to 10 times in comparison to CBZ 
solubility in water. In this region, the solubility limit of the complex formed is not 
exceeded and the solid residue should be CBZ DH only, which was confirmed by DSC, 
FTIR and Raman analyses (figures shown in Appendix, A1.2.1-3; data shown in Table 
6.3). In this region, the measured concentration of NIC was the same as that of the 
initial NIC.  
Region II: from 1000 to 2400 mM initial NIC concentrations, the solubility of CBZ 

















































Tween 80 (mM) 
CMC  
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exceeded in this region, CBZ-NIC cocrystal precipitated. In the meantime, higher order 
complexes of CBZ and NIC were generated, resulting in a further 18 times increase in 
the CBZ equilibrium solubility in water. The solid residue indicated the presence of two 
phases of CBZ-NIC cocrystal and CBZ DH confirmed by DSC, FTIR and Raman 
analyses (figures shown in Appendix, A1.2.1-3; data shown in Table 6.3). According to 
the definition, any point in the region II should be a eutectic point of CBZ-NIC 
cocrystal. In this study, we set the highest total CBZ concentration point as its eutectic 
point shown in Fig.6.4 as [   ]          and [   ]           .     
Region III: from 2400 to 3000 mM initial NIC concentrations, the concentration of CBZ 
decreases with increasing NIC concentration in solution. In this region, all of the solid 
CBZ DH was consumed to form the complex to generate the supersaturated solution of 
the complex, resulting in precipitation of large amount of CBZ-NIC cocrystal and 
reduction of CBZ concentration in solution. For this reason, the overall CBZ 
concentration decreased in solution shown in Fig. 6.4. It has been shown that CBZ-NIC 
cocrystal and NIC are coexisting in solid residues, shown in DSC, FTIR and Raman 
analyses (figures shown in Appendix, A1.2.1-3; data shown in Table 6.3). 
Region IV: Above 3000 mM initial NIC concentration, the concentrations of CBZ and 
NIC in the solution are constant. The solid residues indicated the presence of two phases 
of CBZ-NIC cocrystal and NIC, confirmed by DSC, FTIR and Raman analyses (figures 
shown in Appendix, A1.2.1-3; data shown in Table 6.3).   
Table 6.3 Characteristic peaks for solid forms identification 
 DSC FTIR Raman 
Region I  
 
DH dehydration peak 80-
120C; CBZ I melting 
point 195C 
DH characteristic peak at 
3429, 3360, 3280, 3182cm
-1
 
DH single peak at 253 cm
-
1
; DH ratio of peaks at 
1040 to 1025 cm
-1
 
Region II  
 
DH dehydration peak 80-
120C; cocrystal melting 
point around 163C 
DH characteristic peak at 
3429cm
-1
; cocrystal show 




show DH characteristic 
peaks; cocrystal 
characteristic peaks were 
overlayed by DH peaks 





NIC melting point around 
130C; cocrystal melting 
point around 163C 
NIC peak at 1680cm
-1
; 
cocrystal characteristic peak 
at 3449cm
-1
; the mixture of 




NIC peak at 1042, 3060 
cm
-1
; cocrystal single peak 
at 264 cm
-1
, peak ratio 
around 1000 show 
cocrystal characteristics  
Region IV  
 
relative larger NIC melting 
point around 130C, 
indicate more NIC; 
cocrystal melting point 
around 163C 
NIC peak at 1680cm
-1
; 
cocrystal characteristic peak 
at 3449cm
-1
; the mixture of 




NIC peak at 1042, 3060 
cm
-1
; cocrystal single peak 
at 264 cm
-1
, peak ratio 
around 1000 show 
cocrystal characteristics  
 
 
Fig. 6.4 CBZ solubility profile as a function of NIC concentration after 72 hours 
Table 6.3 shows the total concentrations of CBZ and NIC at the eutectic points of 
different concentrations of SLS and Tween 80. Compared with the eutectic point in 
water, the solubility of CBZ increased slightly with an increase in SLS concentration 
while the concentration of NIC was constant with SLS concentration (which was 
slightly smaller than that in pure water). According to the solubility definition of a 1:1 
cocrystal shown in Equ. 6-1, the solubility of CBZ-NIC cocrystal at different 
concentrations of SLS is shown in Table 6.3. The solubility of CBZ-NIC cocrystal was 
nearly constant and same as that in water when SLS concentration was below its CMC 
and it increased slightly when the SLS concentration was above its CMC.     
 Compared with the eutectic point in water, the solubility of CBZ was almost constant 
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higher concentration of Tween 80 solutions.  The solubility of the CBZ-NIC cocrystal 
was nearly same as that in water at a lower concentration of Tween 80 solution and then 
decreased slightly when Tween 80 concentration increased (see Table 6.4). 
Table 6.4 CBZ-NIC cocrystal eutectic point, cocrystal solubility and solubility ratio 
Solvent 
concentration (mM) 






Scc /       




0.35 15.91.8 1665.262.6 162.8 302 
1.7 16.30.76 1807.990.3 171.5 319 
3.5 17.60.63 1818.957.0 178.7 332 
6.7 17.50.65 1914.0136.3 183.2 340 
10.4 17.70.42 1811.165.7 179.2 333 
17.3 18.10.70 1934.651.8 187.3 348 
34.7 16.12.77 1839.5255.9 171.8 319 
Tween80 
0.076 15.50.68 1847.315.6 169.5 315 
0.76 15.90.37 1852.356.9 171.7 319 
1.5 16.00.70 2024.350.9 180.2 335 
2.3 17.41.65 1853.3109.9 179.5 334 
3.8 16.752.78 1624.569.1 164.9 306 
7.6 14.980.45 1691.187.4 159.2 296 
17.3 15.330.89 1638.979.8 158.5 294 
6.3.2 Results of intrinsic dissolution rate 
The IDR profiles from compacts of the pure CBZ III, CBZ-NIC cocrystal, and physical 
mixtures of CBZ III and NIC at different dissolution media are shown in Fig. 6.5.  









Fig. 6.5 Dissolution profiles of test samples at different dissolution media: (a) CBZ-NIC cocrystal; (b) 
CBZ III; (c) equimolar physical mixture of CBZ III and NIC 
 
Table 6.5 Light microscopy photographs of the sample compacts before and after dissolution tests in 10.4 
mM SLS and 7.7 mM Tween 80 dissolution media 



















Cocrystal in water Cocrystal in 0.35 mM SLS
Cocrystal in 10.4 mM SLS Cocrystal in 0.076 mM Tween 80



















CBZ III in water CBZ III in 0.35 mM SLS
CBZ III in 10.4 mM SLS CBZ III in 0.076 mM Tween 80



















Mixture in water Mixturel in 0.35 mM SLS
Mixture in 10.4 mM SLS Mixture in 0.076 mM Tween 80
Mixture in 7.6 mM Tween 80





10.4 mM SLS 
  
7.6 mM Tween 80 
  
CBZ III 10.4 mM SLS 
  






10.4 mM SLS 
  
7.6 mM Tween 80 
  
 
All IDR profiles show the same trend: (1) within the first 2 minutes IDR of a test 
sample reached its maximum value and then decreased quickly within 10 minutes; (2) 
after 20 minutes of dissolution, all IDRs of test samples reached static values. The IDR 
of each sample during dissolution in each dissolution medium was decreasing, indicated 
by the growth of solid material on the surface of sample compact that can be visualized 
by light microscopy (see Table 6.5). Prior to dissolution tests, all of the compact 
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surfaces were smooth. After dissolution tests,  the microscope images show that small 
needle-shaped crystals have appeared on the compact surfaces, indicating that solid state 
changes due to crystallisation of CBZ DH from the supersaturated solutions on  
compact surfaces.  
The IDRs of CBZ-NIC cocrystal are shown in Fig. 6.5 (a). It was found that IDR profile 
of CBZ in the 0.35 mM SLS dissolution medium was almost identical to that in water. 
In 0.076 mM Tween 80 dissolution medium, its dissolution profile was slightly lower 
than that in pure water. In 10.4 mM SLS dissolution medium, IDR profile of CBZ-NIC 
cocrystal increased significantly in comparison with that in water, indicating that SLS 
can increase cocrystal dissolution rate when its concentration was higher than its CMC. 
To our surprise, in the 7.6 mM Tween 80 dissolution medium, the CBZ dissolution 
profile was much lower than that in water.  
 
(a1) CBZ –NIC cocrystal Raman spectrum 0-3600cm
-1
 









(b1) CBZ III Raman spectrum 0-3600cm
-1
 








Fig. 6.6 Raman spectra of the compacts before and after UV imaging dissolution at different dissolution 
media: (a) CBZ-NIC cocrystal; (b) CBZ III 
Raman spectroscopy was used before and after UV imaging to characterize solid state 
(see Fig. 6.6), and showed some characteristic peaks of starting material has changed 
after the dissolution tests, which are in good agreement with previous findings [151]. 
The ratios of peak intensity at 1035 to 1025 cm
-1
, 1040 to 1025 cm
-1
 have changed for 
CBZ-NIC cocrystal and CBZ III due to the transformation to CBZ DH. In order to 
quantify solid-state change during dissolution, calibration models were built to quantify 
the percentage of CBZ DH on the surface of a sample compacts after dissolution test, 
details about calibration model were shown in section 3.3.2. 
The percentage of CBZ DH covering on the surface of CBZ-NIC cocrystal sample 
compact for each dissolution test is shown in Fig. 6.7(a). Interestingly the percentages 
of CBZ DH crystals on the surfaces of CBZ-NIC cocrystal compacts in 0.35 mM SLS 
and 10.4 mM SLS dissolution media are nearly constant (i.e. 81% in 0.35 mM SLS 
solution and 78% in 10.4 mM SLS dissolution solution), which nearly equal to that (i.e. 
77%) of CBZ-NIC cocrystal in water. By contrast, the percentages of CBZ DH covering 
the surfaces of CBZ-NIC cocrystal compacts in both 0.076 mM Tween 80 and 7.6 mM 
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Tween 80 (i.e. 94% in both Tween 80 solutions) are much higher than that of CBZ-NIC 





Fig. 6.7 Comparison of percentages of CBZ DH on the surfaces of sample compacts after dissolution test: 
(a) CBZ-NIC cocrystal; (b) CBZ III 
CBZ III is an anhydrous form of CBZ and has similar dissolution behavior to that of 
CBZ-NIC cocrystal in different surfactant solutions. If a surfactant concentration was 
lower than its CMC, the IDR profile of CBZ III in the 0.35 mM SLS dissolution or 
0.076 mM Tween 80 was similar to that in water, as shown in Fig. 6.5(b). When 
compared with the dissolution behavior of CBZ III in water, the IDR profile of CBZ III 
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Tween 80 dissolution medium. The percentage of CBZ DH covering on the surface of 
CBZ III sample compact for each dissolution test based on Raman spectra is shown in 
Fig. 6.7(b). The percentages of CBZ DH crystals on the surfaces of CBZ III compacts 
increased significantly with SLS concentration in comparison with that in pure water. A 
similar trend was found in a Tween 80 dissolution medium: the percentages of CBZ DH 
covering the surfaces of CBZ III compacts in both 0.076 mM Tween 80 and 7.6 mM 
Tween 80 dissolution media increased, but to a lesser extent than those in the SLS 
dissolution media.  
Evolution of the IDRs of the equimolar physical mixture of CBZ III and NIC at 
different dissolution media is shown in Fig. 6.5(c). The biggest variability of the IDRs 
of the physical mixture is shown, which is consistent with that of dissolving polyphase 
mixtures in which the more soluble component dissolves more rapidly from the surface 
of compact, leaving behind a porous layer of the less soluble component [88, 172]. 
Light microscopy showed that holes appeared on the compact surface due to dissolved 
NIC (see Table.6.5), resulting in a significant change of the dissolution rate. Similar 
trends of effects of dissolution media on IDR of physical mixture was found with the 
10.4 mM SLS dissolution medium, the IDR profile increased significantly compared 
with that of pure water in Fig.6.5(c).  
6.4 Discussion 
6.4.1 Discussion of solubility enhancement by surfactants 
From this study, it has been shown that CBZ-NIC cocrystal has the same equilibrium 
solubility of CBZ DH (CBZ III) because of dissociation of individual components of 
CBZ-NIC cocrystal, which in turn is due to weak hydrogen bonds in molecular 
assembly of the two components of CBZ and NIC. There was no significant effect of 
the cocrystal coformer NIC on the solubility of CBZ because of a low concentration of 
NIC in solution. Based on the CBZ solubility profile as a function of NIC concentration, 
it has been shown in Fig. 6.4 that at a low NIC concentration (up to 40 mM) solubility 
of CBZ was constant. 
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The phase solubility diagram of CBZ in the presence of NIC has shown that CBZ 
solubility has been enhanced significantly and in a nonlinear fashion as a function of 
NIC concentration (Fig. 6.4). The experimental observations can be explained by 
stacking complexation mechanism of NIC with CBZ [173], in which linear increases in 
the solubility of CBZ may be attributed to the formation of 1:1 complexes in Region I 
and nonlinear increases in Region II, indicating that higher order complexes were 
formed due to self-association of NIC. Due to the strong interaction of CBZ and NIC in 
solution, the eutectic point of the CBZ-NIC cocrystal was not a single point, but 
covered the whole range of Region II from 1000 mM to 2400 mM of NIC 
concentrations. In this study, the highest total measured CBZ concentration was selected 
as eutectic point of CBZ-NIC cocrystal (Fig. 6.4), showing that the solubility ratio of 
Scc /        was 319. If the lowest total measured CBZ concentration in region II was 
selected as eutectic point of CBZ-NIC cocrystal, and the solubility ratio of Scc /        
was 130. The reported value of solubility ratio of Scc /        was 152, which was in 
the region II of phase solubility diagrams [84]. 
SLS and Tween 80 have little effects on enhancing the solubility of CBZ-NIC cocrystal 
in Table 6.4, in which the solubility of the CBZ-NIC cocrystal increased slightly with 
SLS concentration and decreased with Tween 80 concentration, however, significant 
solubility enhancement for CBZ DH by SLS was observed above its CMC. 
6.4.2 Discussion of effects of surfactants on SMPT of CBZ III and CBZ-NIC 
cocrystal 
Comparing IDRs of CBZ III, CBZ-NIC cocrystal and physical mixture of CBZ III and 
NIC in the same dissolution medium, it has been shown that CBZ-NIC cocrystal has the 
highest IDR in Fig. 6.5, indicting the advantages of CBZ-NIC cocrystal in enhancing 
the dissolution rate [151]. 
From this study, it has also shown that SMPT of CBZ III and CBZ-NIC cocrystal can be 
altered by inclusion of a surfactant in dissolution medium. However, CBZ III and CBZ-
NIC cocrystal have shown different transformation behaviour affected by different 
surfactants. 
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It is well known that surfactants can enhance dissolution of poorly water soluble drugs 
in two ways, i.e. either by lowering the surface tension at solid drug surface to increase 
surface area available for dissolution or by increasing drug solubility [174]. The ability 
of surfactants of SLS and Tween 80 to manipulate the SMPT of CBZ-NIC cocrystals 
and CBZ III affects the nucleation and/or growth of new crystalline phase of CBZ DH. 
Dissolution experiments with CBZ III have shown the increased percentages of CBZ 
DH precipitated on the surfaces of sample compacts with increasing surfactant 
concentrations of SLS and Tween 80 (see Fig. 6.7(b)), indicating that both SLS and 
Tween 80 facilitated surface mediated nucleation of CBZ DH on the dissolving CBZ III. 
These results are in line with classic nucleation theory which predicts that crystal 
nucleation increases with decreasing interfacial tension by inclusion of surfactants in 
dissolution medium [175]. Comparing the two surfactants, anionic surfactant SLS has 
shown more significant effects on nucleation of CBZ DH during dissolution of CBZ III 
than Tween 80, indicted by higher percentages of CBZ DH covering on the surface of 
dissolution compact. 
Dissolution experiments of CBZ-NIC cocrystal with and without SLS show the same 
percentage of CBZ DH precipitated on the surface of each sample compact (Fig. 6.7(a)), 
indicating that SLS does not facilitate surface mediated nucleation of CBZ DH on the 
dissolving CBZ-NIC cocrystal. The rate of CBZ DH nucleation for CBZ-NIC cocrystal 
dissolution was influenced mainly by the coformer NIC, rather than as a consequence of 
decreasing the interfacial tension by SLS. Dissolution experiments of CBZ-NIC 
cocrystal with 0.076 and 7.6 mM concentrations of Tween 80 have shown that 
significant higher of CBZ DH was precipitated as a covering on sample compact 
surfaces, (94% compared with 77% of CBZ DH crystallised on the surface in pure 
water), indicating that the rate of CBZ DH nucleation during CBZ-NIC cocrystal 
dissolution was affected by both the coformer NIC and by Tween 80. 
Dissolution rate is the net result of solubilisation rates of original solid phase and 
formation rates of a less soluble solid phase. SLS has a flexible alkyl chain that exhibits 
axial polarity (hydrophilic head group and hydrophobic tail) and a well-defined CMC. 
The transformation process of CBZ-NIC cocrystal and CBZ III to CBZ DH is sensitive 
  Chapter 6 
130 
 
to the SLS concentration in a dissolution medium. The solubility of CBZ for solid of 
CBZ III has not increased in 0.35 mM SLS dissolution medium below its CMC. Due to 
increasing in rate of CBZ DH nucleation, the IDR profile of CBZ III in the 0.35 mM 
SLS dissolution medium was lower than its corresponding profile in water (Fig. 6.5(b)). 
Because SLS does not influence CBZ DH nucleation for the dissolving CBZ-NIC 
cocrystal, the IDR profile of the CBZ-NIC cocrystal in the 0.35 mM SLS dissolution 
medium was almost same as its corresponding profile in water (Fig. 6.5(a)). The 
solubility of CBZ for solids of CBZ III and CBZ-NIC cocrystal have increased 
significantly when concentration of SLS is higher than its CMC due to the inclusion of 
CBZ molecules into the surfactant micelles, resulting in a lack of growth material of 
CBZ in solution which retards crystallization and inhibits growth of stable crystal form 
CBZ DH on compact surface. IDR of CBZ III in the 10.4 mM SLS solution was 
increased 1.3 times relative to that in pure water whilst the IDR of CBZ-NIC cocrystal 
in the same solution was increased to 1.6 times of its corresponding value in pure water. 
Tween 80 is a nonionic surfactant and has a wide range of CMC values because of 
progressive association and heterogeneous distribution of aggregates. Although Tween 
80 can increase the solubility of CBZ in solution, its solubilisation capacity was limited 
- the large molecule sizes of Tween 80 and its aggregates in solution mean it can form 
an interfacial barrier to prevent CBZ molecules getting into the bulk solution, resulting 
in accelerated nucleation and growth of stable crystal form CBZ DH on the sample 
compact surface. Therefore, experimental results in this work indicated that Tween 80 
had opposite effect on IDRs of CBZ III and CBZ-NIC cocrystal as those of SLS, i.e. the 
inclusion of Tween 80 in dissolution medium reduced the IDRs of CBZ III and CBZ-
NIC cocrystal (Fig. 6.5). 
6.5 Chapter conclusions 
The influence of two surfactants (SLS and Tween 80) on the solubility and dissolution 
behavior of the CBZ-NIC cocrystal, CBZ III and the physical mixture of CBZ III and 
NIC has been studied in this chapter. The results show that CBZ DH (CBZ III), CBZ-
NIC cocrystal and physical mixture of CBZ III and NIC have the same equilibrium 
solubility. SLS and Tween 80 have little effect on the solubility of the CBZ-NIC 
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cocrystal in comparison with the significant solubility enhancement for CBZ DH by 
SLS above its CMC. 
The SMPT of CBZ III and CBZ-NIC cocrystal can be altered by inclusion of a 
surfactant in dissolution medium. However, CBZ III and CBZ-NIC cocrystal have 
shown different transformation behavior with different surfactants. IDRs profile of CBZ 
III and CBZ-NIC cocrystal increased significantly when the concentration of SLS was 
higher than its CMC in a dissolution medium. The inclusion of Tween 80 in dissolution 
medium reduced IDRs of CBZ III and CBZ-NIC cocrystal due to its large molecule size 
which can form an interfacial barrier to prevent CBZ molecules getting into the bulk 
solution, resulting in accelerated nucleation and growth of stable crystal form CBZ DH 
on sample compact surface. 
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Chapter 7 Solubility and Dissolution Behaviour of CBZ-NIC, CBZ-
SUC Cocrystals in Biomedia 
7.1 Chapter overview 
Since complex-heterogeneous gastric intestinal environment has a greater impact on 
drug dissolution, in recent years there has been considerable interest in exploring how in 
vitro dissolution testing can be used more effectively in the product development 
phase[176, 177]. An example of this is to using more biorelevant dissolution media, 
such as simulated gastric fluid, with the aim of improving the connection between the 
product behaviour observed in vitro and that in vivo[132]. 
In this chapter, the solubility and dissolution behaviour of CBZ, CBZ-NIC cocrystal, 
CBZ-SUC cocrystal in simulated gastric fluid (SGF), pH1.2 hydrochloride acid buffer 
(pH1.2 HCl buffer), simulated intestinal fluid (SIF), pH 6.8 phosphate buffer (pH 6.8 
PBS buffer) have been investigated. First of all, equilibrium solubility of CBZ and two 
cocrystals in four buffers were determined respectively. Then for the two cocrystals 
above, the complexation behaviour of cocrystal components was studied through 
measuring the solubility of CBZ as function of coformers’ concentration in four buffers. 
Finally, the evolution of intrinsic dissolution rate of CBZ III and two cocrystals in four 
buffers were monitored by ActiPix SDI 300 UV surface imaging dissolution system. 
7.2 Materials and methods 
7.2.1 Materials 
Anhydrous CBZ III, nicotinamide, succinic acid, sodium chloride, potassium phosphate 
monobasic, ethyl acetate, 0.2 M sodium hydroxide, 0.2 M hydrochloric acid, 1M 
hydrochloric acid, ethanol, pepsin powder, and pancreatin powder, 0.45 μm nylon 
syringe filter were used in this chapter. Details about these materials can be found in 
chapter 3 materials and methods. 
The dissolution media used in this chapter were pH 1.2 HCl buffer, SGF, pH 6.8 PBS 
buffer and SIF, which were prepared according to British Pharmacopeia 2013. CBZ DH, 
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CBZ-NIC cocrystal, and CBZ-SUC cocrystal were prepared. The preparation details for 
each buffer and CBZ samples were introduced in section 3.4 Preparations. Details about 
CBZ samples characterisation have been shown in chapter 4 Sample characterisations. 
7.2.2 Methods 
7.2.2.1 Equilibrium solubility 
The solubility of CBZ DH, the CBZ-NIC, CBZ-SUC cocrystal and its physical mixture 
in pH 1.2 HCl buffer, pH 6.8 PBS, SGF, and SIF were determined using air-shaking 
bath method. Experimental procedures were described in details in section 3.3.11.1 
Equilibrium solubility test. The experiment has been performed at 37C at 100 rpm for 
24 hours. CBZ, NIC and SUC concentrations were calculated by Perkin Elmer series 
200 HPLC system. Solid residues were retrieved from the solubility tests and air dried 
for 30 minutes. All of dried solids were characterized by FTIR, Raman and DSC. All 
solubility tests were carried out in triplicate.  
7.2.2.2 Solubility of CBZ as function of coformers 
The solubility of CBZ as function of NIC, and SUC in pH 1.2 HCl buffer, pH 6.8 PBS, 
SGF, and SIF was determined respectively at 37C. Experimental procedures were 
described in details in section 3.3.11.2 Cocrystal eutectic points measurement test.  
7.2.2.3 UV imaging dissolution experiment 
The dissolution behavior of CBZ III, CBZ DH, CBZ-NIC cocrystal, and CBZ-SUC 
cocrystal in four biomedia, pH 1.2 HCl buffer, pH 6.8 PBS, SGF, and SIF, were studied 
by ActiPix SDI 300 UV surface imaging system (Paraytec Ltd., York, UK). Details 
about the operation can be found in section 3.3.1 ActiPix SDI300 UV imaging 
dissolution system. All dissolution tests were performed at 37 C in triplicate.  




7.3.1 Equilibrium solubility 
The equilibrium solubility of CBZ DH (CBZ III), 1:1 CBZ-NIC, 2:1 CBZ-SUC 
cocrystal and physical mixture in SGF, pH1.2 buffer, pH6.8 PBS, SIF after 24 hours are 
shown in Fig. 7.1 and details of data are shown in Table 7.1. 
Comparing the solubility of one sample in different buffer, for CBZ DH, the highest 
solubility was found in SGF, which was 0.95 mM. And the solubility of CBZ DH in 
four mediums was decreasing gradually in the order of SGF, pH1.2, pH6.8 and SIF. The 
lowest CBZ DH solubility was 0.64 mM in SIF. For the two cocrystals, the highest 
solubilities were also found in SGF buffer. Generally, the solubilities of cocrystals in 
four buffers are decreasing in the order of SGF, pH1.2, SIF and pH6.8.  
Comparing the solubility between different samples, all cocrystal has higher solubility 
than CBZ DH in same buffer. CBZ-SUC cocrystal has the highest solubility in all 
buffers among all tested samples. Most notably, the solubility of CBZ-SUC cocrystal in 
SGF buffer was the highest of all and which was increased to more than twice level than 
that of other samples. 
There was no big difference between the solubility of CBZ of mixtures in four buffers. 
Generally, the highest solubility of mixtures was found in pH 1.2 buffer, followed by 
SIF. The solubility of mixtures in SGF and pH 6.8 buffer were relative lower. Compare 
the solubility of different mixture, there was no extremely high solubility obtained, all 
sample have similar solubility. 
Table 7.1 CBZ solubility of CBZ DH, CBZ-NIC cocrystal and mixture, CBZ-SUC cocrystal and mixture 
in SGF, pH1.2 HCl buffer, pH6.8 PBS buffer, SIF (mM) 
mM CBZ DH CBZ-NIC  CBZ-SUC 
  cocrystal mixture cocrystal mixture 
SGF 0.95±0.17 1.05±0.22 0.97±0.13 2.37±0.18 0.89±0.13 
pH1.2 0.86±0.14 1.00±0.15 1.04±0.17 1.19±0.25 0.96±0.19 
pH6.8 0.79±0.13 0.84±0.13 0.94±0.22 0.96±0.25 0.85±0.18 
SIF 0.64±0.14 0.89±0.18 0.99±0.07 1.12±0.18 0.89±0.17 
 





Fig. 7.1 Equilibrium solubility of CBZ DH, cocrystal and mixture in SGF, pH1.2 HCl buffer, pH6.8 PBS 
buffer, and SIF 
The pH value of solutions in each vial was measured by JENWAY 350 pH meter after 
24 hours equilibrium and the results were shown in Table 7.2. After 24 hours 
dissolution, all solutions’ pH value has some variations from its original value. For CBZ 
DH, after 24 hours dissolution in SGF and pH1.2, the pH of solution was increased 
from 1.2 to 1.46 and 1.43 respectively. Different from CBZ DH, pH of all cocrystal and 
mixture solutions in SGF medium were decreased slightly (except the pH of CBZ-NIC 
cocrystal in SGF increased to 1.3). For pH 6.8 buffer, CBZ DH and CBZ-NIC mixture 
increased its pH value to 7.03 and 6.99 respectively after 24 hours dissolution in it, the 
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dissolution in SIF caused a decrease in the solution pH value. And the biggest decrease 
was found with CBZ-NIC cocrystal which decreased the pH value from 6.8 to 4.95. 
Table 7.2 pH of CBZ DH, CBZ-NIC cocrystal and mixture, CBZ-SUC cocrystal and mixture in SGF, pH 
1.2 HCl buffer, pH 6.8 PBS buffer, SIF 
mM CBZ DH CBZ-NIC CBZ-SUC 
  cocrystal mixture cocrystal mixture 
SGF 1.46±0.01 1.30±0.01 1.14±0.01 1.19±0.01 1.16+0.01 
pH1.2 1.43±0.01 1.19±0.01 1.07±0.04 1.16±0.01 1.14±0.01 
pH 6.8 7.03±0.01 6.79±0.02 6.99±0.01 6.60±0.01 6.50±0.02 
SIF 5.02±0.03 4.95±0.07 5.61±0.42 5.18±0.02 5.16±0.02 
IR, Raman, and DSC characterization results of the solid residue after equilibrium tests 
were shown in appendix A.2.1.1-3.  Characterization results show that solid residue of 
cocrystal and mixture samples in all media have transformed to DH, except the CBZ-
SUC cocrystal in SGF buffer. DSC, IR, and Raman characterization results of solid 
residue after equilibrium solubility test in four biomedia for CBZ-SUC cocrystal shown 
in Fig. 7.2 demonstrate that after equilibrium solubility test in SGF CBZ-SUC cocrystal 
still keep cocrystal structure. In Fig. 7.2.(a), DSC results of CBZ-SUC cocrystal after 
equilibrium solubility test in SGF has a single endothermic peak around 195C 
corresponding to the  melting of CBZ-SUC cocrystal; while the DSC results of solid 
residue from other three media show dehydration peaks around  80 to 120C due to 
CBZ DH. In Fig. 7.2.(b), the IR spectrum of solid from equilibrium solubility test in 
SGF show characteristic peaks of CBZ-SUC cocrystal around 3400-3000 cm
-1
 range, 
while the other three spectra show the  CBZ DH IR patterns.  In Fig. 7.2.(c), Raman 
spectrum of solid residue from SGF biomedium shows characteristic peak of CBZ-SUC 
cocrystal around 400, 100 and 2900 cm
-1
. The above three characteristic technique can 
demonstrate that CBZ-SUC cocrystal after equilibrium solubility test in SGF still keep 
its cocrystal structure. 
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(b) IR  
 
(c) Raman 
Fig. 7. 2 DSC, IR, Raman characterisation of solid residue from equilibrium solubility test of CBZ-
SUC cocrystal in four biomedia: pH1.2, pH6.8, SGF, SIF 
7.3.2 Solubility of CBZ as function of coformers 
Before measuring the solubility of CBZ as function of coformers in biomedia at 37 C, 
coformers solubility in biomedia at 37C were measured, and the results were shown in 
Table 7.3. 
Table 7.3 NIC and SUC solubility in SGF, pH1.2 HCl buffer, pH6.8 PBS buffer, SIF at 37C (mM) 
mM SGF pH1.2 pH6.8 SIF 
NIC 4771.17±259.30 5815.65±302.96 5626.71±272.23 5124.06±391.99 
SUC 933.00±148.11 943.75±74.57 1094.11±49.76 1079.67±28.05 
7.3.2.1 CBZ solubility as function of NIC in biomedia 
Based on NIC solubility, the maximum NIC concentration in each medium was set at a 
value near to its solubility. The equilibrium solubility of CBZ was measured as a 
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function of the NIC concentration, results were shown in Fig. 7.3, 7.4 and data were 
shown in Table 7.4.  
 
Fig. 7.3 CBZ solubility as function of NIC in four media 
 
Fig. 7.4 Measured NIC concentration vs. add in NIC concentration 














818.87 7.95±0.52 812.67±77.99 818.87 7.84±0.72 905.24±6.42 
1637.73 18.36±0.75 1573.03±131.35 1637.73 17.28±0.30 1529.38±105.83 
2456.60 23.20±0.27 2247.71±23.45 2456.60 14.71±0.67 2127.73±158.46 
3275.47 23.67±1.33 2700.76±151.22 3275.47 20.31±1.50 2814.17±195.92 
4094.33 27.62±0.17 3109.98±291.29 4094.33 26.84±0.53 3436.38±168.10 
4913.20 30.53±1.09 3869.27±112.06 4913.20 30.16±0.82 3668.90±106.98 
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3275.47 28.68±1.56 2586.20±105.19 3275.47 22.59±0.69 2665.32±96.41 
4094.33 31.51±0.84 3059.37±123.67 4094.33 24.74±3.57 3190.93±230.88 
4749.43 32.70±1.75 3303.63±173.67 4913.20 29.09±3.58 3363.02±147.27 
The solubility of CBZ increased rapidly as NIC adding in at the beginning of solubility 
curves indicating the 1:1 complex formation of CBZ and NIC. The rapid increasing in 
SGF, pH1.2, and SIF buffer is corresponding to initial concentration of NIC from 
818.87 to 2456.6 mM. The rapid increasing in pH6.8 buffer is corresponding to initial 
concentration of NIC from 818.87 to 1637.73 mM. The highest CBZ solubility was 
found in SGF with initial NIC concentration 2456.6 mM. At the beginning of this rapid 
increasing stage, the solubility limit of the complex formed was not exceeded and the 
solid residue should be CBZ DH only (IR, DSC, and Raman characterisation shown in 
appendix, A2.2.1-3), the measured concentration of NIC was the same as that of the 
initial NIC, shown in Table 7.4. In the later part of this stage, the solubility limit of the 
1:1 complex formed was gradually obtained and exceeded, CBZ-NIC cocrystal start to 
precipitate (IR, DSC, and Raman characterisation shown in appendix, A2.2.1-3). The 
highest CBZ concentration point in this stage was set as eutectic point of CBZ-NIC 
cocrystal. The total concentrations of CBZ and NIC at the eutectic points, and cocrystal 
solubility calculated based on solubility definition of a 1:1 cocrystal in Equ.6-1, are 
shown in Table 7.5. CBZ-NIC cocrystal solubility was found higher in acidic buffer 
than in alkalic buffers. For the two acidic buffers, cocrystal has a higher solubility in 
SGF than in pH1.2 HCl buffer; for the two alkalic buffers, cocrystal in SIF was also 
higher than that in the simple pH 6.8 buffer. Cocrystal has a better solubility in 
simulated buffer. 
Table 7.5 CBZ-NIC cocrystal eutectic point, cocrystal solubility and solubility ratio in SGF, pH1.2 buffer, 
pH6.8 buffer, SIF 
Solvent [CBZ]eu (mM) [NIC]eu (mM) Cocrystal solubility Scc (mM) 
Solubility ratio 
Scc / S CBZ, buffer 
SGF 29.30±0.24 2190.66±64.59 253.34±3.85 268.08 
pH1.2 23.20±0.27 2247.71±23.45 227.13±31.48 263.97 
pH6.8 17.28±0.30 1529.38±105.83 162.53±6.91 206.32 
SIF 22.41±2.5 2148.70±151.48 219.39±19.91 342.66 
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As solubility limit of the 1:1 complex formed was gradually obtained and exceeded, the 
concentration of CBZ stop rapid increasing as NIC initial concentration. For SGF, 
pH1.2, and SIF, CBZ solubility level around eutectic point as NIC initial concentration 
increase from 2456.6 to 3275.47 mM. CBZ solubility in pH6.8 buffer has slightly 
decreased as NIC initial concentration increase from1637.73 mM to 2456.6 mM. All of 
the solid CBZ DH was consumed to form the complex to generate the supersaturated 
solution of the complex, resulting in precipitation of large amount of CBZ-NIC 
cocrystal and reduction of CBZ concentration in solution. It has been shown that the 
CBZ-NIC cocrystal and NIC were coexisting in the solid residues, shown in DSC, FTIR 
and Raman analysis (A2.2.1-3). NIC measured concentration was lower than that of the 
initial NIC in this region. As NIC initial concentrations continue increasing, the 
concentrations of CBZ increase, resulting from higher order complexes of CBZ and 
NIC were generated. The solid residues were CBZ-NIC cocrystal and NIC, confirmed 
by DSC, FTIR and Raman, shown in appendix (A2.2.1-3). 
Table 7.6 pH of dissolution medium of SGF, pH 1.2 buffer, pH6.8 buffer, and SIF after 24 hours 
dissolution of CBZ as function of NIC 










818.87 3.88±0.02 818.87 3.95±0.01 818.87 7.18±0.01 818.87 6.89±0.01 
1637.73 4.16±0.01 1637.73 4.21±0.01 1637.73 7.26±0.00 1637.73 6.98±0.01 
2456.60 4.29±0.01 2456.60 4.35±0.01 2456.60 7.34±0.01 2456.60 7.06±0.01 
3275.47 4.41±0.00 3275.47 4.42±0.01 3275.47 7.40±0.01 3275.47 7.15±0.01 
4094.33 4.49±0.01 4094.33 4.51±0.01 4094.33 7.48±0.01 4094.33 7.23±0.00 
4749.43 4.54±0.01 4913.20 4.58±0.01 4913.20 7.55±0.01 4913.20 7.32±0.01 
  5732.07 4.64±0.01 5568.29 7.60±0.01   
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The pH value of each buffer after 24 hours dissolution was shown in Table 7.6, and Fig. 
7.5.  The pH value increased to the range of 3.9-4.6 from the original level of 1.2 as 
NIC original concentration increasing in SGF and pH 1.2 HCl buffer. There is no big 
difference in pH value between the two buffers with same NIC initial concentration. For 
pH 6.8 PBS buffer and SIF, the pH value was also increased after 24 hours CBZ 
dissolution in it. The pH value was increased to the range of 7.18 to 7.6 in pH 6.8 PBS 
buffer as initial NIC concentration increasing. In SIF buffer, the pH value was slightly 
lower than that in PBS buffer with same initial NIC concentration. 
7.3.2.2 CBZ solubility as function of SUC in biomedia 
Based on SUC solubility in four media, the maximum SUC concentration in each 
medium was set at a value near to its solubility. The equilibrium solubility of CBZ was 
measured as a function of SUC concentration; results were shown in Fig. 7.6, 7.7 and 
Table 7.7.  
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Fig. 7.7 Measured SUC concentration vs. add in SUC concentration 
Table 7.7 CBZ solubility as function of SUC in pH1.2 buffer, SGF, pH6.8 buffer, and SIF (mM) 











84.68 1.75±0.69 44.68±12.82 2.07±1.09 43.09±7.57 
169.36 0.68±0.40 159.86±63.75 0.92±0.24 93.06±40.44 
338.72 0.30±0.08 187.15±53.20 0.26±0.14 164.71±8.81 
508.09 0.18±0.06 362.87±28.92 0.26±0.09 314.15±11.21 
677.45 0.24±0.02 498.61±32.82 0.28±0.09 522.78±18.03 
846.81 0.27±0.09 691.85±37.16 0.26±0.04 705.68±45.24 











84.68 0.89±0.13 54.79±38.10 1.01±0.19 86.71±17.36 
169.36 0.54±0.10 165.58±13.55 0.96±0.39 135.41±28.11 
338.72 0.30±0.02 286.86±23.93 0.80±0.19 328.96±36.44 
677.45 0.30±0.05 549.97±27.85 0.44±0.14 668.35±30.70 
846.81 0.28±0.13 717.99±55.46 0.43±0.13 758.98±66.79 
1016.17 0.29±0.06 888.69±28.86 0.51±0.08 947.88±70.33 
Figure of CBZ solubility as function of SUC concentration showed a different trend as 
that as function of NIC concentration. At beginning, CBZ solubility in four biomedia 
with lowest initial concentration of SUC (84.68 mM) has been increased slightly. As 
initial SUC concentration increase, CBZ solubility was gradually decreased to very low 
level, which is lower than CBZ solubility in pure buffers. 
The pH value of each buffer after 24 hours dissolution of CBZ as function of SUC was 
shown in Fig. 7.8 and Table 7.8. pH value of pH 1.2 HCl buffer and SGF decreased 
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from 6.8 to 3.83 and 3.57 at lowest SUC initial concentration, and pH in the two buffers 
continue to decrease to around 2.6 at the highest SUC initial concentration.  
Table 7.8 pH of dissolution medium of SGF, pH1.2 buffer, pH6.8buffer, and SIF after 24 hours 
dissolution of CBZ as function of SUC concentration 










84.68  1.12±0.02 84.68  1.07±0.01 84.68 3.83±0.01 84.68  3.57±0.01 
169.36  1.14±0.01 169.36  1.05±0.01 169.36 3.45±0.01 169.36  3.32±0.01 
338.72  1.11±0.01 338.72  1.03±0.01 338.72 3.10±0.01 338.72  3.01±0.00 
508.09  1.08±0.01 508.09  1.02±0.01 677.45 2.79±0.00 677.45  2.72±0.01 
677.45  1.07±0.00 677.45  1.00±0.01 846.81 2.75±0.01 846.81  2.63±0.01 
846.81 1.07±0.01 846.81  0.99±0.01 1016.17 2.73±0.01 1016.17  2.56±0.01 
 
 
Fig. 7.8 pH vs. initial SUC concentration in four dissolution media after 24hours dissolution of CBZ 
7.3.3 Intrinsic dissolution rate 
The dissolution behavior of CBZ III, CBZ-NIC cocrystal, and CBZ-SUC cocrystal in 
pH 1.2 HCl buffer, pH 6.8 PBS, SGF, and SIF, were studied by ActiPix SDI 300 UV 
surface imaging system. The IDR profiles of CBZ III, CBZ-NIC cocrystal, and CBZ-
SUC cocrystal in four biomedia are shown in Fig. 7.9. The IDR profiles of all samples 
in different biomedia have some properties in common: in first 10 minutes, IDR 
increased to maximum value and then decreased quickly; in the following 50 minutes, 
IDR kept decreasing at very slow rate and approach a static rate. To compare the IDRs 
of samples in four buffers after the first 10 minutes quick change, generally, the IDR of 
CBZ III in SGF was the largest, followed by SIF and pH 1.2 buffer, the lowest IDR 
figure was found in pH6.8 PBS buffer (Fig. 7.9.a).  IDR of CBZ-NIC cocrystal in 
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7.9.b). For CBZ-SUC cocrystal, its IDR in SGF is much higher than that in the other 







Fig. 7.9 Dissolution profiles of CBZ DH and cocrystals in biomedia: (a) CBZ DH; (b) CBZ-NIC cocrystal; 
(c) CBZ-SUC cocrystal 
Photos of sample compacts before and after UV imaging dissolution test were taken by 
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compact surfaces became rough, and small needle-shaped crystals appeared on the 
compact surfaces, indicating that the solid state changes due to crystallisation of CBZ 
DH from the supersaturated solutions on the compact surfaces.  


































Fig. 7.10 Light microscopy photographs of the sample compacts before and after dissolution tests 
Raman spectra of sample before and after dissolution test in different biomedia were 
shown in Fig. 7.11. After one hour dissolution, Raman spectra of sample compacts 
showed some change from the original material indicating solid state transformation. 
Spectra of CBZ III, CBZ-NIC cocrystal, after one hour dissolution in all medium 
showed the tendency to become CBZ DH. Raman spectra of CBZ-SUC cocrystal after 
dissolution in SIF, pH6.8 buffer and pH1.2 buffer, showed some change around 400 and 
3050 cm
-1
 to become CBZ DH, and the change is more obviously in SIF, pH6.8 buffer 
than in pH1.2 buffer. But the Raman spectrum of CBZ-SUC cocrystal in SGF did not 
show the any change. 
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Fig. 7.11 Raman spectra of the compacts before and after UV imaging dissolution: (a) CBZ III; (b) CBZ-
NIC cocrystal; (c) CBZ-SUC cocrystal 
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7.4.1 Discussion of solubility in biomedia 
7.4.1.1 Equilibrium solubility 
Equilibrium solubilities of CBZ DH, CBZ-NIC CBZ-SUC cocrystals and mixtures have 
been tested in this chapter. Because the transformation from original forms to CBZ DH, 
the solubilities of most tested samples did not show significant difference. Compared 
with lots of published CBZ solubilities measured under different experimental settings 
[178-183], the results in this thesis are at the same level as published data. 
Generally, the solubility of CBZ from CBZ DH and two cocrystals has a relative higher 
solubility in SGF and pH 1.2 buffer than that in SIF and pH 6.8 buffer. This is due to 
the alkali properties of CBZ which has a higher solubility in acidic buffer. The higher 
solubility in lower pH buffer are in good agreement with published data[179]. However, 
the solubility of CBZ from mixture in acidic buffers is not always higher. Probably, the 
coformer changes the dissolution medium.  After 24 hours dissolution, all solutions’ pH 
value has some variations from its original value. 
The most distinguish founding from equilibrium solubility test results is that CBZ 
solubility from CBZ-SUC cocrystal in SGF is more than double as others, which means 
that CBZ-SUC cocrystal has a more stable structure in SGF buffer. The more stable 
structure of CBZ-SUC cocrystal in SGF enables part of the cocrystal still keep the 
original state to reach a higher solubility level after 24 hours dissolution process. Except 
CBZ-SUC cocrystal in SGF, generally, all cocrystal has a little bit higher solubility than 
CBZ DH, while these CBZ solubility data does not show big difference. This can be 
explained by the dissociation of the individual components of cocrystals after long time 
equilibrium, which in turn is due to the weak hydrogen bonds in the molecular assembly 
of the two components of cocrystal. 
7.4.1.2 CBZ solubility as function of coformer’s concentration 
The solubility of CBZ in the presence of NIC in four media has increased as NIC initial 
concentration increasing due to the complexation of NIC and CBZ. CBZ-NIC cocrystal 
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solubility calculated based on CBZ and NIC concentration at eutectic point show that 
CBZ-NIC cocrystal solubility was higher in acidic buffer than in alkalic buffers. For the 
two acidic buffers, cocrystal has a higher solubility in SGF than in pH1.2 HCl buffer; 
for the two alkalic buffers, cocrystal in SIF was also higher than that in the simple pH 
6.8 buffer. Cocrystal has a better solubility in simulated buffer than inorganic buffer. 
The solubility of CBZ in the presence of SUC shows different trend as in presence of 
NIC, which does not show significant increasing as coformer initial concentration 
increasing. The solubility of CBZ in the presence of SUC has been increased slightly 
when SUC at relative lower initial concentration. As SUC initial concentration 
increasing, CBZ solubility decreased and level around 0.4 mM. 
7.4.2 Discussion of intrinsic dissolution rates 
The dissolution behaviour of CBZ III, CBZ-NIC cocrystal, and CBZ-SUC cocrystal in 
SGF, pH1.2 buffer, SIF, pH 6.8 buffer was monitored by UV imaging dissolution 
system. The results show that four biomedia researched in this study have different 
effect on the IDR of CBZ III and two cocrystals.  For parent drug, CBZ III, its IDR in 
SGF and pH1.2 are higher than that in SIF and pH6.8 buffer respectively. This is 
because CBZ III is more soluble in lower pH buffer. IDR of CBZ III in SGF and SIF 
buffer, simulated buffer with organic material (protein), are higher than that in the 
buffer prepared with only inorganic material at similar pH value. This could be 
explained by that CBZ III has a special binding reaction with the protein in simulated 
biomedia, and the binding reaction result in a higher dissolution rate. In sum, pH value 
and protein binding reaction affect the IDR of CBZ III. The two cocrystals dissolution 
rate in SGF, pH1.2 buffer, SIF, and pH 6.8 buffer show different trend as that of parent 
drug CBZ III. This can be explained by that the formation of cocrystal change the 
ability of CBZ III to bind with organic material in buffer, and also change its pH 
property. Although cocrystal partly transformed to CBZ DH later, cocrystal still 
occupied large area of the compact surface. 
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7.5 Chapter Conclusions 
The solubility and dissolution behaviour of CBZ, CBZ-NIC cocrystal, CBZ-SUC 
cocrystal in SGF, pH1.2 buffer, SIF, pH 6.8 buffer were studied in this chapter. From 
the study, it has shown that CBZ solubility from CBZ-SUC cocrystal in SGF is more 
than double as others. Except CBZ-SUC cocrystal in SGF, generally, all cocrystal has a 
little bit higher solubility than CBZ DH, while these CBZ solubility data does not show 
big difference. Due to the alkali properties of CBZ which has a higher solubility in 
acidic buffer, the equilibrium solubility of CBZ from CBZ DH and two cocrystals has a 
relative higher solubility in SGF and pH 1.2 buffer than that in SIF and pH 6.8 buffer.  
The solubility of CBZ in the presence of NIC has increased as NIC initial concentration 
increasing due to the complexation of NIC and CBZ. CBZ-NIC cocrystal has a higher 
solubility in acidic buffer than in alkalic buffers and a better solubility in simulated 
buffer than inorganic buffer. The solubility of CBZ in the presence of SUC shows 
different trend as in presence of NIC, which does not show significant increasing as 
coformer initial concentration increasing. 
The dissolution behaviour study results show that pH value and protein binding reaction 
affect the IDR of CBZ III. IDRs of CBZ III in four buffers are decreasing in the order of 
SGF, SIF, pH 1.2 buffer, and pH6.8 buffer. The two cocrystals dissolution rate show 
different trend as that of parent drug CBZ III. This can be explained by that the 
formation of cocrystal change the ability of CBZ III to bind with organic material in 
buffer, and also change its pH property. 
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Chapter 8 Conclusions and Future Work 
In this chapter, a summary of the presented work and main findings are presented. 
Limitations of the research are briefly discussed along with potential areas for further 
research. 
8.1 Summary of the presented work 
This research mainly investigated solubility and dissolution behaviour of 
pharmaceutical cocrystal with novel technique of UV surface imaging dissolution 
system which is expected to provide more contribution on pharmaceutical cocrystal 
research area.  
The research commenced with a critical review about pharmaceutical cocrystal from the 
basic theory to design strategies, formation and characterisation method and recent 
progress. The review work helps understand the current status of pharmaceutical 
cocrystal progress, develop the potential research topics to further improve the 
performance and our understanding about pharmaceutical cocrystals. Depending upon 
above review results, the primary aim of this work was established, which is to 
synthesize pharmaceutical cocrystals, and investigate the solubility and dissolution 
behavior of cocrystals under different environments using UV surface imaging 
dissolution system.  
Based on cocrystal screening theory and the feasibility of testing dissolution behaviour 
by UV imaging system, CBZ was selected to be the model drug in this research, and 
two cocrystals of CBZ, which are 1: 1 CBZ-NIC cocrystal, 2:1 CBZ-SUC cocrystal 
were prepared and characterised. 
This research subsequently studied dissolution and transformation behaviour of CBZ-
NIC cocrystal, physical mixture and different forms of CBZ: CBZ I, CBZ III and CBZ 
DH, by in situ techniques of UV imaging and Raman spectroscopy. Solution mediated 
phase transformation of cocrystals, which could greatly reduce the enhancement of its 
apparent solubility and dissolution rate, was discussed in this part of research. 
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This research further investigated the role of surfactants on inhibiting the SMPT of 
cocrystal. Two surfactants of sodium lauryl sulfate and Tween 80 were chosen to 
investigate their effects on the solubility and intrinsic dissolution rate of CBZ-NIC 
cocrystal. 
This research finally studied the solubility and dissolution behaviour of CBZ, CBZ-NIC 
cocrystal, CBZ-SUC cocrystal in simulated gastric fluid, pH1.2 HCl buffer, simulated 
intestinal fluid, and pH 6.8 PBS buffer. 
8.2 Conclusions 
This thesis established a method to monitor the dissolution process of cocrystal through 
in situ UV imaging and Raman spectroscopy combined with a complementary 
technique of SEM, which can provide an in depth understanding of the dissolution 
process of cocrystals through studying the kinetics and mechanism of drug substance 
release into dissolution medium.  
Dissolution and transformation behavior of CBZ-NIC cocrystal was studied by different 
in situ techniques of UV imaging and Raman spectroscopy. It has been found that CBZ-
NIC cocrystal including other polymorphs of CBZ III and I and mixture are converting 
to CBZ DH during dissolution. Compared with CBZ III and I, the rate of IDR of CBZ-
NIC cocrystal decreases slowly, indicating the rate of crystallization of CBZ DH from 
the solution is slow. In situ solid-state characterization during dissolution has shown the 
evolution of conversion of CBZ-NIC cocrystal and polymorphs to its dihydrate form, 
which cannot completely be understood by merely measuring the dissolved drug 
concentration. The information from the experiments on transformation behavior of 
CBZ-NIC cocrystal is valuable for understanding the mechanisms of cocrystal 
dissolution, which helps to develop a correlation between in vitro-in vivo absorption for 
formulation development. 
The investigation results about surfactants effects show that CBZ DH (CBZ III), CBZ-
NIC cocrystal and physical mixture of CBZ III and NIC have the same equilibrium 
solubility. SLS and Tween 80 have little effect on the solubility of the CBZ-NIC 
cocrystal in comparison with the significant solubility enhancement for CBZ DH by 
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SLS above its CMC. The SMPT of CBZ III and CBZ-NIC cocrystal can be altered by 
inclusion of a surfactant in dissolution medium. However, CBZ III and CBZ-NIC 
cocrystal have shown different transformation behavior with different surfactants. IDRs 
profile of CBZ III and CBZ-NIC cocrystal increased significantly when the 
concentration of SLS was higher than its CMC in a dissolution medium. The inclusion 
of Tween 80 in dissolution medium reduced IDRs of CBZ III and CBZ-NIC cocrystal 
due to its large molecule size which can form an interfacial barrier to prevent CBZ 
molecules getting into the bulk solution, resulting in accelerated nucleation and growth 
of stable crystal form CBZ DH on sample compact surface. 
Research of cocrystal solubility and dissolution in biomedium has shown that CBZ 
solubility from CBZ-SUC cocrystal in SGF is more than double as others. Except CBZ-
SUC cocrystal in SGF, generally, all cocrystal has a little bit higher solubility than CBZ 
DH, while these CBZ solubility data does not show big difference. Due to the alkali 
properties of CBZ which has a higher solubility in acidic buffer, the equilibrium 
solubility of CBZ from CBZ DH and two cocrystals has a relative higher solubility in 
SGF and pH 1.2 buffer than that in SIF and pH 6.8 buffer. However, the solubility of 
CBZ from mixture in acidic buffers is not always higher. The solubility of CBZ in the 
presence of NIC has increased as NIC initial concentration increasing due to the 
complexation of NIC and CBZ. CBZ-NIC cocrystal has a higher solubility in acidic 
buffer than in alkalic buffers and a better solubility in simulated buffer than inorganic 
buffer. The solubility of CBZ in the presence of SUC shows different trend as in 
presence of NIC, which does not show significant increasing as coformer initial 
concentration increasing. The dissolution behavior study results show that pH value and 
protein binding reaction affect the IDR of CBZ III. IDRs of CBZ III in four buffers are 
decreasing in the order of SGF, SIF, pH 1.2 buffer, and pH6.8 buffer. The two 
cocrystals dissolution rate show different trend as that of parent drug CBZ III. This can 
be explained by that the formation of cocrystal change the ability of CBZ III to bind 
with organic material in buffer, and also change its pH property. 
8.3 Future work 
The future research about pharmaceutical cocrystal in our lab will be focused on 




Cocrystal crystallography structure, preparation scale up, stability test, formulation, 
commercial products 
Cocrystals can provide higher and lower dissolution rates compared to the API, while 
the concepts of cocrystal and crystal engineering remain largely underexploited, and 
there are many basic questions about pharmaceutical cocrystal that remain unanswered. 
It is necessary to get a thoroughly understanding about the relations between the 
structure and dissolution behaviour. Effort should be made to study the structure of 
cocrystal from the crystallography aspect.  
To date, no cocrystal drug products appear to be on the market, there is still a long time 
to waiting before this pharmaceutical cocrystal research in lab becomes a product in 
market. Further research is desirable to test the physicochemical stability of cocrystal, 
formulation development and implement manufacturing of final dosage forms on 
commercial scale. To achieve all the above targets, the first thing we need to do is to 
scale up cocrystal preparation. Because the amount of cocrystal needed in the following 
research is greatly increased, which cannot easily provided by slow evaporation method.  
Processes to produce cocrystals on a large scale will likely require different approaches. 
UV imaging system improvement  
The ActiPix SDI 300 UV surface imaging system, as a new technology that has been 
designed to improve our understanding of the kinetics and mechanism of drug substance 
release into dissolution medium, can provide two-dimensional images of the dissolution 
process. The employ of UV imaging system in this research has obtained good results; 
however, there are still some obvious limitations about this method. First of all, the 
target drug should be the only one among all components in drug sample which can be 
quantitative measured under the present used UV filter. This limitation poses a 
difficulty on selected research objects for researchers, due to cocrystal always have 
more than one component, and what is more, the API and coformers have overplayed 
UV absorption area most time. Efforts should be made on enlargement of application of 
UV imaging dissolution system. Secondly, lots of practice is needed to operate this 
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testing system proficiently. In order to make the system more easy control, it is highly 
necessary to do some modification to optimize the operation, such as decrease the 
probability of bubbles emerging during dissolution testing, simplify the loading process 
of sample compact, automatically provide visualisation information as soon as the 
contact of drug component and medium. Last, in some cases the effluent should be 
collected and tested to validate the IDRs calculated by the software based on the images. 
This can be done manually or can be done automatically through connecting the UV 
imaging system with quantitative analysing equipment.  
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A1 Figures for Chapter 6 
A 1.1 Figures for equilibrium solubility tests in chapter 6 
A 1.1.1 IR spectra of solid residue from equilibrium solubility tests 
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A 1.1.2 Raman spectra of solid residue from equilibrium solubility tests 
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A 1.2 Figures for CBZ solubility as function of NIC tests in chapter 6 
A1.2.1 DSC thermal graphs of solid residue from solubility test of CBZ as function of 
NIC 
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A1.2.2 IR spectra of solid residue from solubility test of CBZ as function of NIC 
4000 3500 3000 2500 2000 1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500
4000 3500 3000 2500 2000 1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500














































  APPENDIXS 
170 
 
A1.2.3 Raman spectra of solid residue from solubility test of CBZ as function of NIC 
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A2 Figures for Chapter 7 
A 2.1 Figures for equilibrium solubility tests in chapter 7 
A2.1.1 DSC thermal graphs of solid residue from the experiment of equilibrium 
solubility test in four buffers: (a) CBZ DH; (b) CBZ-NIC cocrystal; (c) CBZ-NIC 
mixture; (d) CBZ-SUC cocrystal; (e) CBZ-SUC mixture. 
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(a) CBZ DH 
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(b) CBZ-NIC cocrystal 
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(c) CBZ-NIC mixture 
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(d) CBZ-SUC cocrystal 
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(e) CBZ-SUC mixture 
A2.1.2 IR spectra of solid residue from the experiment of equilibrium solubility test in 
four buffers: (a) CBZ DH; (b) CBZ-NIC cocrystal; (c) CBZ-NIC mixture; (d) CBZ-
SUC cocrystal; (e) CBZ-SUC mixture. 
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(a) CBZ DH 
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(b) CBZ-NIC cocrystal 
4000 3500 3000 2500 2000 1500 1000 500 4000 3500 3000 2500 2000 1500 1000 500


















(c) CBZ-NIC mixture 
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(d) CBZ-SUC cocrystal 
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(e) CBZ-SUC mixture 
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A2.1.3 Raman spectra of solid residue from the experiment of equilibrium solubility test 
in four buffers: (a) CBZ DH; (b) CBZ-NIC cocrystal; (c) CBZ-NIC mixture; (d) CBZ-
SUC cocrystal; (e) CBZ-SUC mixture. 
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(a) CBZ DH 
0 500 1000 1500 3000 3500 0 500 1000 1500 3000 3500


















  APPENDIXS 
177 
 
(b) CBZ-NIC cocrystal 
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(b) CBZ-NIC mixture 
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(c) CBZ-SUC cocrystal 
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(d) CBZ-SUC mixture 
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A 2.2 Figures for CBZ solubility tests as function of coformers in chapter 7 
A2.2.1 DSC thermal graphs of solid residue from the experiment of CBZ solubility tests 
as function of coformer in biomedia:  
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(a) CBZ solubility as function of NIC in pH1.2 buffer 
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(b) CBZ solubility as function of NIC in pH6.8 buffer 
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(c) CBZ solubility as function of NIC in SGF 
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(d) CBZ solubility as function of NIC in SIF 
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(e) CBZ solubility as function of SUC in pH1.2 
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(f) CBZ solubility as function of SUC in pH6.8 
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(g) CBZ solubility as function of SUC in SGF 
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(h) CBZ solubility as function of SUC in SIF 
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A2.2.2 IR spectra of solid residue from the experiment of CBZ solubility tests as 
function of coformer in biomedia:  
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(a) CBZ solubility as function of NIC in pH1.2 buffer 
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(b) CBZ solubility as function of NIC in pH6.8 buffer 
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(c) CBZ solubility as function of NIC in SGF 
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(d) CBZ solubility as function of NIC in SIF 
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(e) CBZ solubility as function of SUC in pH1.2 
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(f) CBZ solubility as function of SUC in pH6.8 
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(g) CBZ solubility as function of SUC in SGF 
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(h) CBZ solubility as function of SUC in SIF 
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A2.2.3 Raman spectra of solid residue from the experiment of CBZ solubility tests as 
function of coformer in biomedia:  
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(a) CBZ solubility as function of NIC in pH1.2 buffer 
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(b) CBZ solubility as function of NIC in pH6.8 buffer 
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(c) CBZ solubility as function of NIC in SGF 
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(d) CBZ solubility as function of NIC in SIF 
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(e) CBZ solubility as function of SUC in pH1.2 
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(f) CBZ solubility as function of SUC in pH6.8 
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(g) CBZ solubility as function of SUC in SGF 
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(h) CBZ solubility as function of SUC in SIF 
 
